



REPUBLIC OF ESTONIA
AGENCY OF MEDICINES



State Agency
of Medicines
Republic of Latvia



Baltic Statistics on Medicines 2013–2015

Baltic Statistics on Medicines 2013–2015

Baltic Statistics on Medicines 2013–2015
2nd edition

Edited by:
Latvian State Agency of Medicines
Andis Seilis, Elma Gailīte

Estonian State Agency of Medicines
Ly Rootslane, Ott Laius

Lithuanian State Medicines Control Agency
Linas Savaikis, Renata Tomaševič

Published by:
Latvian State Agency of Medicines
15 Jersikas Street
LV-1003 Riga
Latvia
info@zva.gov.lv
www.zva.gov.lv

Visual design by:
Uģis Desmitnieks

Printed by:
Dardedze hologrāfija SIA

When using or quoting the data included in this issue, please indicate the source.

ISBN 978-9934-8602-1-8 (print)
ISBN 978-9934-8602-2-5 (pdf)

Contents

1. Preface	5	
2. Facts about the Baltic countries	7	
3. Medicinal products regulation and pharmaceutical services in the Baltic countries	8	
3.1 Procedures of marketing authorisation of medicinal products in Baltic States	8	
3.2 Marketing authorisation licences	9	
3.3 Non-authorised medicinal products	9	
3.4 Medicinal products mark-up	10	
3.5 Generics market	14	
3.6 Retail and hospital pharmacies and wholesalers	15	
4. Drug reimbursement systems in the Baltic countries	18	
4.1 Description of the reimbursement systems	18	
4.2 Changes in the reimbursement systems (during the period of 2013–2015)	21	
4.3 Reference price systems	23	
5. Materials and methods used for the Baltic Statistics on Medicines	25	
5.1 Data collection in the Baltic States	25	
5.2 ATC/DDD methodology and interpretation of drug sales statistics	26	
5.3 Factors affecting the interpretation of drug utilization data ..	27	
6. Cost of drugs as a share of total health care expenditure in the Baltic countries	28	
6.1 The medicinal products market	28	
6.2 Sale of drugs according to the ATC main groups (DDD/1000 inhabitants/day)	30	
6.3 Sale of drugs according to the ATC main groups (turnover) ..	31	
7. Sales statistics 2013–2015	34	
8. Top 15 of prescription-only medicines in 2015	195	
9. Top 15 of over-the-counter medicines in 2015	196	
10. Top 15 most used ATC 3rd level groups in 2015	197	
11. Contacts	198	
12. References	199	

1. Preface



Kristin Raudsepp
Director General
State Agency of
Medicines
Estonia



Svens Henkuzens
Director
State Agency of
Medicines
Latvia



Gintautas Barcys
Director
State Medicines
Control Agency
Lithuania

This book continues the tradition of publishing data regarding consumption of medicines in the Baltic States over a three-year period. The first edition of “Baltic Statistics on Medicines 2010–2012” was published in 2013. It is really gratifying that the medicines agencies in Latvia, Estonia and Lithuania are continuing their collaboration in the exchange of information in the area of consumption of medicines and it is the reason why you can now hold in your hands the new edition of “Baltic Statistics on Medicines 2013–2015”.

Latvia, Estonia and Lithuania are regularly assembling national statistics on consumption of medicines. This publication reflects the similarities and differences of consumption in the Baltic States and allows to compare the trends. Which analgesics are usually chosen by patients in Latvia? Do Estonians prefer the same blood pressure lowering medicines as Lithuanians? What is the amount of financial resources allocated by national governments to the reimbursement systems for medicines? The answers to these questions can be found in this book.

The medicines in this publication are classified in accordance with the Anatomic Therapeutic Chemical (ATC) classification system and consumption is expressed as defined daily doses per 1000 inhabitants per day (DID). Both the ATC classification codes and the DID units are broadly used in medical and pharmaceutical research throughout the world.

The historical events and social processes in Latvia, Estonia and Lithuania have developed similarly in the previous century. During the last 20 years the countries have built stable regulatory systems which attempt to balance the interests of public health and of enterprises in the pharmaceutical field. Since the Baltic States joined the European Union (EU), the Baltic medicines agencies have been operating in compliance with EU and national legal acts and have been ensuring the functions of a pharmaceutical regulator.

The statistics on medicines is a data source for adoption of decisions to promote the safe and rational use of medicines, for analysis of consumption within a region and for finding solutions for issues regarding disruptions in the availability of medicines in the Baltic States. The book also contains a short description of the pharmaceutical market, regulatory requirements and medicinal product reimbursement systems in the three countries.

Since 2013 until 2015 the overall consumption of medicines increased in all three Baltic States similarly to the period covered in the previous report (Baltic Statistics on Medicines 2010–2012). There are still groups of medicines which consumption is rather similar between countries and others with substantial differences in utilization. For example, there are differences in consumption of antidepressants, anxiolytics, sleep and sedative medicines and statins.

In order to ensure that the results would be comparable and representative, specialists from the medicines agencies in Latvia, Estonia and Lithuania were in close collaboration with each other.

2. Facts about the Baltic countries

	Estonia	Latvia	Lithuania
Population (01.01.2016)	1 315 944	1 968 957	2 888 558
Total health expenditure (2014, euro)	998 mln	1 626 mln	2 300 mln
Total health expenditure per capita (2014, euro)	930	812	781
GDP per capita (2014, euro)	15 186	11 782	12 428
Total health expenditure as a % of GDP (2014)	6.1%	5.9%	6.3%
Medicinal products turnover (2015, wholesale, VAT excluded, euro)	265 mln	292 mln	502 mln
Number of general pharmacies per 100 000 inhabitants (01.01.2016)	37	44	48
Number of physicians per 100 000 inhabitants (01.01.2016)	336	347	436
Total number of reimbursed prescriptions (2015)	8.1 mln	6.2 mln	11.5 mln

3. Medicinal products regulation and pharmaceutical services in the Baltic countries

3.1 Procedures of marketing authorisation of medicinal products in Baltic States

The procedure of the marketing authorisation of the medicinal products in the Baltic States is following the EU laws as well as the EU and international guidelines. The procedures are similar in all EU Member States. An application for a marketing authorisation for a medicinal product may be filled under the mutual recognition, decentralised, centralised or national procedure.

The **National Procedure** may be used when an application for the marketing authorisation of a product is filled for the first time in the European Union. This procedure may also be applied to the 'extensions of marketing authorisations', wherein an application is filled, for example, for a new strength or pharmaceutical form of a product already approved nationally. After the evaluation of the application the product may be granted a marketing authorisation nationally.

The **Mutual Recognition Procedure (MRP)** makes use of a marketing authorisation already granted for the medicinal product by an EU Member State (or by Norway, Iceland or Liechtenstein). The Member State whose evaluation statement (assessment report) is used as grounds for recognising the marketing authorisation is known as the Reference Member State (RMS), while the Member State recognising the authorisation is known as the Concerned Member State (CMS).

The **Decentralised Procedure (DCP)** may be applied for products that do not have a marketing authorisation in any Member State. This procedure will allow concomitant application for authorisations in both the RMS and the CMS. The process is conducted by the RMS while the CMSs participate in the evaluation of the application prior to the granting of the marketing authorisation in any of the Member States taking part in the process.

In the event that a marketing authorisation is recognised, the product will be granted a national marketing authorisation as soon as the national translations of its summary of product characteristics (SmPC), package information leaflet (PIL) and labelling confirming to the SmPC mutually agreed in the Mutual Recognition or Decentralised Procedure are ready and approved.

The **Centralised Procedure** is used when a marketing authorisation is applied within the entire EU area for the new biotechnological and other innovative medicinal products. Such marketing authorisation applications are filled with the European Medicines Agency (EMA). Applications for the marketing authorisation concerning the medicinal products for human use are evaluated by the Committee for Medicinal Products for Human Use (CHMP) and those for veterinary use by the Committee for Medicinal Products for Veterinary Use (CVMP). Each Member State has nominated one regular member and one alternate member to each of

these committees. Furthermore, five auxiliary members have been elected to each committee based on their scientific competence.

For each application the Committees will elect a rapporteur and a co-rapporteur from among their members to carry out the evaluation of the application with the aid of the resources made available by the medicines agencies of the Member States. Based on the reviews obtained, the committees will issue a scientific statement to be submitted to the EU Commission for the actual decision-making process. The marketing authorisation granted by the Commission is valid in every Member State as well as in the European Economic Area (EEA) countries - Iceland, Liechtenstein and Norway.

3.2 Marketing authorisation licences

Table 1. Marketing authorisations in January 2016

	Estonia	Latvia	Lithuania	Centrally Authorised Products (CAP) in EU
Number of trade names	2670	2678	2737	940
Number of INN	856	1316	922	570
Number of products	3795	4407	4725	2240

INN - International Non-proprietary Name

3.3 Non-authorised medicinal products

As a general rule, the medicines used in all three Baltic States must have a valid marketing authorisation. Considering the relatively small size of the pharmaceutical market in all three countries, non-authorised medicines may be used exceptionally if there is no suitable authorised medicine in the Register or if the authorised medicine is not available.

■ ESTONIA

The use of the non-authorised medicines is permitted on the basis of applications from doctors (for ambulatory use per patient or for in-hospital use per medical institution for a maximum of 1 year) or from professional organisations (for a cohort of patients). The Agency assesses whether there are grounds for using a particular medicine and in justified cases may issue a permission for the use of a non-authorised medicine.

■ LATVIA

In exceptional cases the State Agency of Medicines issues a permit to wholesalers for the distribution of the medicines authorised in other countries. The medicines wholesaler bases its request for the distribution of the non-authorised medicines on a request from a pharmacy or from a healthcare institution.

■ LITHUANIA

To ensure the availability of all the necessary medicines for the patients the use of the non-authorised medicines is permitted under exceptional circumstances. The non-authorised medicines may be used in the ambulatory care and at the hospital on the basis of a special application from a doctor with signed informed consent of the patient. The treating physician is responsible for prescribing, information and safe use of the non-authorised medicines.

3.4 Medicinal products mark-up

All Baltic States regulate the maximum value that wholesalers and pharmacies are allowed to add to their purchasing price (PP).

■ ESTONIA

The level of maximum limits is required by law to allow the weighted average mark-up of 7-10% in wholesale and 21-25% in retail sale of pharmaceuticals and should be adjusted accordingly based on an annual market analysis by the Ministry of Social Affairs. In practice the applied mark-up may be lower than this maximum, which is frequent for the over-the-counter (OTC) pharmaceuticals. This is one of the commercial possibilities for the wholesalers and pharmacies to attract clients.

Table 2. Wholesale mark-up scheme in Estonia

Ex-factory price in €	Maximum mark-up (% of ex-factory price)
up to 1.60	20
1.61–2.88	15
2.89–6.39	10
6.40–12.78	5
over 12.78	3

Table 3. Pharmacy mark-up scheme in Estonia

Pharmacy purchasing price in €	Pharmacy mark-up coefficient (%)	Fixed pharmacy mark-up in €
up to 0.64	-	0.38
0.65–1.28	40	0.38
1.29–1.92	35	-
1.93–2.56	30	-
2.57–3.20	25	-
3.21–6.39	20	-
6.40–44.74	15	-
over 44.74	-	5.11

A value-added tax (VAT) of 9% is applied for all pharmaceuticals and nutritional mixtures used for medicinal purposes. A standard value-added tax (VAT) of 20% is applied for other goods in Estonia.

■ LATVIA

The principles for the determination of the price of the medicinal products are described in the legislation.

The maximum wholesale price is determined by the manufacturer's price multiplied by correction factor and added correction sum and VAT. The correction factor and correction sum shall be determined on the basis of the manufacturer's price (see Table 4).

Table 4. Wholesale mark-up scheme in Latvia

Manufacturer's price in €	Correction factor	Correction sum in €
up to 4.26	1.18	-
4.27-14.22	1.15	0.13
14.23 and more	1.10	0.84

The maximum retail price is determined by the wholesale price multiplied by correction factor and added correction sum and VAT. The correction factor and correction sum shall be determined on the basis of the procurement price (see Table 5).

Table 5. Pharmacy mark-up scheme in Latvia

Procurement price €	Correction factor	Correction sum €
up to 1.41	1.40	-
1.42-2.84	1.35	0.07
2.85-4.26	1.30	0.21
4.27-7.10	1.25	0.43
7.11-14.22	1.20	0.78
14.23-28.45	1.15	1.49
28.46 and more	1.10	2.92

The manufacturer's prices are declared to the State Agency of Medicines by the manufacturers twice a year and every time the prices are changed or a new product is placed on the market. The maximum retail prices are then calculated and published on the Agency's website for consumers and other interested parties.

The standard rate of value added tax (VAT) in Latvia is 21%. The reduced rate of 12% is applied to the medicinal products. The VAT for medicines in Latvia was increased twofold from 5% to 10% in 2010 and then to 12% in 2011.

■ LITHUANIA

Wholesalers and pharmacy maximum mark-ups of pharmaceuticals are regulated by law and a combination of linear and regressive schemes is used. In practice the applied mark-up may be lower than this maximum, which is frequent for the over-the-counter (OTC) pharmaceuticals. This is one of the commercial possibilities for the wholesalers and pharmacies to attract clients.

In Lithuania standard rate of VAT consists of 21%. The VAT for reimbursed pharmaceuticals is 5% and 21% for not reimbursed pharmaceuticals.

Table 6. Wholesale mark-up scheme in Lithuania for non – reimbursed pharmaceuticals

Ex-Factory Price in €	Maximum wholesale mark-up in %	Maximum wholesale mark-up in €
up to 1.86	18%	-
1.87 – 2.89	16%	-
2.90 – 5.63	9%	-
5.64 – 7.24	8%	-
7.25 – 15.51	7%	-
15.52 – 19.74	6%	-
19.75 – 263.29	5%	-
263.30 and more	-	14.48

Table 7. Wholesale mark-up scheme in Lithuania for reimbursed pharmaceuticals

Ex-Factory Price in €	Maximum wholesale mark-up in %	Maximum wholesale mark-up in €
up to 1.86	14%	-
1.87 – 2.89	-	0.26
2.90 – 5.63	9%	-
5.64 – 7.24	-	0.51
7.25 – 15.51	7%	-
15.52 – 19.74	-	1.09
19.75 – 263.29	5.5%	-
263.30 and more	-	14.48

Table 8. Pharmacy mark-up scheme in Lithuania for non – reimbursed pharmaceuticals

Pharmacy purchase price (PPP) in €	Maximum pharmacy mark-up in %	Maximum pharmacy mark-up in €
up to 2.37	30%	-
2.38 – 2.89	25%	-
2.90 – 4.42	23%	-
4.43 – 7.24	22%	-
7.25 – 7.90	19%	-
7.91 – 21.72	17%	-
21.73 – 144.81	15%	-
144.82 and more	-	17.38

Table 9. Pharmacy mark-up scheme in Lithuania for reimbursed pharmaceuticals

Pharmacy purchase price (PPP) in €	Maximum pharmacy mark-up in %	Maximum pharmacy mark-up in €
up to 2.37	22%	-
2.38 – 2.89	-	0.52
2.90 – 4.42	18%	-
4.43 – 7.24	-	0.80
7.25 – 7.90	11%	-
7.91 – 21.72	-	0.87
21.73 – 144.81	4%	-
144.82 and more	-	5.79

3.5 Generics market

■ ESTONIA

Although there is no explicit regulation on the (mandatory) use of generics in Estonia (i.e. generic substitution), there are some regulative measures in place, directing doctors and patients towards the wider use of generics where these are available.

Doctors have to prescribe pharmaceuticals by INN as the default option; if prescribing by the trade name, they have to document this in the medical record of the patient providing the justification and to mark “not to substitute” on the prescription.

If the pharmaceutical has been prescribed by the INN, the pharmacist has to offer different preparations to the patient, including the cheapest alternative for the patient. In discussion with the patient the most appropriate preparation is to be chosen.

The prevailing reference price system, establishing the reference price of a pharmaceutical as the basis for the reimbursed amount, is a strong incentive to accept substitution, as patients would have to pay the price difference between the reference price and the reimbursed amount on top of their statutory out-of-pocket payments.

■ LATVIA

According to the Latvian legislation a physician may prescribe the medicinal product by the trade name and the pharmacist is allowed to substitute it with an analogue if the doctor has not forbidden this possibility on the prescription.

However, in case of the first prescription of a reimbursed medicinal product the INN name of the medicinal product should be indicated on the prescription and the pharmacist has to offer different preparations to the patient, including the cheapest alternative for the patient.

■ LITHUANIA

Several measures have been introduced in order to stimulate the use of generic medicines.

According to the Lithuanian legislation the medicines should be prescribed by the INN. The prescribing by the trade name is only allowed for the biological pharmaceuticals. Some medicines with narrow therapeutic window may be prescribed by the trade name after the decision of the specialists' commission. All pharmacies are obliged to provide data on prices to the patients via computer screens and are obliged to have the cheapest product in the store.

3.6 Retail and hospital pharmacies and wholesalers

Table 10. Pharmacies and wholesalers in the Baltic States

	Estonia	Latvia	Lithuania
Retail pharmacies	493 (including 163 structural units)	871 (including 95 structural units)	1387 (including 1174 structural units)
Hospital pharmacies	24 (including 1 structural unit)	33 (no structural units)	47 (including 3 structural units)
Wholesalers of medicinal products (human and veterinary medicines)	54	77	171
Veterinary medicines wholesalers	6	24	45

Structural unit - a separate pharmacy acting under the same activity licence as the main pharmacy

■ ESTONIA

In January 2016 there were 60 drug wholesalers in Estonia and 6 of them were specialised only in veterinary drugs. 18 wholesalers had both, human and veterinary products wholesale licences.

In 2015, 29 wholesale companies sold drugs to general or hospital pharmacies or to other institutions. 75% of medicinal products market was covered by three major wholesalers: Magnum Medical (30.1%), Tamro Estonia (24.5%), Apteekide Koostöö Wholesale (21.0%). Followed by Estonian Health Board (5.9%), Roche Estonia (4.7%), Baltfarma (4.2%). The total market share of other wholesalers remained under 10%

Table 11. Wholesalers of the medicinal products in Estonia

	2012	2013	2014	2015	2016
Wholesalers of medicinal products (human and veterinary medicines)	50	53	51	51	54
Veterinary medicines wholesalers	5	5	6	6	6
Total	55	58	57	57	60

At the beginning of 2016 there were 493 general pharmacies (including 163 structural units), 24 hospital pharmacies (including 1 structural unit) and 4 veterinary pharmacies in Estonia.

Table 12. Pharmacies in Estonia

	2012	2013	2014	2015	2016
Retail pharmacies	469	475	478	476	493
Hospital pharmacies	24	25	24	24	24
Veterinary pharmacies	5	4	4	4	4

■ LATVIA

In January 2016 there were 74 human medicines wholesalers in Latvia. 4 of them had wholesale licences with special activity type that allows to distribute veterinary medicines as well, only one of those 4 was actually selling veterinary medicines.

Since January 1st 2011 the licences for the distribution of veterinary medicines are being issued by the Food and Veterinary Service. Before that from 2008 till 2011 veterinary medicines wholesalers and veterinary pharmacies were licenced by the State Agency of Medicines.

In 2015, 50 wholesalers of human medicines distributed medicines to the pharmacies, health care institutions, medical practitioners and other recipients. Over 91% of medicinal products market was covered by the nine major wholesalers: Recipe Plus (36.7%), Tamro (19.6%), Magnum Medical (14.2%), Euroaptieka (7.5%), Oriola Rīga (3.9%), Vakcīna (2.9%), Olainfarm (2.4%), Medelens+ (2.4%), Vita-Farm (Baltfarma) (1.8%) and Saules aptieka (1.4%). The market share of other wholesalers covered 9% of the total market.

Table 13. Wholesalers of the medicinal products in Latvia in January

	2012	2013	2014	2015	2016
Wholesalers of medicinal products (human and veterinary medicines)	55	56	65	63	74
Veterinary medicines wholesalers	24	25	23	23	24
Total	79	81	88	86	98

At the beginning of 2016 there were 871 retail pharmacies (including 95 structural units) and 33 hospital pharmacies in Latvia. 54% of all retail pharmacies are located in the 9 largest cities of Latvia - 33% in Riga, 5% in Daugavpils, 4% in Liepāja, 3% in each Jelgava and Jūrmala, 2% in each Rēzekne and Ventspils, 1% in each Jekabpils and Valmiera.

Table 14. Pharmacies in Latvia

	2012	2013	2014	2015	2016
Retail pharmacies (including structural units)	873 (95)	873 (96)	874 (95)	867 (95)	871 (95)
Hospital pharmacies	36	36	34	33	33
Veterinary pharmacies	86	97	92	97	122

■ LITHUANIA

In 2015, 40 out of 126 wholesalers sold medicines to the general or hospital pharmacies or to other institutions. The following 6 wholesalers cover 94% of the medicinal product market: UAB EVD (34%), UAB LIMEDIKA (24%), UAB Nemuno vaistinė (23%), UAB Tamro (6%), UAB ARMILA (4%) and UAB Medikona (3%). The market share of the other wholesalers made up 6% of the total market.

Table 15. Wholesalers of the medicinal products in Lithuania

	2012	2013	2014	2015	2016
Human medicines wholesalers	96	105	111	123	126
Veterinary medicines wholesalers	37	36	36	40	45
Total	133	141	147	163	171

Hospital pharmacies are funded by the hospitals and do not dispense medicines to outpatients. Not every hospital has a hospital pharmacy for inpatients; however, the majority of health care providers have ordinary community pharmacies on the premises.

Table 16. Pharmacies in Lithuania

	2012	2013	2014	2015	2016
Retail pharmacies	1442	1404	1383	1380	1387
Hospital pharmacies	54	50	48	47	47
Veterinary pharmacies	135	137	148	158	167

4. Drug reimbursement systems in the Baltic countries

4.1 Description of the reimbursement systems

The structure of the reimbursement systems has similarities in Baltic States:

- Medicinal products are compensated for on the basis of the diagnosis.
- Reimbursement rates are divided according to the severity of the disease. There are Positive Lists of the products.
- For certain patient groups additional discounts are provided, for example, children and the elderly.
- Medicinal products are compensated for according to the reference prices in case it exists.

Details of the systems are described below.

■ ESTONIA

The Estonian health insurance relies on the principle of solidarity. The Estonian Health Insurance Fund (EHIF) covers the costs of health services required by a person in case of an illness regardless of the amount of the social tax paid for the person concerned. The Fund uses the social tax paid for the working population also for covering the cost of the health services provided to the persons who have no income with regard to work activities. The employers are required by law to pay social tax for all persons employed, the rate of this tax is 33% of the taxable amount, 20% of which is allocated for the pension insurance and 13% for the health insurance.

The purpose of the health insurance in Estonia is to cover the costs of the health services provided to the insured persons to prevent and cure diseases, finance the purchase of the medicinal products and medical devices, and provide the benefits for the temporary incapacity for work and other benefits.

Only the medicinal products included in the EHIF's list of medicinal products and authorised in Estonia are compensated for. Special reimbursement mechanism is available for the products not having a marketing authorisation in Estonia. Medicinal products are compensated for according to the reference prices and price agreements in case these exist; in other cases the refund is based on the product's retail price. At the manufacturing level there is statutory pricing (after the negotiations) for reimbursable pharmaceuticals. The process of pricing is incorporated into the procedure of reimbursement decision making. Medicinal products are compensated for on the basis of the diagnosis. Medicinal products intended for hospital use are compensated to health care providers if their cost is included in service fee.

Reimbursement rates for medicinal products for out-patient use:

100% reimbursement – Pharmaceuticals for the treatment of choice of serious, life-threatening or epidemic diseases.

Patient shall make an own contribution of 1.27 EUR and in case there is a reference price or a price agreement, pay the sum that exceeds that price. Health Insurance Fund will cover 100% of the sum that exceeds 1.27 EUR and is within the reference price or price agreement.

75% reimbursement – Pharmaceuticals for the treatment of choice of chronic diseases, threatening the quality of life.

The patient makes an own contribution of 1.27 EUR per prescription, pays 25% of the sum remaining between 1.27 EUR and the reference price/price agreement and everything exceeding the reference price/price agreement. The Health Insurance Fund shall pay 75% of the amount between 1.27 EUR and the reference price/price agreement.

50% reimbursement – all other pharmaceuticals in the Positive List.

The patient shall make an own contribution of 3.19 EUR, pay 50% of the sum between 3.19 EUR and the reference price/price agreement and everything exceeding the reference price/price agreement. The Health Insurance Fund shall pay 50% of the amount exceeding 3.19 EUR.

A **compensation rate of 90%** applies to medicinal products with a discount rate of 75% in case of the following patient groups:

- children aged 4 to 16 years;
- insured persons over 63 years of age, in addition, all persons who have been granted pension under the State Pension Insurance Act.

For children under 4 years old, compensation rate of 100% is applied on all medicinal products included in the EHIF list of medicinal products.

The out-of-pocket payment (OPP) system is rather intricate and combines fixed co-payments, percentage co-payments and deductibles. The fixed co-payments are, e.g., prescription fees of € 1.28 at the 100% and 75/90% reimbursement levels and € 3.20 at the 50% reimbursement level. These prescription fees have not been changed since the mid-1990s and there have been minor changes in the overall unavoidable percentage of OPP (90% reimbursement level divided into 75/90% in 2002).

■ LATVIA

The general principles of the reimbursement system of pharmaceuticals are set in the legislation. The reimbursement of pharmaceuticals shall be provided according to the character and severity of the disease. The following categories are applied:

100% reimbursement – for chronic, life threatening diseases or diseases causing irreversible disability, where the use of pharmaceuticals ensures and maintains the patient's life functions,

75% reimbursement – for chronic diseases, for which the maintenance of the patient's life functions are aggravated without the use of pharmaceuticals,

50% reimbursement – for diseases where pharmaceuticals maintain or improve the patient's health and for vaccines.

All drugs for the same indication are reimbursed at the same rate. For the pharmaceuticals for which the reference price is calculated the reimbursement rate is applied to the reference price.

The pharmaceuticals eligible for the reimbursement are listed in the Positive List elaborated by the National Health Service (NHS) of Latvia.

The Positive List consists of three parts – List A, List B and List C according to the following basic principles:

- List A includes pharmaceuticals, which have several preparations of the same therapeutic effectiveness within the scope of the INN or the pharmaco-therapeutic group and medical devices of the same type.
- List B includes pharmaceuticals and medical devices, without an authorised alternative.
- List C includes pharmaceuticals, costs of which exceed 4270 € per patient per year and special medical restrictions cannot be applied to reduce the expenditure.

Reimbursable pharmaceuticals are prescribed by family doctors and certain specialists who have an agreement with the NHS of Latvia.

Reimbursement is provided through pharmacies on the basis of a special reimbursable prescription, patients have to pay the co-payment in the case of the 75% or 50% reimbursement levels, or € 0.71 at the 100% reimbursement level.

A pharmaceutical to be included in the Positive List is to:

- be authorised by the national medicines agency or by the European Commission, or parallel imported according to the regulations;
- be classified as a “prescription only” (over-the-counter (OTC) products are not reimbursable);
- have an approved indication relevant to the diseases listed in Appendix of the Regulation of Cabinet of Ministers.

In Latvia, there is statutory pricing (after the negotiations) for reimbursable pharmaceuticals and free pricing for non-reimbursable pharmaceuticals at the manufacturer level. The process of pricing is incorporated into the procedure of the reimbursement decision making. During the price negotiations both external and internal price referencing mechanisms are used.

Prescription-only medicines that are not included in the Positive List, are reimbursed for children up to 24 months of age (reimbursement rate 50%) and for pregnant women and women within 42 days of postnatal period (reimbursement rate 25%) (list M).

■ LITHUANIA

The state health care system is intended to serve the entire population, and the Health Insurance Law requires all permanent residents to participate in the compulsory health insurance scheme without an option to opt-out. Compulsory health insurance covers almost all inhabitants. Compulsory health insurance provides a standard benefits package for all beneficiaries. There is no positive list of health services provided in the state-financed health care facilities. Emergency care is rendered free of charge to all permanent residents irrespective of their insurance status. Drugs prescribed by a physician are reimbursed according to the reimbursement lists. Expensive hospital medicines are centrally purchased by the National Health Insurance Fund (NHIF).

There are two reimbursement lists, A and B.

List A covers pharmaceuticals for specific diseases in four reimbursement categories:

100% reimbursement: Covers the most serious and expensive diseases, including oncology, diabetes, haemophilia, schizophrenia, asthma etc.

80% reimbursement: Provides coverage for less serious diseases such conditions as cardiovascular diseases.

At **90% and 50% reimbursement** level are reimbursed only a few diseases.

Reimbursement from the disease-based list A accounts to approximately 95% of the country's total pharmaceutical reimbursement.

List B is a list of 75 active substances or combinations reimbursed for certain social groups, including children under 18 years old, the disabled and pensioners with two reimbursement rates:

- 100% is granted to children and the severely disabled,
- 50% is given for other disabled patients and pensioners.

4.2 Changes in the reimbursement systems (during the period of 2013–2015)

■ ESTONIA

There were no major changes in the reimbursement system during this period in Estonia. New active substances have been added to the list of reimbursed medicines quarterly according to the decisions of the Minister of Social Affairs.

■ LATVIA

The Positive list is updated not less than 4 times a year.

The reference countries for external price referencing have been specified (Estonia, Lithuania, Czech Republic, Romania, Slovakia, Hungary, Denmark).

The pharmaceuticals and medical devices included in the Positive list are reimbursed at 100% rate for children up to 18 years (*except for non-reference products within list A*).

■ LITHUANIA

From 2011 to 2015 the expenditure on pharmaceuticals and medical devices covered by the NHIF has increased from 180 to 213 million Euros (average annual growth 4,6 %). The patients co-payments also increased during this period (average annual growth 5,6 %).

During 2011–2015 various measures to increase rational drug prescribing and cost effective drug usage were implemented. New requirements for generic pricing such that the first generic has to be priced 50% below the originator, while the second and third generics must be priced at least 15% below the first generic to be reimbursed, new managed entry agreements schemes (outcomes based agreements) were implemented in 2014.

4.3 Reference price systems

■ ESTONIA

Estonia established a reference price system in January 2003. The reference price is based on the internal price referencing, where the pharmaceuticals are grouped on the basis of active ingredients (Anatomic Therapeutic Chemical classification ATC-5 level), route of administration and pharmaceutical forms. Parallel traded pharmaceuticals have been incorporated into the reference price system as well.

The procedures for setting manufacturer prices differ depending on whether the pharmaceutical in questions is an innovative or a generic product. There are specific criteria for reimbursement of the parallel traded pharmaceuticals: the price for these has to be 10% lower than the price of the primary authorised product on the market.

Statutory pricing – in combination with price negotiations – is applied to the innovative and in-patent reimbursable pharmaceuticals in Estonia. The statutory price levels are set according to the prices of the product in the reference countries (Latvia, Lithuania, Hungary, Portugal, France and the country of origin). If applicable, and similarity is proven, the prices of pharmaceuticals of similar effect are also compared.

The Ministry of Social Affairs is the main authority involved in the pricing decisions, receiving advice from the Pharmaceutical Committee.

If the price of the pharmaceutical is according to the opinion of the Pharmaceutical Committee set too high, price negotiations with the manufacturer are started. Negotiations are possible for the same pharmaceuticals and on the basis of the same legal framework/procedure as statutory pricing. This has been applied since 2003.

■ LATVIA

The reference price system is used in Latvia. The products are grouped into clusters:

- within the INN or
- within the pharmacotherapeutic group if there are no clinically relevant differences in the effectiveness and side-effects for the same indication and drugs are intended for the same patient group.

Products are clustered according to the pharmaceutical form, dosage and pack size. Then the reference product for each cluster is identified (the cheapest pharmaceutical) and on the basis of the price of the reference product the reimbursement price for each pharmaceutical in the cluster is calculated.

■ LITHUANIA

There have been a number of changes to the reference price system in Lithuania in the recent years. The system is based on both external and internal reference pricing measures. Previously, maximum reimbursement prices, or reference prices, were set taking into account the lowest price on the Lithuanian market and ex-manufacturers' prices were negotiated taking into account prices in the neighbouring markets, including Latvia and Estonia. With effect from 2002, phased changes were introduced, to take into account the pricing of products relative to that in other EU states. In 2004, a temporary external reference pricing mechanism was based on a review of pricing in the then 15 EU Member States (prior to the EU accession of Lithuania and other countries included in this report). This identified the lowest price in these states, to which 5% was added for Lithuanian pricing.

From 2005, six countries deemed to have similar per capita income to Lithuania: Latvia, Estonia, Poland, Czech Republic, Slovakia and Hungary are used to detect reference price level. Under the revised approach, the declared manufacturer price is compared with a level which is 95% of the average of that found in the reference countries. In cases where the product is not on the market in some of these countries, the average is taken from the markets in which it is present. In cases where the product is not on the market in any of the reference countries, the price of the product in the country of manufacture is used. From 2009 onwards, Romania and Bulgaria were added to the list of reference countries.

Both patent-protected and off-patent medicines are covered by the reference price system:

- **Patent-protected drugs:** the maximum reimbursement price (reference price) for each INN is determined with a reference to the reference country/EU prices
- **Off-patent drugs:** the reference price is calculated taking into account the reference country/EU prices for the active ingredient, as well as the cheapest version of the drug available in Lithuania. In cases where the price of the cheapest version of the drug in Lithuania is above the level of 95% of the average seen in the reference countries, the reimbursed price may be reduced to this level.

For the purposes of determining the reference price, products are grouped by the active ingredient, with separate clusters drawn up for the same route of administration and pharmaceutical form. Separate clusters are formed for products for paediatric use. There are 445 clusters, corresponding to 1876 reimbursed pharmaceuticals, covered by the reference price system.

Given the nature of the system, patented products are at the moment protected from the impact of internal price referencing, which in effect results in reimbursement pricing at the level of the cheapest product in the group.

5. Materials and methods used for the Baltic Statistics on Medicines

5.1 Data collection in the Baltic States

■ ESTONIA

Estonian State Agency of Medicines (SAM) is collecting and analysing drug utilization data in Estonia.

According to the Medicinal Product Act and Decree of the Minister of Social Affairs all wholesalers of medicinal products have to report their sales data quarterly to SAM. The reports include the following data for each product: package ID, ATC code, active substance(s), trade name, pharmaceutical form, strength, package size and the manufacturer. The sales data are presented in monetary value and by unit of volume (number of packages).

From these reports only the sale to end-consumers (retail and hospital pharmacies, nursing homes etc.) are used for calculating the medicines consumption.

Estonian SAM has been collecting and analysing the data since 1994. Statistics on medicines are annually published on the Agency's website (www.ravimiamet.ee).

■ LATVIA

Statistical data regarding consumption of medicines in Latvia is collected and processed by the State Agency of Medicines (SAM). In accordance with the Pharmaceutical Law and Regulations of the Cabinet of Ministers all wholesalers of medicines submit their sales data (including data regarding parallel imported and parallel distributed medicines) each month by uploading it to the Agency's database. The reports include the following data for each product: medicinal product identification code in accordance with Medicinal Product Register; trade name; price per package; number of packages sold for the particular price and consumer group to which the product was sold.

Only data regarding sales of medicines to the final recipient (pharmacies, healthcare institutions, private practices) are used for calculating medicines consumption statistics. Latvian SAM has been collecting and analysing the data since 2001. The report on statistics on medicines consumption is annually published on the Agency's website (www.zva.gov.lv).

■ LITHUANIA

Lithuanian State Medicines Control Agency (SMCA) is responsible for collection and analysis of drug utilization data in Lithuania.

According to the Pharmaceutical Law and Order of the Head of State Medicines Control Agency all wholesalers of medicinal products have to report their sales data monthly to SMCA. The reports include the following data: a number of wholesaler's licence, package ID of medicinal product, and the number of packages sold. The sales data are presented in volume (number of packages).

From these reports only the sale to end-consumers are used to calculate the medicines consumption.
The Lithuanian SMCA has been collecting and analysing the data since 2009. Since 2010 statistics on medicines are annually published on the Agency’s website (www.vvkt.lt.)

5.2 ATC/DDD methodology and interpretation of drug sales statistics

The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit have become the gold standard for international drug utilization research. The ATC/DDD system is developed and maintained by the WHO Collaborating Centre for Drug Statistics Methodology situated in Oslo (www.whocc.no).
The purpose of the ATC/DDD system is to serve as a tool for drug utilization research in order to improve quality of drug use. One component of this is the presentation and comparison of the drug consumption statistics at international and national levels.

In the Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. The complete classification of metformin illustrates the structure of the code:

A	Alimentary tract and metabolism (1st level, anatomical main group)
A10	Drugs used in diabetes (2nd level, therapeutic subgroup)
A10B	Blood glucose lowering drugs, excl. insulins (3rd level, pharmacological subgroup)
A10BA	Biguanides (4th level, chemical subgroup)
A10BA02	Metformin (5th level, chemical substance)

Thus, in the ATC system all plain metformin preparations are given the code A10BA02.

Medicinal products are classified according to the main therapeutic use of their main active ingredient, on the basic principle of assigning only one ATC code for each pharmaceutical formulation (i.e. similar ingredients, strength and pharmaceutical form). A medicinal product can be given more than one ATC code if it is available in two or more strengths or formulations with clearly different therapeutic uses.

The Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults.

A DDD will only be assigned for drugs that already have an ATC code. DDDs are not established for topical products (e.g. dermatologicals), sera, vaccines, antineoplastic agents, allergen extracts, general and local anaesthetics and contrast media.

It should be emphasised that the defined daily dose is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose (PDD). Doses for individual patients and patient groups will often differ from the DDD and will necessarily have to be based on individual characteristics (e.g. age and weight) and pharmacokinetic considerations.

Drug consumption data presented in DDDs only give a rough estimate of consumption and not an exact picture of actual use. The DDD provide a fixed unit of measurement independent of price and dosage form (e.g. tablet strength) enabling the researcher to assess trends in drug consumption and to perform comparisons between population groups.

Drug consumption figures are usually presented as numbers of DDDs/1000 inhabitants/day. Sales data presented in DDD/1000 inhabitants/day provides a rough estimate of the proportion of the population within a defined area treated daily with certain drugs. For example, the figure 10 DDDs/1000 inhabitants/day indicates that 1% of the population on average gets a certain treatment daily.

The use of a drug expressed as DDD/1000 population/day is derived by calculating the overall amount of a drug being used over a specified period of time (e.g. a year) and dividing this by the DDD multiplied by the population and the number of days in the period.

$$\frac{\text{DDD/1000 population/day}}{\text{DDD(mg) x population x 365(days)}} = \text{Amount used in 1 year (mg)*1000}$$

Collecting and publishing drug utilization statistics are critical elements in the process of improving the prescription and dispensing of medicines. For drug utilization statistics to have the best possible impact on drug use, the statistics need to be used in a focused and active manner.

All figures presented in this publication are based on the ATC/DDD version valid from January 2016.

More detailed information can be found at www.whocc.no.

5.3 Factors affecting the interpretation of drug utilization data

Classification of the medicinal products in the Baltic States


The classification of medicinal products may vary between countries. Consequently, data on drug use in different countries may not be directly comparable in all of the drug classes. For example, some products may be classified as food supplements or natural remedies in one country and as a medicine in another country. For this reason, the ATC groups A11 (vitamins) and A12 (mineral supplements) have been excluded from this publication.

6. Cost of drugs as a share of total health care expenditure in the Baltic countries

6.1 The medicinal products market


■ **ESTONIA**

As shown below, the Estonian human medicines market showed a slight increase from 2011 to 2015 reaching 265 mln euros (excl. VAT).




■ **LATVIA**

Looking back at the last 5 years the total turnover of medicines in Latvia has slightly increased from year to year reaching 292 million euros (excl. VAT) in 2015.



■ LITHUANIA

In 2013 the human medicinal products market decreased by 4.2% and in 2014 reached the 2012 level. In 2015 market increased by 5.5%, reaching 502 mln euros (excl. VAT).




6.2 Sale of drugs according to the ATC main groups
(DDD/1000 inhabitants/day)

Consumption data analysed using ATC/DDD methodology show that the most widely used in all three Baltic countries is the group of cardiovascular drugs. The consumption of cardiovascular drugs more than threefold exceeds the consumption of the second most widely used groups of drugs in each country. As observed in previous years the second most widely used is the group of alimentary tract and metabolism drugs in Latvia and Estonia and the nervous system drugs in Lithuania.

On average the differences between main 10 most consumed ATC groups (see chart below) are around 7-20% from median to minimum and maximum consumption. The biggest differences remain in consumption of the genitourinary system and sex hormones and the nervous system drugs with 35-64% differences in median to maximum consumption. Comparing to 2012 the differences have increased in consumption of sensory organs drugs and respiratory system drugs.


Consumption of medicinal products in the Baltic countries in 2015
(defined daily doses/1000 inhabitants/day)



6.3 Sale of drugs according to the ATC main groups (turnover)

■ ESTONIA


In 2015, 2491 different medicinal preparations of 1262 active substances were used in Estonia. Based on ATC classification antineoplastic and immunomodulating drugs had the greatest market share (20%), alimentary tract and metabolism medicines followed with 12%, antiinfectives for systemic use with 12% and cardiovascular drugs with 12%.



LATVIA


3633 different medicines containing 1563 different active substances were distributed in Latvia in 2015. When comparing turnover of the main ATC groups of medicines, similarly as in previous years the medicines intended for treatment of cardiovascular system diseases make up the largest part i.e. 16% of the market in Latvia. Although the turnover of this group of medicines has shown a slight decrease of 3 percent points compared to 2012.

The second and the third most sold groups of medicines have switched places in 2015 thereby the antineoplastic medicines and immunomodulating agents has the second largest turnover (14.2%) and medicines for treatment of alimentary tract and metabolic diseases are the third most sold (13.7%) medicines in Latvia followed by medicines for treatment of nervous system diseases (11%) and anti-infectives for systemic use (10%). The other ATC groups covered about one third of medicinal products market (35%).



LITHUANIA

Lithuanian expenditure data is based on the NHIF database and depicts expenditure for medicines reimbursement and not wholesale turnover as the Estonian and Latvian data. OTC medicines and non-reimbursed medicines are not included on the figure.



7. Sales statistics 2013–2015


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A	ALIMENTARY TRACT AND METABOLISM				
	Estonia	120.04	125.81	132.81	6
	Latvia	108.11	111.81	119.39	7
	Lithuania	96.71	103.87	107.55	4
A01	STOMATOLOGICAL PREPARATIONS				
	Estonia	0.07	0.08	0.07	-3
	Latvia	5.33	3.67	3.56	-3
	Lithuania	1.10	0.99	0.90	-9
A01A	STOMATOLOGICAL PREPARATIONS				
	Estonia	0.07	0.08	0.07	-3
	Latvia	5.33	3.67	3.56	-3
	Lithuania	1.10	0.99	0.90	-9
A01AA	Caries prophylactic agents				
	Estonia	-	-	-	
	Latvia	5.33	3.67	3.49	-5
	Lithuania	0.28	0.24	0.15	-36
A01AA01	sodium fluoride				
	Estonia	-	-	-	
	Latvia	5.33	3.67	3.49	-5
	Lithuania	0.28	0.24	0.15	-36
A01AB	Antiinfectives and antiseptics for local oral treatment				
	Estonia	0.07	0.08	0.07	-3
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.08	0.08	0.07	-6
A01AB03	chlorhexidine				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
A01AB09	miconazole				
	Estonia	0.07	0.08	0.07	-3
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.08	0.08	0.07	-6
A01AD	Other agents for local oral treatment				
	Estonia	-	-	-	
	Latvia	-	<0.01	0.07	
	Lithuania	0.75	0.67	0.68	1
A01AD02	benzydamine				
	Estonia	-	-	-	
	Latvia	-	<0.01	0.07	
	Lithuania	0.75	0.67	0.68	1

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A02	DRUGS FOR ACID RELATED DISORDERS				
	Estonia	38.21	39.82	43.52	9
	Latvia	30.86	33.42	37.72	13
	Lithuania	34.40	37.01	39.68	7
A02A	ANTACIDS				
	Estonia	0.94	1.00	1.02	2
	Latvia	-	-	-	
	Lithuania	0.67	0.64	0.64	
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds				
	Estonia	0.94	1.00	1.02	2
	Latvia	-	-	-	
	Lithuania	0.65	0.62	0.63	1
A02AD01	ordinary salt combinations				
	Estonia	0.94	1.00	1.02	2
	Latvia	-	-	-	
	Lithuania	-	-	-	
A02AF	Antacids with antiflatulents				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.02	0.01	-42
A02AF02	ordinary salt combinations and antiflatulents				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.02	0.01	-42
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)				
	Estonia	37.28	38.81	42.49	9
	Latvia	30.86	33.42	37.72	13
	Lithuania	33.73	36.36	39.04	7
A02BA	H2-receptor antagonists				
	Estonia	6.91	3.06	2.66	-13
	Latvia	3.00	2.71	2.37	-12
	Lithuania	10.27	10.74	10.55	-2
A02BA01	cimetidine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
A02BA02	ranitidine				
	Estonia	3.45	3.06	2.66	-13
	Latvia	2.92	2.63	2.30	-13
	Lithuania	10.10	10.57	10.37	-2
A02BA03	famotidine				
	Estonia	3.45	<0.01	-	
	Latvia	0.07	0.07	0.07	-4
	Lithuania	0.17	0.17	0.18	8

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A02BB	Prostaglandins				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
A02BB01	misoprostol				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
A02BC	Proton pump inhibitors				
	Estonia	30.37	35.76	39.83	11
	Latvia	27.72	30.56	35.19	15
	Lithuania	23.39	25.56	28.42	11
A02BC01	omeprazole				
	Estonia	21.33	24.61	26.29	7
	Latvia	20.66	22.00	25.37	15
	Lithuania	15.81	17.17	19.25	12
A02BC02	pantoprazole				
	Estonia	5.06	5.94	7.34	24
	Latvia	6.02	6.52	6.96	7
	Lithuania	5.76	5.95	5.71	-4
A02BC03	lansoprazole				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.18	0.14	0.11	-22
	Lithuania	0.58	0.59	0.61	4
A02BC04	rabeprazole				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.16	
	Lithuania	0.43	0.88	1.28	46
A02BC05	esomeprazole				
	Estonia	3.97	5.21	6.20	19
	Latvia	0.87	1.90	2.59	37
	Lithuania	0.82	0.97	1.19	23
A02BC06	dexlansoprazole				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	0.39	
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)				
	Estonia	-	-	-	
	Latvia	0.14	0.15	0.15	6
	Lithuania	0.07	0.06	0.06	3
A02BX01	carbenoxolone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A02BX02	sucralfate				
	Estonia	-	-	-	
	Latvia	0.11	0.13	0.14	5
	Lithuania	0.06	0.06	0.06	3
A02BX05	bismuth subcitrate				
	Estonia	-	-	-	
	Latvia	0.03	0.02	0.02	13
	Lithuania	-	-	-	
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS				
	Estonia	7.43	7.75	7.79	
	Latvia	8.01	8.17	7.77	-5
	Lithuania	7.74	8.39	7.89	-6
A03A	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS				
	Estonia	6.40	6.70	6.79	1
	Latvia	5.49	5.77	5.38	-7
	Lithuania	6.02	6.43	6.27	-2
A03AA	Synthetic anticholinergics, esters with tertiary amino group				
	Estonia	0.70	0.79	0.88	11
	Latvia	0.16	0.18	0.19	7
	Lithuania	0.27	0.28	0.30	9
A03AA04	mebeverine				
	Estonia	0.70	0.79	0.88	11
	Latvia	0.16	0.18	0.19	7
	Lithuania	0.27	0.28	0.30	9
A03AA07	dicycloverine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

Consumption of drugs for acid related disorders (A02)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A03AB	Synthetic anticholinergics, quaternary ammonium compounds				
	Estonia	-	<0.01	-	
	Latvia	0.06	0.06	0.06	-2
	Lithuania	-	-	-	
A03AB02	glycopyrronium bromide				
	Estonia	-	<0.01	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
A03AB05	propantheline				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
A03AB06	otilonium bromide				
	Estonia	-	<0.01	-	
	Latvia	0.06	0.06	0.06	-2
	Lithuania	-	-	-	
A03AB07	methantheline				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A03AD	Papaverine and derivatives				
	Estonia	4.13	4.37	4.36	
	Latvia	4.58	4.77	4.34	-9
	Lithuania	5.15	5.35	5.14	-4
A03AD01	papaverine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A03AD02	drotaverine				
	Estonia	4.13	4.37	4.36	
	Latvia	4.58	4.77	4.33	-9
	Lithuania	5.15	5.35	5.14	-4
A03AX	Other drugs for functional gastrointestinal disorders				
	Estonia	1.57	1.54	1.55	1
	Latvia	0.69	0.76	0.80	5
	Lithuania	0.61	0.81	0.84	4
A03AX13	silicones				
	Estonia	1.57	1.54	1.55	1
	Latvia	0.69	0.76	0.80	5
	Lithuania	0.61	0.56	0.58	4
A03AX58	alverine, combinations				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	0.25	0.25	3

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A03B	BELLADONNA AND DERIVATIVES, PLAIN				
	Estonia	0.11	0.10	0.11	6
	Latvia	0.97	0.93	1.02	9
	Lithuania	0.06	0.07	0.07	-4
A03BA	Belladonna alkaloids, tertiary amines				
	Estonia	0.09	0.08	0.09	6
	Latvia	0.95	0.92	1.01	10
	Lithuania	0.06	0.07	0.07	-4
A03BA01	atropine				
	Estonia	0.09	0.08	0.09	6
	Latvia	0.06	0.05	0.05	-4
	Lithuania	0.06	0.07	0.07	-4
A03BA04	belladonna total alkaloids				
	Estonia	-	-	-	
	Latvia	0.90	0.87	0.96	11
	Lithuania	-	-	-	
A03BB	Belladonna alkaloids, semisynthetic, quaternary ammonium compounds				
	Estonia	0.02	0.02	0.02	8
	Latvia	0.02	0.02	0.01	-34
	Lithuania	-	-	-	
A03BB01	butylscopolamine				
	Estonia	0.02	0.02	0.02	8
	Latvia	0.02	0.02	0.01	-34
	Lithuania	-	-	-	
A03F	PROPULSIVES				
	Estonia	0.92	0.95	0.89	-6
	Latvia	1.55	1.46	1.37	-6
	Lithuania	1.66	1.89	1.55	-18
A03FA	Propulsives				
	Estonia	0.92	0.95	0.89	-6
	Latvia	1.55	1.46	1.37	-6
	Lithuania	1.66	1.89	1.55	-18
A03FA01	metoclopramide				
	Estonia	0.87	0.89	0.84	-5
	Latvia	1.15	1.05	0.98	-7
	Lithuania	1.24	1.48	1.18	-21
A03FA02	cisapride				
	Estonia	<0.01	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
A03FA03	domperidone				
	Estonia	0.04	0.05	0.04	-22
	Latvia	0.40	0.41	0.39	-3
	Lithuania	0.42	0.41	0.37	-9

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A04	ANTIEMETICS AND ANTINAUSEANTS				
	Estonia	0.13	0.14	0.14	-4
	Latvia	0.05	0.06	0.06	7
	Lithuania	0.10	0.11	0.12	12
A04A	ANTIEMETICS AND ANTINAUSEANTS				
	Estonia	0.13	0.14	0.14	-4
	Latvia	0.05	0.06	0.06	7
	Lithuania	0.10	0.11	0.12	12
A04AA	Serotonin (5HT3) antagonists				
	Estonia	0.12	0.13	0.12	-4
	Latvia	0.05	0.06	0.06	8
	Lithuania	0.10	0.11	0.12	12
A04AA01	ondansetron				
	Estonia	0.01	0.01	0.01	-10
	Latvia	0.04	0.04	0.05	9
	Lithuania	0.10	0.10	0.12	12
A04AA02	granisetron				
	Estonia	0.11	0.12	0.12	-4
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
A04AA03	tropisetron				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
A04AA05	palonosetron				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	16
	Lithuania	<0.01	<0.01	<0.01	
A04AD	Other antiemetics				
	Estonia	0.01	0.02	0.02	3
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A04AD12	aprepitant				
	Estonia	0.01	0.02	0.02	3
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A05	BILE AND LIVER THERAPY				
	Estonia	0.42	0.45	0.47	5
	Latvia	0.24	0.30	0.31	4
	Lithuania	0.14	0.17	0.13	-26
A05A	BILE THERAPY				
	Estonia	0.42	0.45	0.47	5
	Latvia	0.24	0.30	0.31	4
	Lithuania	0.14	0.17	0.13	-26

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A05AA	Bile acid preparations				
	Estonia	0.42	0.45	0.47	5
	Latvia	0.24	0.30	0.31	4
	Lithuania	0.14	0.17	0.13	-26
A05AA02	ursodeoxycholic acid				
	Estonia	0.42	0.45	0.47	5
	Latvia	0.24	0.30	0.31	4
	Lithuania	0.14	0.17	0.13	-26
A06	DRUGS FOR CONSTIPATION				
	Estonia	13.58	14.21	15.05	6
	Latvia	7.63	8.26	9.19	11
	Lithuania	9.00	9.74	10.39	7
A06A	DRUGS FOR CONSTIPATION				
	Estonia	13.58	14.21	15.05	6
	Latvia	7.63	8.26	9.19	11
	Lithuania	9.00	9.74	10.39	7
A06AA	Softeners, emollients				
	Estonia	-	-	-	
	Latvia	0.04	0.04	0.04	-10
	Lithuania	-	-	-	
A06AA01	liquid paraffin				
	Estonia	-	-	-	
	Latvia	0.04	0.04	0.04	-10
	Lithuania	-	-	-	
A06AB	Contact laxatives				
	Estonia	6.84	6.84	7.16	5
	Latvia	5.11	5.35	5.93	11
	Lithuania	5.11	5.22	5.42	4
A06AB02	bisacodyl				
	Estonia	3.61	3.31	3.45	4
	Latvia	2.73	2.74	3.13	14
	Lithuania	2.63	2.41	2.45	2
A06AB05	castor oil				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.06	-3
	Lithuania	-	-	-	
A06AB08	sodium picosulfate				
	Estonia	3.23	3.54	3.71	5
	Latvia	2.31	2.54	2.73	8
	Lithuania	2.48	2.82	2.97	5
A06AC	Bulk-forming laxatives				
	Estonia	-	-	-	
	Latvia	0.05	0.04	0.06	53
	Lithuania	0.07	0.09	0.08	-9

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A06AC01	ispaghula (psylla seeds)				
	Estonia	-	-	-	
	Latvia	0.05	0.04	0.06	53
	Lithuania	0.07	0.09	0.08	-9
A06AD	Osmotically acting laxatives				
	Estonia	6.10	6.58	7.08	8
	Latvia	2.10	2.43	2.72	12
	Lithuania	3.40	3.94	4.37	11
A06AD11	lactulose				
	Estonia	5.95	6.38	6.82	7
	Latvia	1.84	2.17	2.44	13
	Lithuania	2.73	3.24	3.66	13
A06AD15	macrogol				
	Estonia	0.15	0.20	0.26	29
	Latvia	0.18	0.19	0.21	13
	Lithuania	0.67	0.70	0.72	2
A06AD65	macrogol, combinations				
	Estonia	-	-	-	
	Latvia	0.08	0.07	0.06	-8
	Lithuania	-	-	-	
A06AG	Enemas				
	Estonia	0.63	0.78	0.82	5
	Latvia	0.34	0.40	0.45	12
	Lithuania	0.42	0.49	0.52	5
A06AG11	sodium lauryl sulfoacetate, incl. combinations				
	Estonia	0.63	0.78	0.82	5
	Latvia	0.34	0.40	0.45	12
	Lithuania	0.42	0.49	0.52	5
A06AX	Other drugs for constipation				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
A06AX04	linaclotide				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS				
	Estonia	3.49	3.66	3.67	
	Latvia	3.12	3.18	3.27	3
	Lithuania	3.09	3.17	3.38	7
A07A	INTESTINAL ANTIINFECTIVES				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.13	0.14	0.14	3

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A07AA	Antibiotics				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.13	0.14	0.14	3
A07AA02	nystatin				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.13	0.14	0.14	3
A07AA03	natamycin				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
A07AA06	paromomycin				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
A07AA09	vancomycin				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
A07AA11	rifaximin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A07AX	Other intestinal antiinfectives				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
A07AX03	nifuroxazide				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
A07B	INTESTINAL ADSORBENTS				
	Estonia	0.49	0.49	0.44	-10
	Latvia	0.71	0.74	0.72	-3
	Lithuania	0.95	0.93	0.95	2
A07BA	Charcoal preparations				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
A07BA01	medicinal charcoal				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A07BC	Other intestinal adsorbents				
	Estonia	0.49	0.49	0.44	-10
	Latvia	0.71	0.74	0.72	-3
	Lithuania	0.95	0.93	0.95	2
A07BC05	diosmectite				
	Estonia	0.49	0.49	0.44	-10
	Latvia	0.71	0.74	0.72	-3
	Lithuania	0.95	0.93	0.95	2
A07D	ANTIPROPULSIVES				
	Estonia	0.84	0.89	0.93	4
	Latvia	0.91	0.90	0.78	-14
	Lithuania	0.97	0.99	1.02	2
A07DA	Antipropulsives				
	Estonia	0.84	0.89	0.93	4
	Latvia	0.91	0.90	0.78	-14
	Lithuania	0.97	0.99	1.02	2
A07DA03	loperamide				
	Estonia	0.84	0.89	0.93	4
	Latvia	0.91	0.90	0.78	-14
	Lithuania	0.97	0.99	1.02	2
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS				
	Estonia	1.74	1.81	1.80	-1
	Latvia	0.98	0.96	1.15	20
	Lithuania	0.88	0.97	1.10	14
A07EA	Corticosteroids acting locally				
	Estonia	<0.01	-	<0.01	
	Latvia	0.01	0.01	0.01	-9
	Lithuania	0.01	<0.01	0.01	
A07EA06	budesonide				
	Estonia	<0.01	-	<0.01	
	Latvia	0.01	0.01	0.01	-9
	Lithuania	0.01	<0.01	0.01	
A07EB	Antiallergic agents, excl. corticosteroids				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
A07EB01	cromoglicic acid				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
A07EC	Aminosalicilic acid and similar agents				
	Estonia	1.74	1.81	1.79	-1
	Latvia	0.98	0.95	1.14	21
	Lithuania	0.87	0.96	1.10	14

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A07EC01	sulfasalazine				
	Estonia	0.90	0.88	0.86	-2
	Latvia	0.74	0.69	0.80	16
	Lithuania	0.28	0.29	0.37	27
A07EC02	mesalazine				
	Estonia	0.83	0.93	0.94	1
	Latvia	0.24	0.26	0.34	32
	Lithuania	0.59	0.67	0.73	9
A07EC03	olsalazine				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
A07F	ANTIDIARRHEAL MICROORGANISMS				
	Estonia	0.42	0.47	0.51	8
	Latvia	0.51	0.57	0.62	8
	Lithuania	0.16	0.15	0.17	13
A07FA	Antidiarrheal microorganisms				
	Estonia	0.42	0.47	0.51	8
	Latvia	0.51	0.57	0.62	8
	Lithuania	0.16	0.15	0.17	13
A07FA01	lactic acid producing organisms				
	Estonia	-	-	-	
	Latvia	0.25	0.27	0.30	8
	Lithuania	-	-	-	
A07FA02	saccharomyces boulardii				
	Estonia	0.42	0.47	0.51	8
	Latvia	0.26	0.30	0.32	8
	Lithuania	0.16	0.15	0.17	13
A08	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS				
	Estonia	0.03	0.03	0.02	-6
	Latvia	0.04	0.03	0.03	-21
	Lithuania	0.03	0.03	0.02	-25
A08A	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS				
	Estonia	0.03	0.03	0.02	-6
	Latvia	0.04	0.03	0.03	-21
	Lithuania	0.03	0.03	0.02	-25
A08AB	Peripherally acting antiobesity products				
	Estonia	0.03	0.03	0.02	-6
	Latvia	0.04	0.03	0.03	-21
	Lithuania	0.03	0.03	0.02	-25
A08AB01	orlistat				
	Estonia	0.03	0.03	0.02	-6
	Latvia	0.04	0.03	0.03	-21
	Lithuania	0.03	0.03	0.02	-25

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A09	DIGESTIVES, INCL. ENZYMES				
	Estonia	1.30	1.35	1.41	5
	Latvia	4.43	4.61	4.87	6
	Lithuania	-	-	-	
A09A	DIGESTIVES, INCL. ENZYMES				
	Estonia	1.30	1.35	1.41	5
	Latvia	4.43	4.61	4.87	6
	Lithuania	-	-	-	
A09AA	Enzyme preparations				
	Estonia	1.30	1.35	1.41	5
	Latvia	4.43	4.61	4.87	6
	Lithuania	-	-	-	
A09AA02	multienzymes (lipase, protease etc.)				
	Estonia	1.30	1.35	1.41	5
	Latvia	4.43	4.61	4.87	6
	Lithuania	-	-	-	
A10	DRUGS USED IN DIABETES				
	Estonia	54.74	57.47	59.66	4
	Latvia	44.86	46.36	48.53	5
	Lithuania	40.59	43.66	44.26	1
A10A	INSULINS AND ANALOGUES				
	Estonia	15.40	15.94	15.93	
	Latvia	11.29	11.53	11.72	2
	Lithuania	12.03	13.03	12.44	-5
A10AB	Insulins and analogues for injection, fast-acting				
	Estonia	5.76	6.17	6.07	-2
	Latvia	3.73	3.80	3.86	2
	Lithuania	3.03	3.33	2.50	-25
A10AB01	insulin (human)				
	Estonia	0.06	0.06	0.05	-17
	Latvia	0.12	0.10	0.09	-15
	Lithuania	0.06	0.06	0.06	-3
A10AB04	insulin lispro				
	Estonia	1.24	1.29	1.28	-1
	Latvia	0.24	0.19	0.20	3
	Lithuania	0.77	0.93	1.00	7
A10AB05	insulin aspart				
	Estonia	3.85	4.12	4.04	-2
	Latvia	2.31	2.36	2.40	2
	Lithuania	1.44	1.49	0.52	-65
A10AB06	insulin glulisine				
	Estonia	0.61	0.70	0.71	1
	Latvia	1.07	1.14	1.17	3
	Lithuania	0.75	0.85	0.93	10

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A10AC	Insulins and analogues for injection, intermediate-acting				
	Estonia	0.21	0.20	0.18	-10
	Latvia	2.51	2.59	2.68	4
	Lithuania	0.51	0.47	0.43	-9
A10AC01	insulin (human)				
	Estonia	0.21	0.20	0.18	-10
	Latvia	1.81	1.82	1.85	2
	Lithuania	0.08	0.07	0.06	-15
A10AC04	insulin lispro				
	Estonia	-	-	-	
	Latvia	0.71	0.77	0.83	8
	Lithuania	0.43	0.40	0.37	-8
A10AD	Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting				
	Estonia	1.96	1.84	1.64	-11
	Latvia	2.55	2.48	2.40	-3
	Lithuania	5.89	6.35	6.33	
A10AD04	insulin lispro				
	Estonia	0.68	0.65	0.62	-5
	Latvia	1.09	1.05	1.04	-1
	Lithuania	2.37	3.05	3.24	6
A10AD05	insulin aspart				
	Estonia	1.28	1.19	1.02	-14
	Latvia	1.46	1.43	1.36	-5
	Lithuania	3.52	3.30	3.10	-6
A10AE	Insulins and analogues for injection, long-acting				
	Estonia	7.46	7.73	8.03	4
	Latvia	2.49	2.66	2.78	4
	Lithuania	2.61	2.88	3.17	10
A10AE04	insulin glargine				
	Estonia	3.91	4.02	4.26	6
	Latvia	1.46	1.59	1.66	4
	Lithuania	1.66	1.89	2.12	13
A10AE05	insulin detemir				
	Estonia	3.56	3.71	3.77	2
	Latvia	1.03	1.07	1.12	5
	Lithuania	0.96	0.99	1.02	3
A10AE06	insulin degludec				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	0.03	

Consumption of Insulins (A10A)




ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS				
	Estonia	39.33	41.53	43.73	5
	Latvia	33.57	34.82	36.81	6
	Lithuania	28.55	30.63	31.83	4
A10BA	Biguanides				
	Estonia	18.33	19.07	19.71	3
	Latvia	13.74	14.03	14.87	6
	Lithuania	14.10	15.75	16.72	6
A10BA02	metformin				
	Estonia	18.33	19.07	19.71	3
	Latvia	13.74	14.03	14.87	6
	Lithuania	14.10	15.75	16.72	6
A10BB	Sulfonylureas				
	Estonia	16.89	16.85	16.23	-4
	Latvia	14.78	14.66	14.28	-3
	Lithuania	12.81	13.19	13.32	1
A10BB01	glibenclamide				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A10BB07	glipizide				
	Estonia	0.44	0.38	0.33	-14
	Latvia	0.60	0.55	0.47	-14
	Lithuania	0.99	1.06	0.87	-17
A10BB08	gliquidone				
	Estonia	-	-	-	
	Latvia	0.25	0.22	0.23	2
	Lithuania	0.09	0.09	0.09	3

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A10BB09	gliclazide				
	Estonia	9.37	9.39	9.06	-4
	Latvia	8.14	8.50	8.68	2
	Lithuania	8.46	9.04	9.59	6
A10BB12	glimepiride				
	Estonia	7.08	7.08	6.84	-3
	Latvia	5.78	5.39	4.91	-9
	Lithuania	3.27	3.01	2.77	-8
A10BD	Combinations of oral blood glucose lowering drugs				
	Estonia	1.35	2.08	3.13	50
	Latvia	3.39	3.98	4.71	18
	Lithuania	0.33	0.40	0.45	15
A10BD05	metformin and pioglitazone				
	Estonia	-	-	-	
	Latvia	1.21	1.11	1.01	-9
	Lithuania	0.14	0.12	0.10	-19
A10BD07	metformin and sitagliptin				
	Estonia	1.26	1.57	1.80	15
	Latvia	1.52	1.57	1.70	8
	Lithuania	0.18	0.28	0.36	29
A10BD08	metformin and vildagliptin				
	Estonia	-	0.06	0.49	768
	Latvia	0.43	0.71	0.94	33
	Lithuania	-	-	-	
A10BD09	pioglitazone and alogliptin				
	Estonia	-	-	-	
	Latvia	-	-	0.08	
	Lithuania	-	-	-	
A10BD10	metformin and saxagliptin				
	Estonia	0.02	0.17	0.27	62
	Latvia	0.04	0.15	0.21	42
	Lithuania	-	-	-	
A10BD11	metformin and linagliptin				
	Estonia	0.07	0.29	0.53	85
	Latvia	0.19	0.41	0.53	29
	Lithuania	-	-	-	
A10BD13	metformin and alogliptin				
	Estonia	-	-	-	
	Latvia	-	0.04	0.20	371
	Lithuania	-	-	-	
A10BD15	metformin and dapagliflozin				
	Estonia	-	-	0.03	
	Latvia	-	-	0.05	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A10BD20	metformin and empagliflozin				
	Estonia	-	-	0.01	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
A10BG	Thiazolidinediones				
	Estonia	0.18	0.14	0.11	-23
	Latvia	0.40	0.36	0.30	-16
	Lithuania	0.30	0.27	0.23	-16
A10BG03	pioglitazone				
	Estonia	0.18	0.14	0.11	-23
	Latvia	0.40	0.36	0.30	-16
	Lithuania	0.30	0.27	0.23	-16
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors				
	Estonia	2.14	2.55	2.95	16
	Latvia	1.06	1.44	1.83	27
	Lithuania	0.72	0.78	0.80	3
A10BH01	sitagliptin				
	Estonia	1.73	1.66	1.56	-6
	Latvia	0.51	0.62	0.56	-10
	Lithuania	0.72	0.73	0.72	
A10BH02	vildagliptin				
	Estonia	-	0.02	0.13	649
	Latvia	-	0.04	0.18	382
	Lithuania	-	-	0.01	
A10BH03	saxagliptin				
	Estonia	0.02	0.15	0.21	39
	Latvia	0.11	0.13	0.12	-4
	Lithuania	<0.01	0.05	0.04	-4
A10BH04	alogliptin				
	Estonia	-	-	<0.01	
	Latvia	-	0.02	0.04	139
	Lithuania	-	-	-	
A10BH05	linagliptin				
	Estonia	0.38	0.72	1.04	44
	Latvia	0.44	0.65	0.93	44
	Lithuania	-	0.01	0.02	300
A10BX	Other blood glucose lowering drugs, excl. insulins				
	Estonia	0.45	0.85	1.59	87
	Latvia	0.21	0.34	0.81	136
	Lithuania	0.30	0.25	0.31	23
A10BX02	repaglinide				
	Estonia	-	-	-	
	Latvia	0.19	0.20	0.17	-12
	Lithuania	0.04	0.02	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A10BX04	exenatide				
	Estonia	<0.01	0.03	0.06	77
	Latvia	<0.01	<0.01	0.02	
	Lithuania	0.26	0.23	0.26	13
A10BX07	liraglutide				
	Estonia	0.45	0.76	0.96	25
	Latvia	0.02	0.03	0.13	332
	Lithuania	-	-	0.01	
A10BX09	dapagliflozin				
	Estonia	-	0.02	0.30	1722
	Latvia	<0.01	0.10	0.37	259
	Lithuania	-	<0.01	0.01	
A10BX10	lixisenatide				
	Estonia	-	0.04	0.14	278
	Latvia	-	0.01	0.05	328
	Lithuania	-	-	0.04	
A10BX12	empagliflozin				
	Estonia	-	-	0.13	
	Latvia	-	-	0.08	
	Lithuania	-	-	-	
A14	ANABOLIC AGENTS FOR SYSTEMIC USE				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.13	0.11	0.09	-25
	Lithuania	0.09	0.07	0.06	-17
A14A	ANABOLIC STEROIDS				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.13	0.11	0.09	-25
	Lithuania	0.09	0.07	0.06	-17

Consumption of blood glucose lowering drugs excl. insulins (A10B)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A14AA	Androstan derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
A14AA05	oxymetholone				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
A14AB	Estren derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.13	0.11	0.09	-25
	Lithuania	0.09	0.07	0.06	-17
A14AB01	nandrolone				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.13	0.11	0.09	-25
	Lithuania	0.09	0.07	0.06	-17
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS				
	Estonia	0.64	0.86	1.01	17
	Latvia	3.40	3.65	4.00	9
	Lithuania	0.43	0.54	0.72	33
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS				
	Estonia	0.64	0.86	1.01	17
	Latvia	3.40	3.65	4.00	9
	Lithuania	0.43	0.54	0.72	33
A16AA	Amino acids and derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A16AA01	levocarnitine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A16AA06	betaine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A16AB	Enzymes				
	Estonia	<0.01	0.01	0.01	5
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
A16AB02	imiglucrase				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
A16AB03	agalsidase alfa				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
A16AB04	agalsidase beta				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	<0.01	
A16AB05	laronidase				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
A16AB07	alglucosidase alfa				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A16AB10	velaglucerase alfa				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
A16AX	Various alimentary tract and metabolism products				
	Estonia	0.63	0.85	1.00	18
	Latvia	3.40	3.65	3.99	9
	Lithuania	0.43	0.54	0.72	32
A16AX01	thioctic acid				
	Estonia	0.62	0.84	0.99	18
	Latvia	3.40	3.65	3.99	9
	Lithuania	0.42	0.54	0.72	33
A16AX03	sodium phenylbutyrate				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
A16AX04	nitisinone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
A16AX05	zinc acetate				
	Estonia	0.01	0.01	0.01	-15
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B	BLOOD AND BLOOD FORMING ORGANS				
	Estonia	95.39	100.56	101.27	1
	Latvia	83.49	84.51	86.39	2
	Lithuania	72.30	78.59	78.37	
B01	ANTITHROMBOTIC AGENTS				
	Estonia	82.25	84.42	84.26	
	Latvia	77.68	78.58	80.22	2
	Lithuania	67.14	72.34	71.84	-1
B01A	ANTITHROMBOTIC AGENTS				
	Estonia	82.25	84.42	84.26	
	Latvia	77.68	78.58	80.22	2
	Lithuania	67.14	72.34	71.84	-1
B01AA	Vitamin K antagonists				
	Estonia	8.03	7.89	7.55	-4
	Latvia	4.50	5.06	5.38	6
	Lithuania	8.77	9.60	9.90	3
B01AA03	warfarin				
	Estonia	8.03	7.89	7.55	-4
	Latvia	4.50	5.06	5.37	6
	Lithuania	8.77	9.59	9.89	3
B01AA04	phenprocoumon				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AA07	acenocoumarol				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	<0.01	0.01	0.01	20
B01AB	Heparin group				
	Estonia	2.17	2.36	2.75	16
	Latvia	1.38	1.36	1.39	2
	Lithuania	1.42	1.52	1.46	-4
B01AB01	heparin				
	Estonia	0.10	0.10	0.11	7
	Latvia	0.20	0.18	0.23	24
	Lithuania	0.33	0.34	0.36	7
B01AB04	dalteparin				
	Estonia	0.07	0.10	0.10	
	Latvia	0.33	0.31	0.27	-12
	Lithuania	0.04	<0.01	<0.01	
B01AB05	enoxaparin				
	Estonia	1.66	1.76	2.03	15
	Latvia	0.37	0.39	0.37	-4
	Lithuania	0.17	0.15	0.19	21

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B01AB06	nadroparin				
	Estonia	0.09	0.05	0.04	-22
	Latvia	0.44	0.43	0.45	3
	Lithuania	0.60	0.63	0.68	7
B01AB12	bemiparin				
	Estonia	0.25	0.36	0.47	32
	Latvia	0.04	0.04	0.07	66
	Lithuania	0.28	0.39	0.23	-43
B01AC	Platelet aggregation inhibitors excl. heparin				
	Estonia	71.12	71.08	68.51	-4
	Latvia	71.39	71.40	71.90	1
	Lithuania	56.68	60.62	59.70	-2
B01AC04	clopidogrel				
	Estonia	4.21	4.50	4.55	1
	Latvia	3.12	3.28	3.74	14
	Lithuania	6.78	7.84	7.89	1
B01AC06	acetylsalicylic acid				
	Estonia	14.64	15.16	14.55	-4
	Latvia	66.85	66.36	66.20	
	Lithuania	49.68	52.31	51.12	-2
B01AC07	dipyridamole				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AC11	iloprost				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AC13	abciximab				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
B01AC16	eptifibatide				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B01AC17	 tirofiban				
	Estonia	<0.01	<0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B01AC22	prasugrel				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	0.01	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B01AC23	cilostazol				
	Estonia	-	-	-	
	Latvia	<0.01	0.06	0.11	82
	Lithuania	-	0.14	0.30	120
B01AC24	ticagrelor				
	Estonia	0.57	0.73	0.79	8
	Latvia	0.03	0.12	0.32	171
	Lithuania	0.07	0.12	0.21	70
B01AC30	combinations				
	Estonia	51.58	50.69	48.62	-4
	Latvia	1.35	1.58	1.53	-3
	Lithuania	0.14	0.19	0.18	-5
B01AC56	acetylsalicylic acid, combinations with proton pump inhibitors				
	Estonia	0.13	-	-	
	Latvia	0.04	-	-	
	Lithuania	-	-	-	
B01AD	Enzymes				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AD01	streptokinase				
	Estonia	-	-	<0.01	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	
B01AD02	alteplase				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AD04	urokinase				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AD07	reteplase				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
B01AD11	tenecteplase				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B01AE	Direct thrombin inhibitors				
	Estonia	0.40	0.60	0.96	58
	Latvia	0.20	0.33	0.45	36
	Lithuania	0.08	0.11	0.15	32

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B01AE07	dabigatran etexilate				
	Estonia	0.40	0.60	0.96	58
	Latvia	0.20	0.33	0.45	36
	Lithuania	0.08	0.11	0.15	32
B01AF	Direct factor Xa inhibitors				
	Estonia	0.51	2.46	4.47	82
	Latvia	0.20	0.41	1.10	168
	Lithuania	0.21	0.49	0.64	29
B01AF01	rivaroxaban				
	Estonia	0.50	2.39	3.98	67
	Latvia	0.20	0.38	1.08	184
	Lithuania	0.20	0.44	0.58	33
B01AF02	apixaban				
	Estonia	0.01	0.07	0.50	600
	Latvia	0.01	0.03	0.02	-28
	Lithuania	<0.01	0.06	0.05	-4
B01AX	Other antithrombotic agents				
	Estonia	0.02	0.02	0.02	-2
	Latvia	0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B01AX05	fondaparinux				
	Estonia	0.02	0.02	0.02	-2
	Latvia	0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B02	ANTIHEMORRHAGICS				
	Estonia	0.14	0.15	0.16	8
	Latvia	0.04	0.04	0.05	12
	Lithuania	0.06	0.06	0.07	13

Consumption of antithrombotic agents (B01A)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B02A	ANTIFIBRINOLYTICS				
	Estonia	0.10	0.11	0.12	7
	Latvia	0.02	0.02	0.02	6
	Lithuania	-	-	-	
B02AA	Amino acids				
	Estonia	0.10	0.11	0.12	7
	Latvia	0.02	0.02	0.02	6
	Lithuania	-	-	-	
B02AA01	aminocaproic acid				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B02AA02	tranexamic acid				
	Estonia	0.09	0.11	0.12	7
	Latvia	0.02	0.02	0.02	5
	Lithuania	-	-	-	
B02B	VITAMIN K AND OTHER HEMOSTATICS				
	Estonia	0.04	0.04	0.04	10
	Latvia	0.02	0.02	0.03	19
	Lithuania	0.06	0.06	0.07	13
B02BA	Vitamin K				
	Estonia	0.02	0.01	0.02	31
	Latvia	0.01	0.01	0.02	25
	Lithuania	0.04	0.03	0.04	12
B02BA01	phytomenadione				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.01	0.02	27
	Lithuania	0.04	0.03	0.04	12
B02BA02	menadione				
	Estonia	0.01	0.01	0.01	45
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B02BB	Fibrinogen				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B02BB01	fibrinogen, human				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B02BD	Blood coagulation factors				
	Estonia	0.02	0.02	0.02	3
	Latvia	0.01	0.01	0.01	16
	Lithuania	0.02	0.03	0.03	8

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B02BD01	coagulation factor IX, II, VII and X in combination				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B02BD02	coagulation factor VIII				
	Estonia	0.01	0.01	0.01	-11
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.01	0.02	0.02	13
B02BD03	factor VIII inhibitor bypassing activity				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B02BD04	coagulation factor IX				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	
B02BD05	coagulation factor VII				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B02BD06	von Willebrand factor and coagulation factor VIII in combination				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B02BD08	eptacog alfa (activated)				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B02BX	Other systemic hemostatics				
	Estonia	<0.01	0.01	0.01	-14
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B02BX04	romiplostim				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
B02BX05	eltrombopag				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	-	
	Lithuania	<0.01	<0.01	<0.01	
B03	ANTIANEMIC PREPARATIONS				
	Estonia	13.01	16.00	16.86	5
	Latvia	5.76	5.90	6.11	4
	Lithuania	5.10	6.19	6.46	4

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B03A	IRON PREPARATIONS				
	Estonia	1.85	2.36	2.23	-6
	Latvia	2.63	2.66	2.73	3
	Lithuania	2.27	2.39	2.46	3
B03AA	Iron bivalent, oral preparations				
	Estonia	1.81	2.32	2.19	-6
	Latvia	0.02	0.06	0.06	
	Lithuania	1.88	2.01	2.11	5
B03AA01	ferrous glycine sulfate				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B03AA05	ferrous chloride				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.03	0.02	-24
B03AA07	ferrous sulfate				
	Estonia	1.81	2.32	2.19	-6
	Latvia	0.02	0.06	0.06	
	Lithuania	1.85	1.98	2.09	5
B03AB	Iron trivalent, oral preparations				
	Estonia	-	-	-	
	Latvia	2.53	2.54	2.61	3
	Lithuania	0.33	0.33	0.29	-11
B03AB05	ferric oxide polymaltose complexes				
	Estonia	-	-	-	
	Latvia	2.53	2.54	2.61	3
	Lithuania	0.33	0.33	0.29	-11
B03AC	Iron, parenteral preparations				
	Estonia	0.04	0.04	0.04	-5
	Latvia	0.07	0.07	0.07	-5
	Lithuania	0.06	0.06	0.07	8
B03B	VITAMIN B12 AND FOLIC ACID				
	Estonia	10.65	13.13	14.07	7
	Latvia	2.28	2.26	2.52	12
	Lithuania	2.03	3.02	3.30	9
B03BA	Vitamin B12 (cyanocobalamin and analogues)				
	Estonia	5.09	5.32	6.18	16
	Latvia	2.28	2.26	2.52	12
	Lithuania	2.03	3.02	3.30	9
B03BA01	cyanocobalamin				
	Estonia	5.08	5.29	6.14	16
	Latvia	2.28	2.26	2.52	12
	Lithuania	2.03	3.02	3.30	9

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B03BA03	hydroxocobalamin				
	Estonia	0.01	0.03	0.04	24
	Latvia	-	-	-	
	Lithuania	-	-	-	
B03BB	Folic acid and derivatives				
	Estonia	5.56	7.81	7.89	1
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
B03BB01	folic acid				
	Estonia	5.56	7.81	7.89	1
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
B03X	OTHER ANTIANEMIC PREPARATIONS				
	Estonia	0.51	0.51	0.56	10
	Latvia	0.86	0.97	0.86	-12
	Lithuania	0.80	0.77	0.70	-9
B03XA	Other antianemic preparations				
	Estonia	0.51	0.51	0.56	10
	Latvia	0.86	0.97	0.86	-12
	Lithuania	0.80	0.77	0.70	-9
B03XA01	erythropoietin				
	Estonia	0.10	0.11	0.11	4
	Latvia	0.04	0.07	0.04	-36
	Lithuania	0.22	0.22	0.23	2
B03XA02	darbepoetin alfa				
	Estonia	0.35	0.33	0.37	14
	Latvia	0.50	0.56	0.48	-14
	Lithuania	0.58	0.55	0.48	-14
B03XA03	methoxy polyethylene glycol-epoetin beta				
	Estonia	0.06	0.08	0.08	1
	Latvia	0.31	0.35	0.34	-3
	Lithuania	-	-	-	
B06	OTHER HEMATOLOGICAL AGENTS				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B06A	OTHER HEMATOLOGICAL AGENTS				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
B06AC	Drugs used in hereditary angioedema				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
B06AC02	icatibant				
	Estonia	-	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
B06AC04	conestat alfa				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C	CARDIOVASCULAR SYSTEM				
	Estonia	402.28	408.57	416.87	2
	Latvia	346.89	362.22	370.18	2
	Lithuania	438.91	451.85	439.56	-3
C01	CARDIAC THERAPY				
	Estonia	32.28	32.06	30.91	-4
	Latvia	27.59	28.04	26.86	-4
	Lithuania	49.14	48.74	44.63	-8
C01A	CARDIAC GLYCOSIDES				
	Estonia	4.84	4.54	4.18	-8
	Latvia	4.42	3.88	3.66	-6
	Lithuania	3.96	3.84	3.45	-10
C01AA	Digitalis glycosides				
	Estonia	4.84	4.54	4.18	-8
	Latvia	4.42	3.88	3.66	-6
	Lithuania	3.96	3.84	3.45	-10
C01AA01	acetyldigitoxin				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
C01AA02	acetyldigoxin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01AA05	digoxin				
	Estonia	4.84	4.54	4.18	-8
	Latvia	4.42	3.88	3.66	-6
	Lithuania	3.96	3.84	3.45	-10
C01AA06	lanatoside C				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C01B	ANTIARRHYTHMICS, CLASS I AND III				
	Estonia	6.11	6.72	6.95	3
	Latvia	2.41	2.49	2.62	5
	Lithuania	6.52	6.84	6.90	1
C01BA	Antiarrhythmics, class Ia				
	Estonia	<0.01	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01BA01	quinidine				
	Estonia	<0.01	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C01BA02	procainamide				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
C01BC	Antiarrhythmics, class Ic				
	Estonia	3.21	3.72	4.04	8
	Latvia	0.54	0.64	0.81	26
	Lithuania	2.19	2.49	2.77	11
C01BC03	propafenone				
	Estonia	3.16	3.65	3.96	8
	Latvia	0.54	0.64	0.81	26
	Lithuania	2.19	2.49	2.77	11
C01BC04	flecainide				
	Estonia	0.05	0.07	0.08	19
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
C01BD	Antiarrhythmics, class III				
	Estonia	2.90	3.00	2.91	-3
	Latvia	1.87	1.84	1.81	-2
	Lithuania	4.33	4.35	4.14	-5
C01BD01	amiodarone				
	Estonia	2.88	2.97	2.89	-3
	Latvia	1.87	1.84	1.80	-2
	Lithuania	4.32	4.34	4.13	-5
C01BD07	dronedaron				
	Estonia	0.03	0.03	0.03	-23
	Latvia	-	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	-9
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES				
	Estonia	0.83	0.78	0.91	17
	Latvia	0.40	0.38	0.42	10
	Lithuania	0.96	0.98	0.97	-1
C01CA	Adrenergic and dopaminergic agents				
	Estonia	0.82	0.78	0.91	17
	Latvia	0.40	0.38	0.42	10
	Lithuania	0.96	0.98	0.97	-1
C01CA01	etilefrine				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01CA02	isoprenaline				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C01CA03	norepinephrine				
	Estonia	0.07	0.08	0.11	36
	Latvia	0.02	0.02	0.02	5
	Lithuania	-	-	-	
C01CA04	dopamine				
	Estonia	0.01	0.01	0.01	-30
	Latvia	0.01	0.01	0.01	26
	Lithuania	0.02	0.02	0.02	-8
C01CA06	phenylephrine				
	Estonia	0.12	0.15	0.14	-6
	Latvia	-	-	-	
	Lithuania	-	-	-	
C01CA07	dobutamine				
	Estonia	<0.01	0.01	0.01	2
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
C01CA17	midodrine				
	Estonia	-	<0.01	<0.01	
	Latvia	-	<0.01	<0.01	
	Lithuania	<0.01	<0.01	-	
C01CA24	epinephrine				
	Estonia	0.58	0.50	0.60	21
	Latvia	0.37	0.34	0.36	8
	Lithuania	0.93	0.95	0.94	-1
C01CA26	ephedrine				
	Estonia	0.04	0.03	0.04	26
	Latvia	<0.01	0.01	0.02	75
	Lithuania	-	-	-	
C01CE	Phosphodiesterase inhibitors				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01CE02	milrinone				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01CX	Other cardiac stimulants				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01CX08	levosimendan				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C01D	VASODILATORS USED IN CARDIAC DISEASES				
	Estonia	10.40	9.52	8.86	-7
	Latvia	8.52	7.85	7.04	-10
	Lithuania	12.94	12.35	11.46	-7
C01DA	Organic nitrates				
	Estonia	10.40	9.52	8.86	-7
	Latvia	8.52	7.85	7.04	-10
	Lithuania	12.94	12.35	11.46	-7
C01DA02	glyceryl trinitrate				
	Estonia	0.61	0.59	0.53	-10
	Latvia	0.85	0.88	0.78	-11
	Lithuania	3.60	3.44	3.20	-7
C01DA05	pentaerithrityl tetranitrate				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01DA08	isosorbide dinitrate				
	Estonia	0.60	0.56	0.51	-9
	Latvia	0.41	0.34	0.29	-15
	Lithuania	1.40	1.38	1.29	-7
C01DA14	isosorbide mononitrate				
	Estonia	9.19	8.37	7.81	-7
	Latvia	7.26	6.63	5.97	-10
	Lithuania	7.95	7.53	6.97	-7
C01E	OTHER CARDIAC PREPARATIONS				
	Estonia	10.09	10.50	10.02	-5
	Latvia	11.84	13.43	13.12	-2
	Lithuania	24.76	24.73	21.86	-12
C01EA	Prostaglandins				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01EA01	alprostadiil				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01EB	Other cardiac preparations				
	Estonia	10.09	10.50	10.02	-5
	Latvia	11.84	13.43	13.12	-2
	Lithuania	24.76	24.73	21.86	-12
C01EB10	adenosine				
	Estonia	0.01	0.01	0.01	72
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	<0.01	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C01EB15	trimetazidine				
	Estonia	9.97	10.21	9.72	-5
	Latvia	10.40	11.41	10.98	-4
	Lithuania	21.66	21.30	18.78	-12
C01EB16	ibuprofen				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C01EB17	ivabradine				
	Estonia	0.09	0.26	0.26	-1
	Latvia	1.41	1.99	2.10	6
	Lithuania	3.09	3.42	2.97	-13
C01EB18	ranolazine				
	Estonia	0.02	0.02	0.03	6
	Latvia	0.02	0.03	0.03	22
	Lithuania	0.01	0.01	0.11	950
C01EB21	regadenoson				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C02	ANTIHYPERTENSIVES				
	Estonia	3.82	3.88	3.81	-2
	Latvia	17.57	18.19	18.58	2
	Lithuania	28.51	29.33	29.25	
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING				
	Estonia	2.22	2.33	2.39	3
	Latvia	14.07	14.89	15.33	3
	Lithuania	19.74	20.53	20.97	2

Consumption of drugs for cardiac therapy (C01)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C02AB	Methyldopa				
	Estonia	-	-	<0.01	
	Latvia	0.08	0.09	0.09	1
	Lithuania	0.06	0.06	0.06	-3
C02AB01	methyldopa (levorotatory)				
	Estonia	-	-	<0.01	
	Latvia	0.08	0.09	0.09	1
	Lithuania	0.06	0.06	0.06	-3
C02AC	Imidazoline receptor agonists				
	Estonia	2.22	2.33	2.39	3
	Latvia	13.99	14.81	15.25	3
	Lithuania	19.67	20.47	20.91	2
C02AC01	clonidine				
	Estonia	0.07	0.06	0.05	-11
	Latvia	1.26	1.22	1.19	-2
	Lithuania	-	-	-	
C02AC05	moxonidine				
	Estonia	2.15	2.27	2.34	3
	Latvia	5.04	5.66	6.16	9
	Lithuania	19.67	20.47	20.91	2
C02AC06	rilménidine				
	Estonia	-	-	-	
	Latvia	7.70	7.92	7.89	
	Lithuania	-	-	-	
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING				
	Estonia	1.59	1.54	1.40	-9
	Latvia	2.37	2.34	2.31	-2
	Lithuania	8.77	8.79	8.27	-6
C02CA	Alpha-adrenoreceptor antagonists				
	Estonia	1.59	1.54	1.40	-9
	Latvia	2.37	2.34	2.31	-2
	Lithuania	8.77	8.79	8.27	-6
C02CA01	prazosin				
	Estonia	-	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C02CA04	doxazosin				
	Estonia	1.59	1.54	1.40	-9
	Latvia	2.37	2.34	2.31	-2
	Lithuania	8.77	8.79	8.27	-6
C02CA06	urapidil				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C02D	ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
C02DA	Thiazide derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
C02DA01	diazoxide				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
C02DB	Hydrazinophthalazine derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C02DB01	dihydralazine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C02DB02	hydralazine				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
C02DD	Nitroferri cyanide derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	-	-	
	Lithuania	<0.01	<0.01	<0.01	
C02DD01	nitroprusside				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	-	-	
	Lithuania	<0.01	<0.01	<0.01	
C02K	OTHER ANTIHYPERTENSIVES				
	Estonia	0.01	0.01	0.01	15
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	17
C02KX	Antihypertensives for pulmonary arterial hypertension				
	Estonia	0.01	0.01	0.01	15
	Latvia	<0.01	<0.01	0.01	
	Lithuania	0.01	0.01	0.01	17
C02KX01	bosentan				
	Estonia	0.01	0.01	0.01	-11
	Latvia	-	<0.01	0.01	
	Lithuania	<0.01	0.01	0.01	33

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C02KX02	ambrisentan				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	0.01	0.01	
C02KX05	riociguat				
	Estonia	-	-	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
C02L	ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION				
	Estonia	-	-	-	
	Latvia	1.12	0.95	0.92	-3
	Lithuania	-	-	-	
C02LA	Rauwolfia alkaloids and diuretics in combination				
	Estonia	-	-	-	
	Latvia	1.12	0.95	0.92	-3
	Lithuania	-	-	-	
C02LA51	reserpine and diuretics, combinations with other drugs				
	Estonia	-	-	-	
	Latvia	1.12	0.95	0.92	-3
	Lithuania	-	-	-	
C03	DIURETICS				
	Estonia	23.56	24.51	25.17	3
	Latvia	19.19	19.22	18.79	-2
	Lithuania	20.71	21.67	21.22	-2
C03A	LOW-CEILING DIURETICS, THIAZIDES				
	Estonia	3.66	3.18	2.72	-14
	Latvia	0.65	0.58	0.51	-13
	Lithuania	0.13	0.13	0.13	6
C03AA	Thiazides, plain				
	Estonia	3.66	3.18	2.72	-14
	Latvia	0.65	0.58	0.51	-13
	Lithuania	0.13	0.13	0.13	6
C03AA03	hydrochlorothiazide				
	Estonia	3.66	3.18	2.72	-14
	Latvia	0.65	0.58	0.51	-13
	Lithuania	0.13	0.13	0.13	6
C03B	LOW-CEILING DIURETICS, EXCL. THIAZIDES				
	Estonia	2.41	2.64	2.52	-4
	Latvia	4.91	4.56	4.07	-11
	Lithuania	5.09	4.89	3.99	-19
C03BA	Sulfonamides, plain				
	Estonia	2.41	2.64	2.52	-4
	Latvia	4.91	4.56	4.07	-11
	Lithuania	5.09	4.89	3.99	-19

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C03BA04	chlortalidone				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
C03BA10	xipamide				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
C03BA11	indapamide				
	Estonia	2.41	2.64	2.52	-4
	Latvia	4.91	4.56	4.07	-11
	Lithuania	5.09	4.89	3.99	-19
C03C	HIGH-CEILING DIURETICS				
	Estonia	14.25	15.49	16.78	8
	Latvia	8.10	8.57	8.81	3
	Lithuania	11.17	11.97	12.53	5
C03CA	Sulfonamides, plain				
	Estonia	14.25	15.49	16.78	8
	Latvia	8.10	8.57	8.81	3
	Lithuania	11.17	11.97	12.53	5
C03CA01	furosemide				
	Estonia	5.18	5.05	5.26	4
	Latvia	3.18	3.09	2.96	-4
	Lithuania	2.89	2.82	2.74	-3
C03CA02	bumetanide				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
C03CA04	torasemide				
	Estonia	9.07	10.44	11.52	10
	Latvia	4.92	5.48	5.85	7
	Lithuania	8.27	9.15	9.80	7
C03D	POTASSIUM-SPARING AGENTS				
	Estonia	3.22	3.19	3.13	-2
	Latvia	5.53	5.51	5.40	-2
	Lithuania	4.34	4.68	4.56	-2
C03DA	Aldosterone antagonists				
	Estonia	3.22	3.19	3.13	-2
	Latvia	5.53	5.51	5.40	-2
	Lithuania	4.34	4.68	4.56	-2
C03DA01	spironolactone				
	Estonia	3.20	3.16	3.12	-1
	Latvia	5.44	5.46	5.36	-2
	Lithuania	4.32	4.67	4.56	-2

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C03DA04	eplerenone				
	Estonia	0.02	0.02	0.01	-63
	Latvia	0.09	0.05	0.04	-33
	Lithuania	0.01	0.01	<0.01	
C03E	DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION				
	Estonia	0.02	0.01	0.02	45
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C03EA	Low-ceiling diuretics and potassium-sparing agents				
	Estonia	0.02	0.01	0.02	45
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C03EA01	hydrochlorothiazide and potassium-sparing agents				
	Estonia	0.02	0.01	0.02	45
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C03EA13	bendroflumethiazide and potassium-sparing agents				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
C04	PERIPHERAL VASODILATORS				
	Estonia	2.84	2.88	2.87	
	Latvia	3.30	3.56	3.57	
	Lithuania	4.92	5.14	4.74	-8
C04A	PERIPHERAL VASODILATORS				
	Estonia	2.84	2.88	2.87	
	Latvia	3.30	3.56	3.57	
	Lithuania	4.92	5.14	4.74	-8
C04AB	Imidazoline derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
C04AB01	phentolamine				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
C04AC	Nicotinic acid and derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C04AC01	nicotinic acid				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C04AD	Purine derivatives				
	Estonia	2.51	2.38	2.28	-4
	Latvia	1.41	1.33	1.19	-11
	Lithuania	4.92	5.14	4.74	-8
C04AD02	xantinol nicotinate				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.03	0.03	-9
C04AD03	pentoxifylline				
	Estonia	2.51	2.38	2.28	-4
	Latvia	1.41	1.33	1.19	-11
	Lithuania	4.89	5.10	4.71	-8
C04AX	Other peripheral vasodilators				
	Estonia	0.33	0.50	0.59	19
	Latvia	1.89	2.23	2.38	7
	Lithuania	-	-	-	
C04AX02	phenoxybenzamine				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
C04AX21	naftidrofuryl				
	Estonia	0.33	0.50	0.59	19
	Latvia	1.89	2.23	2.38	7
	Lithuania	-	-	-	
C07	BETA BLOCKING AGENTS				
	Estonia	42.54	45.36	47.53	5
	Latvia	46.08	50.37	52.50	4
	Lithuania	65.58	71.06	71.60	1
C07A	BETA BLOCKING AGENTS				
	Estonia	42.54	45.36	47.53	5
	Latvia	43.61	46.38	48.06	4
	Lithuania	62.13	66.39	66.71	
C07AA	Beta blocking agents, non-selective				
	Estonia	2.20	2.16	2.08	-4
	Latvia	0.59	0.65	0.75	15
	Lithuania	0.16	0.20	0.23	14
C07AA03	pindolol				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C07AA05	propranolol				
	Estonia	0.44	0.48	0.50	4
	Latvia	0.35	0.35	0.35	-1
	Lithuania	0.16	0.20	0.23	14
C07AA07	sotalol				
	Estonia	1.76	1.68	1.58	-6
	Latvia	0.23	0.30	0.40	33
	Lithuania	-	-	-	
C07AB	Beta blocking agents, selective				
	Estonia	39.58	42.43	44.72	5
	Latvia	42.52	45.26	46.91	4
	Lithuania	58.93	63.09	64.83	3
C07AB02	metoprolol				
	Estonia	22.24	22.62	23.19	3
	Latvia	13.77	13.49	13.17	-2
	Lithuania	19.20	20.47	20.82	2
C07AB03	atenolol				
	Estonia	1.06	0.97	0.88	-10
	Latvia	0.64	0.57	0.48	-16
	Lithuania	0.86	0.82	0.80	-3
C07AB04	acebutolol				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C07AB05	betaxolol				
	Estonia	-	-	-	
	Latvia	2.37	2.60	2.97	14
	Lithuania	5.77	6.08	5.89	-3
C07AB07	bisoprolol				
	Estonia	0.67	1.04	1.37	33
	Latvia	17.68	18.48	18.64	1
	Lithuania	0.08	0.11	0.15	41
C07AB12	nebivolol				
	Estonia	15.61	17.81	19.28	8
	Latvia	8.05	10.13	11.66	15
	Lithuania	33.01	35.61	37.17	4
C07AB13	talinolol				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
C07AG	Alpha and beta blocking agents				
	Estonia	0.76	0.77	0.73	-5
	Latvia	0.50	0.46	0.40	-13
	Lithuania	3.04	3.10	1.66	-46

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C07AG01	labetalol				
	Estonia	0.05	0.06	0.06	5
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C07AG02	carvedilol				
	Estonia	0.71	0.71	0.66	-6
	Latvia	0.50	0.46	0.40	-13
	Lithuania	3.04	3.10	1.66	-46
C07B	BETA BLOCKING AGENTS AND THIAZIDES				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	1.95	3.03	3.25	7
	Lithuania	3.45	4.67	4.89	5
C07BB	Beta blocking agents, selective, and thiazides				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	1.95	3.03	3.25	7
	Lithuania	3.45	4.67	4.89	5
C07BB07	bisoprolol and thiazides				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	1.67	1.68	1.54	-8
	Lithuania	-	-	-	
C07BB12	nebivolol and thiazides				
	Estonia	-	-	-	
	Latvia	0.28	1.35	1.72	27
	Lithuania	3.45	4.67	4.89	5
C07F	BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES				
	Estonia	-	-	-	
	Latvia	0.53	0.96	1.18	23
	Lithuania	-	-	-	
C07FB	Beta blocking agents, selective, and other antihypertensives				
	Estonia	-	-	-	
	Latvia	0.53	0.96	1.18	23
	Lithuania	-	-	-	
C07FB07	bisoprolol and other antihypertensives				
	Estonia	-	-	-	
	Latvia	0.53	0.96	1.18	23
	Lithuania	-	-	-	
C08	CALCIUM CHANNEL BLOCKERS				
	Estonia	64.13	61.20	58.38	-5
	Latvia	37.88	37.51	36.17	-4
	Lithuania	36.87	36.12	32.23	-11

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS				
	Estonia	61.69	58.84	56.14	-5
	Latvia	36.87	36.39	35.08	-4
	Lithuania	32.81	32.20	28.43	-12
C08CA	Dihydropyridine derivatives				
	Estonia	61.69	58.84	56.14	-5
	Latvia	36.87	36.39	35.08	-4
	Lithuania	32.81	32.20	28.43	-12
C08CA01	amlodipine				
	Estonia	33.87	32.02	30.75	-4
	Latvia	19.45	18.61	17.58	-6
	Lithuania	9.98	9.80	8.71	-11
C08CA02	felodipine				
	Estonia	5.81	5.21	4.75	-9
	Latvia	1.32	1.14	0.96	-16
	Lithuania	0.44	0.36	0.30	-18
C08CA05	nifedipine				
	Estonia	2.25	2.09	1.74	-17
	Latvia	1.31	1.25	1.06	-16
	Lithuania	0.19	0.18	0.17	-5
C08CA06	nimodipine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.01	0.01	7
	Lithuania	-	-	-	
C08CA08	nitrendipine				
	Estonia	6.42	6.27	5.87	-6
	Latvia	3.22	3.05	2.89	-5
	Lithuania	0.50	0.74	0.66	-11
C08CA09	lacidipine				
	Estonia	6.20	5.65	5.21	-8
	Latvia	4.19	3.91	3.62	-7
	Lithuania	5.54	5.07	4.16	-18
C08CA13	lercanidipine				
	Estonia	7.15	7.60	7.82	3
	Latvia	7.38	8.42	8.96	6
	Lithuania	16.16	16.05	14.43	-10
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS				
	Estonia	2.44	2.36	2.24	-5
	Latvia	1.01	0.91	0.77	-15
	Lithuania	4.06	3.92	3.80	-3
C08DA	Phenylalkylamine derivatives				
	Estonia	2.35	2.27	2.15	-5
	Latvia	0.69	0.63	0.53	-16
	Lithuania	1.86	1.84	2.09	13

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C08DA01	verapamil				
	Estonia	2.35	2.27	2.15	-5
	Latvia	0.39	0.36	0.34	-6
	Lithuania	1.86	1.84	2.09	13
C08DA51	verapamil, combinations				
	Estonia	-	-	-	
	Latvia	0.30	0.26	0.19	-29
	Lithuania	-	-	-	
C08DB	Benzothiazepine derivatives				
	Estonia	0.09	0.09	0.09	-1
	Latvia	0.32	0.29	0.24	-15
	Lithuania	2.20	2.08	1.72	-18
C08DB01	diltiazem				
	Estonia	0.09	0.09	0.09	-1
	Latvia	0.32	0.29	0.24	-15
	Lithuania	2.20	2.08	1.72	-18
C08G	CALCIUM CHANNEL BLOCKERS AND DIURETICS				
	Estonia	-	-	-	
	Latvia	-	0.21	0.32	55
	Lithuania	-	-	-	
C08GA	Calcium channel blockers and diuretics				
	Estonia	-	-	-	
	Latvia	-	0.21	0.32	55
	Lithuania	-	-	-	
C08GA02	amlodipine and diuretics				
	Estonia	-	-	-	
	Latvia	-	0.21	0.32	55
	Lithuania	-	-	-	
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM				
	Estonia	189.44	191.36	196.58	3
	Latvia	139.69	145.61	148.07	2
	Lithuania	217.85	220.15	214.14	-3
C09A	ACE INHIBITORS, PLAIN				
	Estonia	91.65	88.21	84.85	-4
	Latvia	69.61	68.80	65.57	-5
	Lithuania	109.29	107.57	102.14	-5
C09AA	ACE inhibitors, plain				
	Estonia	91.65	88.21	84.85	-4
	Latvia	69.61	68.80	65.57	-5
	Lithuania	109.29	107.57	102.14	-5
C09AA01	captopril				
	Estonia	0.13	0.11	0.09	-15
	Latvia	0.99	0.96	0.98	2
	Lithuania	10.82	11.02	10.76	-2

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C09AA02	enalapril				
	Estonia	17.14	15.52	13.97	-10
	Latvia	21.42	19.28	16.84	-13
	Lithuania	10.24	8.90	7.66	-14
C09AA03	lisinopril				
	Estonia	<0.01	-	-	
	Latvia	0.95	0.96	0.92	-4
	Lithuania	2.94	2.81	2.45	-13
C09AA04	perindopril				
	Estonia	1.17	1.77	2.36	33
	Latvia	20.85	20.92	20.02	-4
	Lithuania	23.07	25.62	27.30	7
C09AA05	ramipril				
	Estonia	61.60	60.49	59.20	-2
	Latvia	21.88	23.44	23.92	2
	Lithuania	36.61	33.68	30.99	-8
C09AA06	quinapril				
	Estonia	0.03	0.02	0.02	18
	Latvia	1.37	1.23	1.03	-16
	Lithuania	8.21	7.35	5.16	-30
C09AA07	benazepril				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
C09AA09	fosinopril				
	Estonia	11.50	10.17	9.03	-11
	Latvia	1.95	1.77	1.63	-8
	Lithuania	5.94	5.91	5.38	-9
C09AA10	trandolapril				
	Estonia	0.08	0.13	0.18	39
	Latvia	0.18	0.24	0.21	-10
	Lithuania	1.98	1.95	2.14	9
C09AA11	spirapril				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	0.20	0.13	<0.01	
C09AA15	zofenopril				
	Estonia	<0.01	-	<0.01	
	Latvia	0.02	0.02	0.02	-7
	Lithuania	9.28	10.22	10.29	1
C09B	ACE INHIBITORS, COMBINATIONS				
	Estonia	33.91	37.56	41.31	10
	Latvia	47.89	52.65	56.74	8
	Lithuania	48.06	52.90	55.50	5

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C09BA	ACE inhibitors and diuretics				
	Estonia	27.27	28.08	28.21	
	Latvia	34.36	36.10	35.78	-1
	Lithuania	29.31	30.85	30.25	-2
C09BA02	enalapril and diuretics				
	Estonia	13.79	12.57	11.11	-12
	Latvia	6.30	5.54	4.94	-11
	Lithuania	0.62	0.53	0.44	-17
C09BA03	lisinopril and diuretics				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
C09BA04	perindopril and diuretics				
	Estonia	7.17	9.57	11.67	22
	Latvia	19.82	22.72	23.83	5
	Lithuania	21.29	23.21	23.12	
C09BA05	ramipril and diuretics				
	Estonia	3.81	3.67	3.40	-7
	Latvia	1.47	1.56	1.51	-3
	Lithuania	1.44	1.35	1.09	-20
C09BA06	quinapril and diuretics				
	Estonia	0.15	0.12	0.01	-88
	Latvia	5.50	5.16	4.47	-13
	Lithuania	4.29	3.70	2.92	-21
C09BA07	benazepril and diuretics				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
C09BA08	cilazapril and diuretics				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C09BA09	fosinopril and diuretics				
	Estonia	2.36	2.16	2.01	-7
	Latvia	1.27	1.13	1.03	-9
	Lithuania	1.66	1.66	1.57	-5
C09BA15	zofenopril and diuretics				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	0.40	1.11	181
C09BB	ACE inhibitors and calcium channel blockers				
	Estonia	6.64	8.60	9.49	10
	Latvia	13.53	15.52	16.05	3
	Lithuania	18.75	20.78	19.43	-6


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C09BB02	enalapril and lercanidipine				
	Estonia	-	-	-	
	Latvia	-	0.12	0.30	147
	Lithuania	-	-	-	
C09BB03	lisinopril and amlodipine				
	Estonia	2.40	2.44	2.35	-4
	Latvia	1.48	1.55	1.45	-7
	Lithuania	1.87	2.07	2.13	3
C09BB04	perindopril and amlodipine				
	Estonia	2.33	3.54	4.32	22
	Latvia	11.47	12.83	12.99	1
	Lithuania	13.28	14.34	13.60	-5
C09BB07	ramipril and amlodipine				
	Estonia	0.67	1.40	1.69	21
	Latvia	0.59	1.02	1.31	28
	Lithuania	0.44	1.16	1.08	-7
C09BB10	trandolapril and verapamil				
	Estonia	1.23	1.22	1.13	-8
	Latvia	-	-	-	
	Lithuania	3.16	3.21	2.63	-18
C09BX	ACE inhibitors, other combinations				
	Estonia	-	0.88	3.61	312
	Latvia	-	1.02	4.91	381
	Lithuania	-	1.28	5.82	356
C09BX01	perindopril, amlodipine and indapamide				
	Estonia	-	0.88	3.61	312
	Latvia	-	1.02	4.91	381
	Lithuania	-	1.28	5.82	356
C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN				
	Estonia	40.55	40.25	42.27	5
	Latvia	10.82	11.05	11.78	7
	Lithuania	43.47	40.40	37.41	-7
C09CA	Angiotensin II antagonists, plain				
	Estonia	40.55	40.25	42.27	5
	Latvia	10.82	11.05	11.78	7
	Lithuania	43.47	40.40	37.41	-7
C09CA01	losartan				
	Estonia	6.60	5.89	5.29	-10
	Latvia	2.13	2.15	2.00	-7
	Lithuania	9.15	6.94	5.69	-18
C09CA02	eprosartan				
	Estonia	0.02	0.02	0.01	-32
	Latvia	0.01	0.01	0.01	-14
	Lithuania	0.05	0.03	0.03	-15

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C09CA03	valsartan				
	Estonia	6.09	5.50	5.18	-6
	Latvia	0.22	0.26	0.31	21
	Lithuania	20.46	20.23	18.96	-6
C09CA04	irbesartan				
	Estonia	<0.01	-	-	
	Latvia	0.27	0.23	0.19	-17
	Lithuania	0.25	0.21	0.18	-11
C09CA06	candesartan				
	Estonia	6.13	6.15	7.99	30
	Latvia	1.84	1.69	1.74	3
	Lithuania	0.14	0.19	0.44	131
C09CA07	telmisartan				
	Estonia	19.48	20.37	21.48	5
	Latvia	4.68	4.77	5.41	14
	Lithuania	12.53	11.83	11.17	-6
C09CA08	olmesartan medoxomil				
	Estonia	2.23	2.32	2.32	
	Latvia	1.68	1.94	2.11	9
	Lithuania	0.90	0.96	0.95	-1
C09D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS				
	Estonia	23.34	25.33	28.15	11
	Latvia	11.37	13.11	13.99	7
	Lithuania	17.03	19.28	19.10	-1
C09DA	Angiotensin II antagonists and diuretics				
	Estonia	16.84	16.76	17.69	5
	Latvia	8.82	9.94	10.87	9
	Lithuania	13.41	14.29	13.71	-4
C09DA01	losartan and diuretics				
	Estonia	3.43	3.10	2.93	-6
	Latvia	1.79	1.69	1.66	-2
	Lithuania	2.28	1.80	1.52	-16
C09DA03	valsartan and diuretics				
	Estonia	2.01	2.05	2.00	-3
	Latvia	1.01	1.23	1.37	11
	Lithuania	8.81	9.05	8.37	-8
C09DA04	irbesartan and diuretics				
	Estonia	-	-	-	
	Latvia	0.11	0.10	0.08	-17
	Lithuania	-	-	-	
C09DA06	candesartan and diuretics				
	Estonia	1.41	1.35	1.73	28
	Latvia	0.31	0.30	0.38	29
	Lithuania	-	0.19	0.62	230

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C09DA07	telmisartan and diuretics				
	Estonia	9.71	9.93	10.54	6
	Latvia	4.62	5.33	5.70	7
	Lithuania	1.84	2.75	2.68	-3
C09DA08	olmesartan medoxomil and diuretics				
	Estonia	0.28	0.34	0.49	45
	Latvia	0.99	1.30	1.68	29
	Lithuania	0.49	0.50	0.52	5
C09DB	Angiotensin II antagonists and calcium channel blockers				
	Estonia	6.50	8.45	9.51	13
	Latvia	1.98	2.41	2.09	-13
	Lithuania	3.50	4.50	4.57	2
C09DB01	valsartan and amlodipine				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.33	0.38	0.41	9
	Lithuania	1.36	1.73	1.71	-1
C09DB02	olmesartan medoxomil and amlodipine				
	Estonia	1.23	2.45	3.18	30
	Latvia	0.79	1.06	1.03	-3
	Lithuania	0.94	0.93	0.91	-3
C09DB04	telmisartan and amlodipine				
	Estonia	5.27	5.99	6.26	4
	Latvia	0.86	0.94	0.32	-66
	Lithuania	1.20	1.84	1.96	7
C09DB06	losartan and amlodipine				
	Estonia	-	-	-	
	Latvia	-	0.03	0.32	911
	Lithuania	-	-	-	
C09DB07	candesartan and amlodipine				
	Estonia	-	<0.01	0.07	
	Latvia	-	-	0.01	
	Lithuania	-	-	-	
C09DX	Angiotensin II antagonists, other combinations				
	Estonia	-	0.12	0.95	682
	Latvia	0.56	0.76	1.03	36
	Lithuania	0.12	0.49	0.81	67
C09DX01	valsartan, amlodipine and hydrochlorothiazide				
	Estonia	-	<0.01	0.01	
	Latvia	0.56	0.76	0.84	11
	Lithuania	0.02	0.02	0.16	761
C09DX03	olmesartan medoxomil, amlodipine and hydrochlorothiazide				
	Estonia	-	0.12	0.94	686
	Latvia	0.01	<0.01	0.18	
	Lithuania	0.11	0.47	0.66	41


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C09X	OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
C09XA	Renin-inhibitors				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
C09XA02	aliskiren				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
C09XA53	aliskiren and amlodipine				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
C10	LIPID MODIFYING AGENTS				
	Estonia	43.66	47.32	51.62	9
	Latvia	55.59	59.72	65.65	10
	Lithuania	15.33	19.66	21.75	11
C10A	LIPID MODIFYING AGENTS, PLAIN				
	Estonia	42.96	46.53	51.14	10
	Latvia	51.75	56.27	62.49	11
	Lithuania	15.26	19.60	21.70	11

Consumption of antihypertensive drugs (C02–C09)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C10AA	HMG CoA reductase inhibitors				
	Estonia	42.53	46.00	50.53	10
	Latvia	50.87	55.30	61.45	11
	Lithuania	15.01	19.33	21.44	11
C10AA01	simvastatin				
	Estonia	7.04	6.80	6.57	-3
	Latvia	0.62	0.51	0.45	-12
	Lithuania	0.14	0.12	0.11	-11
C10AA03	pravastatin				
	Estonia	0.55	0.50	0.46	-8
	Latvia	-	-	-	
	Lithuania	-	-	-	
C10AA04	fluvastatin				
	Estonia	0.91	0.87	0.78	-11
	Latvia	0.07	0.06	0.06	-9
	Lithuania	0.12	0.12	0.11	-7
C10AA05	atorvastatin				
	Estonia	11.91	13.60	15.74	16
	Latvia	35.43	36.76	39.26	7
	Lithuania	12.77	16.44	18.42	12
C10AA07	rosuvastatin				
	Estonia	22.12	24.24	26.99	11
	Latvia	14.76	17.96	21.68	21
	Lithuania	1.99	2.65	2.79	6
C10AB	Fibrates				
	Estonia	0.24	0.34	0.40	18
	Latvia	0.68	0.78	0.85	9
	Lithuania	0.25	0.26	0.26	

Consumption of statins (C10AA)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C10AB05	fenofibrate				
	Estonia	0.19	0.29	0.37	27
	Latvia	0.68	0.78	0.85	9
	Lithuania	0.25	0.26	0.26	
C10AB08	ciprofibrate				
	Estonia	0.05	0.05	0.03	-35
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
C10AC	Bile acid sequestrants				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C10AC01	colestyramine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C10AC02	colestipol				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
C10AD	Nicotinic acid and derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C10AD02	nicotinic acid				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
C10AX	Other lipid modifying agents				
	Estonia	0.19	0.19	0.21	14
	Latvia	0.20	0.20	0.20	
	Lithuania	<0.01	<0.01	<0.01	
C10AX09	ezetimibe				
	Estonia	0.19	0.19	0.21	14
	Latvia	0.20	0.20	0.20	
	Lithuania	<0.01	<0.01	<0.01	
C10B	LIPID MODIFYING AGENTS, COMBINATIONS				
	Estonia	0.71	0.78	0.47	-40
	Latvia	3.84	3.44	3.15	-8
	Lithuania	0.07	0.07	0.05	-26
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents				
	Estonia	-	-	-	
	Latvia	0.12	0.03	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
C10BA02	simvastatin and ezetimibe				
	Estonia	-	-	-	
	Latvia	0.12	0.03	<0.01	
	Lithuania	-	-	-	
C10BX	HMG CoA reductase inhibitors, other combinations				
	Estonia	0.71	0.78	0.47	-40
	Latvia	3.72	3.41	3.15	-8
	Lithuania	0.07	0.07	0.05	-26
C10BX03	atorvastatin and amlodipine				
	Estonia	0.71	0.78	0.47	-40
	Latvia	3.72	3.41	3.15	-8
	Lithuania	0.07	0.07	0.05	-26

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
D	DERMATOLOGICALS				
	Estonia	1.72	1.76	1.76	
	Latvia	0.38	0.42	0.45	6
	Lithuania	0.59	0.63	0.62	-1
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE				
	Estonia	1.19	1.23	1.22	
	Latvia	0.31	0.35	0.38	8
	Lithuania	0.48	0.50	0.48	-2
D01B	ANTIFUNGALS FOR SYSTEMIC USE				
	Estonia	1.19	1.23	1.22	
	Latvia	0.31	0.35	0.38	8
	Lithuania	0.48	0.50	0.48	-2
D01BA	Antifungals for systemic use				
	Estonia	1.19	1.23	1.22	
	Latvia	0.31	0.35	0.38	8
	Lithuania	0.48	0.50	0.48	-2
D01BA01	griseofulvin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
D01BA02	terbinafine				
	Estonia	1.18	1.23	1.22	
	Latvia	0.31	0.35	0.38	8
	Lithuania	0.48	0.50	0.48	-2
D05	ANTIPSORIATICS				
	Estonia	0.03	0.04	0.05	25
	Latvia	<0.01	0.01	0.01	14
	Lithuania	0.01	<0.01	0.01	
D05B	ANTIPSORIATICS FOR SYSTEMIC USE				
	Estonia	0.03	0.04	0.05	25
	Latvia	<0.01	0.01	0.01	14
	Lithuania	0.01	<0.01	0.01	
D05BB	Retinoids for treatment of psoriasis				
	Estonia	0.03	0.04	0.05	25
	Latvia	<0.01	0.01	0.01	14
	Lithuania	0.01	<0.01	0.01	
D05BB02	acitretin				
	Estonia	0.03	0.04	0.05	25
	Latvia	<0.01	0.01	0.01	14
	Lithuania	0.01	<0.01	0.01	
D10	ANTI-ACNE PREPARATIONS				
	Estonia	0.46	0.45	0.43	-4
	Latvia	0.06	0.06	0.06	-1
	Lithuania	0.11	0.13	0.13	2

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
D10B	ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE				
	Estonia	0.46	0.45	0.43	-4
	Latvia	0.06	0.06	0.06	-1
	Lithuania	0.11	0.13	0.13	2
D10BA	Retinoids for treatment of acne				
	Estonia	0.46	0.45	0.43	-4
	Latvia	0.06	0.06	0.06	-1
	Lithuania	0.11	0.13	0.13	2
D10BA01	isotretinoin				
	Estonia	0.46	0.45	0.43	-4
	Latvia	0.06	0.06	0.06	-1
	Lithuania	0.11	0.13	0.13	2
D11	OTHER DERMATOLOGICAL PREPARATIONS				
	Estonia	0.05	0.05	0.06	33
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
D11A	OTHER DERMATOLOGICAL PREPARATIONS				
	Estonia	0.05	0.05	0.06	33
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
D11AX	Other dermatologicals				
	Estonia	0.05	0.05	0.06	33
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
D11AX10	finasteride				
	Estonia	0.05	0.05	0.06	33
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G	GENITO URINARY SYSTEM AND SEX HORMONES				
	Estonia	50.48	50.90	51.50	1
	Latvia	31.42	31.45	31.37	
	Lithuania	29.85	30.51	30.22	-1
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS				
	Estonia	0.81	0.75	0.70	-7
	Latvia	0.66	0.66	0.62	-8
	Lithuania	1.12	1.18	1.16	-2
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS				
	Estonia	0.81	0.75	0.70	-7
	Latvia	0.66	0.66	0.62	-8
	Lithuania	1.12	1.18	1.16	-2
G01AA	Antibiotics				
	Estonia	0.11	0.09	0.08	-13
	Latvia	0.04	0.04	0.04	-9
	Lithuania	0.41	0.40	0.41	1
G01AA01	nystatin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G01AA02	natamycin				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
G01AA10	clindamycin				
	Estonia	0.11	0.09	0.08	-13
	Latvia	0.04	0.04	0.03	-10
	Lithuania	0.41	0.40	0.41	1
G01AF	Imidazole derivatives				
	Estonia	0.70	0.66	0.62	-6
	Latvia	0.57	0.57	0.54	-4
	Lithuania	0.57	0.62	0.60	-4
G01AF01	metronidazole				
	Estonia	0.12	0.11	0.10	-11
	Latvia	0.03	0.03	0.03	-3
	Lithuania	0.04	0.04	0.04	10
G01AF02	clotrimazole				
	Estonia	0.43	0.40	0.38	-5
	Latvia	0.36	0.37	0.36	-1
	Lithuania	0.18	0.16	0.15	-7
G01AF04	miconazole				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G01AF05	econazole				
	Estonia	0.15	0.15	0.14	-6
	Latvia	0.08	0.08	0.08	-6
	Lithuania	0.04	0.03	0.03	-15
G01AF12	fenticonazole				
	Estonia	-	-	-	
	Latvia	0.07	0.07	0.05	-21
	Lithuania	0.30	0.39	0.37	-3
G01AF15	butoconazole				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.02	-8
	Lithuania	-	-	-	
G01AX	Other antiinfectives and antiseptics				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.04	-39
	Lithuania	0.14	0.15	0.15	1
G01AX05	nifuratel				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.11	0.11	0.12	4
G01AX11	povidone-iodine				
	Estonia	-	-	-	
	Latvia	0.06	0.06	0.04	-40
	Lithuania	0.03	0.03	0.03	-9
G02	OTHER GYNECOLOGICALS				
	Estonia	3.46	3.30	3.17	-4
	Latvia	1.52	1.53	1.52	-1
	Lithuania	1.13	1.02	0.98	-4
G02A	UTEROTONICS				
	Estonia	0.01	0.01	0.01	-22
	Latvia	0.01	0.01	0.01	20
	Lithuania	-	-	-	
G02AB	Ergot alkaloids				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.01	0.01	0.01	27
	Lithuania	-	-	-	
G02AB01	methylergometrine				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.01	0.01	0.01	27
	Lithuania	-	-	-	
G02AD	Prostaglandins				
	Estonia	<0.01	0.01	0.01	11
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G02AD02	dinoprostone				
	Estonia	<0.01	0.01	0.01	11
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G02AD06	misoprostol				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G02B	CONTRACEPTIVES FOR TOPICAL USE				
	Estonia	3.28	3.12	2.99	-4
	Latvia	1.49	1.49	1.48	-1
	Lithuania	0.98	0.86	0.81	-6
G02BB	Intravaginal contraceptives				
	Estonia	3.28	3.12	2.99	-4
	Latvia	1.49	1.49	1.48	-1
	Lithuania	0.98	0.86	0.81	-6
G02BB01	vaginal ring with progestogen and estrogen				
	Estonia	3.28	3.12	2.99	-4
	Latvia	1.24	1.26	1.27	1
	Lithuania	0.98	0.86	0.81	-6
G02C	OTHER GYNECOLOGICALS				
	Estonia	0.17	0.17	0.17	
	Latvia	0.02	0.03	0.03	-3
	Lithuania	0.15	0.16	0.17	7
G02CB	Prolactine inhibitors				
	Estonia	0.17	0.17	0.17	
	Latvia	0.02	0.03	0.03	-3
	Lithuania	0.15	0.16	0.17	7
G02CB01	bromocriptine				
	Estonia	0.15	0.16	0.16	-2
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.15	0.16	0.17	7
G02CB03	cabergoline				
	Estonia	0.01	0.01	0.02	16
	Latvia	0.02	0.03	0.03	-1
	Lithuania	<0.01	<0.01	<0.01	
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM				
	Estonia	36.07	35.25	34.92	-1
	Latvia	21.60	20.95	20.34	-3
	Lithuania	16.93	16.56	15.78	-5
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE				
	Estonia	28.60	28.14	27.99	-1
	Latvia	11.94	12.28	11.82	-4
	Lithuania	12.80	12.71	11.94	-6

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03AA	Progestogens and estrogens, fixed combinations				
	Estonia	25.77	25.06	23.76	-5
	Latvia	10.41	10.49	10.20	-3
	Lithuania	10.82	10.64	10.60	
G03AA05	norethisterone and ethinylestradiol				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
G03AA07	levonorgestrel and ethinylestradiol				
	Estonia	-	0.03	0.10	231
	Latvia	0.51	0.54	0.59	9
	Lithuania	0.32	0.33	0.34	2
G03AA09	desogestrel and ethinylestradiol				
	Estonia	2.58	2.55	2.13	-16
	Latvia	1.53	1.53	1.46	-4
	Lithuania	1.92	1.65	1.54	-7
G03AA10	gestodene and ethinylestradiol				
	Estonia	7.62	7.81	7.57	-3
	Latvia	3.30	3.09	2.87	-7
	Lithuania	3.66	3.35	3.24	-3
G03AA11	norgestimate and ethinylestradiol				
	Estonia	0.06	-	-	
	Latvia	0.07	-	-	
	Lithuania	0.23	0.08	<0.01	
G03AA12	drosiprenone and ethinylestradiol				
	Estonia	10.06	9.38	8.92	-5
	Latvia	3.81	3.88	3.75	-3
	Lithuania	3.80	3.88	4.13	6
G03AA13	norelgestromin and ethinylestradiol				
	Estonia	2.13	2.02	1.91	-5
	Latvia	0.25	0.24	0.22	-9
	Lithuania	0.45	0.41	0.38	-8
G03AA14	nomegestrol and estradiol				
	Estonia	0.11	0.10	0.07	-31
	Latvia	0.31	0.25	0.21	-17
	Lithuania	-	0.30	0.26	-12
G03AA15	chlormadinone and ethinylestradiol				
	Estonia	0.81	0.85	0.77	-9
	Latvia	0.54	0.76	0.82	8
	Lithuania	0.44	0.64	0.72	11
G03AA16	dienogest and ethinylestradiol				
	Estonia	2.40	2.32	2.28	-2
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03AB	Progestogens and estrogens, sequential preparations				
	Estonia	0.70	0.64	0.55	-14
	Latvia	1.00	0.99	0.87	-12
	Lithuania	1.60	1.69	0.92	-46
G03AB03	levonorgestrel and ethinylestradiol				
	Estonia	0.54	0.47	0.40	-16
	Latvia	0.32	0.31	0.26	-16
	Lithuania	0.57	0.50	0.46	-8
G03AB05	desogestrel and ethinylestradiol				
	Estonia	0.05	0.05	0.03	-37
	Latvia	0.09	0.07	0.06	-16
	Lithuania	0.10	0.11	0.08	-23
G03AB06	gestodene and ethinylestradiol				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03AB07	chlormadinone and ethinylestradiol				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.45	0.64	-	
G03AB08	dienogest and estradiol				
	Estonia	0.11	0.12	0.12	2
	Latvia	-	-	-	
	Lithuania	0.48	0.44	0.38	-14
G03AC	Progestogens				
	Estonia	2.07	2.37	3.62	53
	Latvia	0.49	0.77	0.72	-6
	Lithuania	0.32	0.32	0.35	11
G03AC03	levonorgestrel				
	Estonia	-	-	-	
	Latvia	0.01	0.01	<0.01	
	Lithuania	-	-	-	
G03AC08	etonogestrel				
	Estonia	-	0.34	1.49	344
	Latvia	<0.01	0.15	0.09	-38
	Lithuania	-	-	-	
G03AC09	desogestrel				
	Estonia	2.07	2.04	2.14	5
	Latvia	0.48	0.62	0.63	2
	Lithuania	0.32	0.32	0.35	11
G03AD	Emergency contraceptives				
	Estonia	0.07	0.07	0.06	-7
	Latvia	0.04	0.04	0.04	-5
	Lithuania	0.06	0.06	0.06	3

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03AD01	levonorgestrel				
	Estonia	0.07	0.07	0.06	-7
	Latvia	0.04	0.04	0.04	-5
	Lithuania	0.06	0.06	0.06	3
G03AD02	ulipristal				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
G03B	ANDROGENS				
	Estonia	0.16	0.18	0.18	2
	Latvia	0.18	0.20	0.30	45
	Lithuania	0.07	0.08	0.09	13
G03BA	3-oxoandrogen (4) derivatives				
	Estonia	0.16	0.18	0.18	2
	Latvia	0.18	0.20	0.30	45
	Lithuania	0.07	0.08	0.09	13
G03BA03	testosterone				
	Estonia	0.16	0.18	0.18	2
	Latvia	0.18	0.20	0.30	45
	Lithuania	0.07	0.08	0.09	13
G03C	ESTROGENS				
	Estonia	1.76	1.76	1.68	-4
	Latvia	4.67	3.80	3.58	-6
	Lithuania	0.72	0.68	0.65	-4
G03CA	Natural and semisynthetic estrogens, plain				
	Estonia	1.61	1.60	1.52	-5
	Latvia	4.62	3.74	3.53	-6
	Lithuania	0.64	0.61	0.58	-5

Consumption of hormonal contraceptives (G02BB and G03A)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03CA03	estradiol				
	Estonia	1.20	1.21	1.15	-4
	Latvia	4.38	3.50	3.29	-6
	Lithuania	0.42	0.37	0.35	-5
G03CA04	estriol				
	Estonia	0.41	0.39	0.37	-5
	Latvia	0.20	0.20	0.19	-4
	Lithuania	0.23	0.24	0.23	-3
G03CA57	conjugated estrogens				
	Estonia	-	-	-	
	Latvia	0.04	0.04	0.04	-7
	Lithuania	-	-	-	
G03CX	Other estrogens				
	Estonia	0.15	0.16	0.16	
	Latvia	0.06	0.05	0.05	-8
	Lithuania	0.07	0.07	0.07	4
G03CX01	tibolone				
	Estonia	0.15	0.16	0.16	
	Latvia	0.06	0.05	0.05	-8
	Lithuania	0.07	0.07	0.07	4
G03D	PROGESTOGENS				
	Estonia	1.90	1.83	1.78	-3
	Latvia	1.44	1.50	1.56	4
	Lithuania	0.87	0.85	0.84	-2
G03DA	Pregnen (4) derivatives				
	Estonia	1.03	0.99	0.98	-1
	Latvia	0.62	0.71	0.76	7
	Lithuania	0.12	0.01	0.01	
G03DA02	medroxyprogesterone				
	Estonia	0.56	0.53	0.51	-3
	Latvia	0.22	0.18	0.18	-3
	Lithuania	-	-	-	
G03DA03	hydroxyprogesterone				
	Estonia	-	-	-	
	Latvia	0.05	0.06	0.07	8
	Lithuania	-	-	0.01	
G03DA04	progesterone				
	Estonia	0.48	0.46	0.47	2
	Latvia	0.35	0.47	0.52	10
	Lithuania	0.12	0.01	<0.01	
G03DB	Pregnadien derivatives				
	Estonia	0.87	0.84	0.80	-5
	Latvia	0.82	0.79	0.80	2
	Lithuania	0.75	0.84	0.83	-2

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03DB01	dydrogesterone				
	Estonia	0.81	0.75	0.69	-7
	Latvia	0.76	0.73	0.75	2
	Lithuania	0.73	0.80	0.76	-5
G03DB08	dienogest				
	Estonia	0.06	0.09	0.10	10
	Latvia	0.06	0.06	0.06	-2
	Lithuania	0.01	0.04	0.07	72
G03DC	Estren derivatives				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
G03DC02	norethisterone				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION				
	Estonia	2.20	2.13	2.09	-2
	Latvia	2.15	2.13	2.16	1
	Lithuania	1.28	1.31	1.38	6
G03FA	Progestogens and estrogens, fixed combinations				
	Estonia	1.68	1.64	1.60	-2
	Latvia	1.64	1.61	1.65	2
	Lithuania	0.99	1.03	1.09	6
G03FA01	norethisterone and estrogen				
	Estonia	1.30	1.24	1.17	-6
	Latvia	0.64	0.62	0.59	-5
	Lithuania	0.28	0.28	0.27	-3
G03FA11	levonorgestrel and estrogen				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
G03FA12	medroxyprogesterone and estrogen				
	Estonia	-	-	-	
	Latvia	0.01	0.01	<0.01	
	Lithuania	-	-	-	
G03FA13	norgestimate and estrogen				
	Estonia	-	-	-	
	Latvia	0.10	-	-	
	Lithuania	-	-	-	
G03FA14	dydrogesterone and estrogen				
	Estonia	0.09	0.10	0.13	21
	Latvia	0.16	0.23	0.30	32
	Lithuania	0.08	0.12	0.16	37

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03FA15	dienogest and estrogen				
	Estonia	-	-	-	
	Latvia	0.46	0.45	0.43	-3
	Lithuania	0.56	0.56	0.58	3
G03FA17	drosiprenone and estrogen				
	Estonia	0.28	0.30	0.31	5
	Latvia	0.27	0.31	0.32	2
	Lithuania	0.07	0.07	0.08	7
G03FB	Progestogens and estrogens, sequential preparations				
	Estonia	0.52	0.49	0.49	
	Latvia	0.51	0.52	0.51	-1
	Lithuania	0.29	0.28	0.30	5
G03FB05	norethisterone and estrogen				
	Estonia	0.46	0.42	0.41	-2
	Latvia	0.22	0.20	0.19	-3
	Lithuania	0.20	0.19	0.21	11
G03FB06	medroxyprogesterone and estrogen				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.04	0.04	0.02	-55
	Lithuania	-	-	-	
G03FB07	medrogestone and estrogen				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03FB08	dydrogesterone and estrogen				
	Estonia	0.06	0.07	0.07	7
	Latvia	0.10	0.14	0.17	23
	Lithuania	-	-	-	
G03FB09	levonorgestrel and estrogen				
	Estonia	-	-	-	
	Latvia	0.15	0.14	0.13	-5
	Lithuania	0.09	0.10	0.09	-8
G03G	GONADOTROPINS AND OTHER OVULATION STIMULANTS				
	Estonia	0.42	0.42	0.45	7
	Latvia	0.27	0.36	0.35	-3
	Lithuania	0.20	0.22	0.27	21
G03GA	Gonadotropins				
	Estonia	0.14	0.13	0.14	8
	Latvia	0.13	0.16	0.17	5
	Lithuania	0.10	0.11	0.15	35
G03GA01	chorionic gonadotrophin				
	Estonia	0.03	0.02	0.03	58
	Latvia	0.08	0.09	0.10	9
	Lithuania	0.09	0.10	0.12	21

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03GA02	human menopausal gonadotrophin				
	Estonia	<0.01	0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03GA04	urofollitropin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03GA05	follitropin alfa				
	Estonia	0.08	0.08	0.09	21
	Latvia	0.04	0.05	0.05	1
	Lithuania	0.01	0.01	0.01	100
G03GA06	follitropin beta				
	Estonia	0.01	0.01	0.01	-41
	Latvia	0.01	0.01	0.01	1
	Lithuania	<0.01	<0.01	0.01	
G03GA07	lutropin alfa				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
G03GA08	choriogonadotropin alfa				
	Estonia	0.01	0.01	0.01	10
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
G03GA09	corifollitropin alfa				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03GB	Ovulation stimulants, synthetic				
	Estonia	0.29	0.29	0.31	7
	Latvia	0.13	0.20	0.17	-11
	Lithuania	0.10	0.12	0.12	7
G03GB02	clomifene				
	Estonia	0.29	0.29	0.31	7
	Latvia	0.13	0.20	0.17	-11
	Lithuania	0.10	0.12	0.12	7
G03H	ANTIANDROGENS				
	Estonia	1.01	0.77	0.69	-10
	Latvia	0.94	0.66	0.56	-15
	Lithuania	1.00	0.71	0.62	-12
G03HA	Antiandrogens, plain				
	Estonia	0.29	0.21	0.22	2
	Latvia	0.12	0.12	0.10	-19
	Lithuania	0.05	0.05	0.03	-44

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G03HA01	cypoterone				
	Estonia	0.29	0.21	0.22	2
	Latvia	0.12	0.12	0.10	-19
	Lithuania	0.05	0.05	0.03	-44
G03HB	Antiandrogens and estrogens				
	Estonia	0.72	0.55	0.47	-15
	Latvia	0.82	0.54	0.46	-15
	Lithuania	0.95	0.66	0.59	-10
G03HB01	cypoterone and estrogen				
	Estonia	0.72	0.55	0.47	-15
	Latvia	0.82	0.54	0.46	-15
	Lithuania	0.95	0.66	0.59	-10
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM				
	Estonia	0.02	0.04	0.06	63
	Latvia	0.01	0.02	0.02	17
	Lithuania	-	-	-	
G03XA	Antigonadotropins and similar agents				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03XA01	danazol				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03XB	Progesterone receptor modulators				
	Estonia	0.02	0.04	0.06	65
	Latvia	0.01	0.01	0.02	14
	Lithuania	-	-	-	
G03XB01	mifepristone				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G03XB02	ulipristal				
	Estonia	0.01	0.04	0.06	69
	Latvia	0.01	0.01	0.02	14
	Lithuania	-	-	-	
G04	UROLOGICALS				
	Estonia	10.14	11.59	12.71	10
	Latvia	7.63	8.30	8.90	7
	Lithuania	10.67	11.75	12.30	5
G04B	UROLOGICALS				
	Estonia	1.75	2.04	2.21	8
	Latvia	0.88	1.03	1.12	9
	Lithuania	2.22	2.54	2.63	4

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G04BD	Drugs for urinary frequency and incontinence				
	Estonia	0.97	1.09	1.17	7
	Latvia	0.48	0.53	0.59	10
	Lithuania	1.51	1.71	1.69	-1
G04BD02	flavoxate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.03	0.04	0.05	24
G04BD04	oxybutynin				
	Estonia	0.68	0.72	0.71	
	Latvia	0.31	0.28	0.28	-2
	Lithuania	0.36	0.35	0.32	-7
G04BD06	propiverine				
	Estonia	<0.01	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
G04BD07	tolterodine				
	Estonia	0.13	0.20	0.27	33
	Latvia	0.07	0.06	0.07	11
	Lithuania	1.04	1.18	1.11	-6
G04BD08	solifenacin				
	Estonia	-	-	<0.01	
	Latvia	0.10	0.19	0.24	26
	Lithuania	0.09	0.15	0.22	44
G04BD09	trospium				
	Estonia	0.16	0.17	0.18	6
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
G04BD12	mirabegron				
	Estonia	-	-	<0.01	
	Latvia	-	-	<0.01	
	Lithuania	-	-	<0.01	
G04BE	Drugs used in erectile dysfunction				
	Estonia	0.78	0.94	1.03	10
	Latvia	0.40	0.49	0.53	9
	Lithuania	0.71	0.82	0.93	13
G04BE01	alprostadil				
	Estonia	0.01	0.01	0.02	36
	Latvia	0.01	0.01	0.01	45
	Lithuania	<0.01	<0.01	<0.01	
G04BE03	sildenafil				
	Estonia	0.62	0.73	0.79	8
	Latvia	0.30	0.39	0.43	10
	Lithuania	0.60	0.68	0.73	8

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G04BE08	tadalafil				
	Estonia	0.11	0.15	0.16	8
	Latvia	0.04	0.04	0.04	-7
	Lithuania	0.08	0.11	0.13	20
G04BE09	vardenafil				
	Estonia	0.04	0.03	0.03	-11
	Latvia	0.05	0.04	0.04	-8
	Lithuania	0.03	0.02	0.02	-9
G04BE10	avanafil				
	Estonia	-	0.01	0.03	152
	Latvia	-	0.01	0.02	110
	Lithuania	-	0.01	0.05	229
G04BX	Other urologicals				
	Estonia	<0.01	0.01	0.01	40
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	43
G04BX14	dapoxetine				
	Estonia	<0.01	0.01	0.01	40
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	43
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY				
	Estonia	8.38	9.55	10.50	10
	Latvia	6.75	7.28	7.78	7
	Lithuania	8.45	9.21	9.67	5
G04CA	Alpha-adrenoreceptor antagonists				
	Estonia	7.96	9.11	10.03	10
	Latvia	5.34	5.88	6.42	9
	Lithuania	5.69	6.39	7.04	10
G04CA01	alfuzosin				
	Estonia	1.65	1.73	1.89	9
	Latvia	0.15	0.13	0.11	-12
	Lithuania	0.12	0.13	0.11	-15
G04CA02	tamsulosin				
	Estonia	4.59	5.26	5.79	10
	Latvia	2.97	3.26	3.69	13
	Lithuania	4.35	4.84	5.46	13
G04CA03	terazosin				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
G04CA52	tamsulosin and dutasteride				
	Estonia	1.72	2.12	2.36	11
	Latvia	2.22	2.49	2.62	5
	Lithuania	1.22	1.42	1.47	4

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
G04CB	Testosterone-5-alpha reductase inhibitors				
	Estonia	0.43	0.44	0.47	6
	Latvia	1.41	1.40	1.36	-3
	Lithuania	2.76	2.83	2.63	-7
G04CB01	finasteride				
	Estonia	0.16	0.15	0.15	
	Latvia	0.82	0.88	0.90	3
	Lithuania	1.68	1.82	1.73	-5
G04CB02	dutasteride				
	Estonia	0.27	0.29	0.32	8
	Latvia	0.59	0.52	0.46	-13
	Lithuania	1.08	1.01	0.90	-11


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
H	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS				
	Estonia	23.81	25.29	26.33	4
	Latvia	22.88	24.01	24.44	2
	Lithuania	23.00	25.19	26.43	5
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES				
	Estonia	0.34	0.38	0.39	2
	Latvia	0.47	0.48	0.46	-4
	Lithuania	0.32	0.35	0.38	10
H01A	ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES				
	Estonia	0.09	0.10	0.10	-4
	Latvia	0.22	0.22	0.19	-13
	Lithuania	0.14	0.16	0.18	13
H01AA	ACTH				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01AA02	tetracosactide				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01AB	Thyrotropin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01AB01	thyrotropin alfa				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01AC	Somatropin and somatropin agonists				
	Estonia	0.09	0.10	0.10	-4
	Latvia	0.22	0.22	0.19	-13
	Lithuania	0.14	0.16	0.18	13
H01AC01	somatropin				
	Estonia	0.09	0.10	0.10	-4
	Latvia	0.22	0.22	0.19	-13
	Lithuania	0.14	0.16	0.18	13
H01AC03	mecasermin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
H01B	POSTERIOR PITUITARY LOBE HORMONES				
	Estonia	0.18	0.19	0.19	1
	Latvia	0.18	0.19	0.18	-2
	Lithuania	0.14	0.15	0.14	-1
H01BA	Vasopressin and analogues				
	Estonia	0.08	0.09	0.10	5
	Latvia	0.06	0.07	0.07	3
	Lithuania	0.10	0.11	0.11	-1
H01BA01	vasopressin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
H01BA02	desmopressin				
	Estonia	0.08	0.09	0.10	1
	Latvia	0.06	0.07	0.07	3
	Lithuania	0.10	0.11	0.11	-1
H01BB	Oxytocin and analogues				
	Estonia	0.10	0.10	0.09	-4
	Latvia	0.12	0.11	0.11	-5
	Lithuania	0.04	0.04	0.04	-3
H01BB01	demoxytocin				
	Estonia	0.08	0.07	0.06	-10
	Latvia	0.08	0.07	0.06	-9
	Lithuania	-	-	-	
H01BB02	oxytocin				
	Estonia	0.03	0.03	0.03	15
	Latvia	0.04	0.04	0.04	1
	Lithuania	0.04	0.04	0.04	-3
H01C	HYPOTHALAMIC HORMONES				
	Estonia	0.07	0.09	0.10	12
	Latvia	0.07	0.07	0.08	22
	Lithuania	0.04	0.05	0.06	33
H01CA	Gonadotropin-releasing hormones				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01CA02	nafarelin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01CB	Somatostatin and analogues				
	Estonia	0.06	0.07	0.08	12
	Latvia	0.06	0.06	0.08	23
	Lithuania	0.04	0.05	0.06	31

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
H01CB02	octreotide				
	Estonia	0.04	0.05	0.04	-10
	Latvia	0.03	0.03	0.04	22
	Lithuania	0.04	0.04	0.05	15
H01CB03	lanreotide				
	Estonia	0.02	0.02	0.04	61
	Latvia	0.03	0.03	0.04	23
	Lithuania	-	0.01	0.01	160
H01CB05	pasireotide				
	Estonia	-	<0.01	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
H01CC	Anti-gonadotropin-releasing hormones				
	Estonia	0.01	0.01	0.01	13
	Latvia	0.01	0.01	0.01	15
	Lithuania	<0.01	<0.01	<0.01	
H01CC01	ganirelix				
	Estonia	0.01	0.01	0.01	16
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H01CC02	cetrorelix				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
H02	CORTICOSTEROIDS FOR SYSTEMIC USE				
	Estonia	7.41	7.76	7.90	2
	Latvia	8.71	8.73	8.80	1
	Lithuania	8.64	9.31	9.69	4
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN				
	Estonia	7.40	7.75	7.90	2
	Latvia	8.71	8.73	8.80	1
	Lithuania	8.64	9.31	9.69	4
H02AA	Mineralocorticoids				
	Estonia	0.12	0.14	0.14	1
	Latvia	0.07	0.07	0.07	
	Lithuania	0.06	0.07	0.07	6
H02AA02	fludrocortisone				
	Estonia	0.12	0.14	0.14	1
	Latvia	0.07	0.07	0.07	
	Lithuania	0.06	0.07	0.07	6
H02AB	Glucocorticoids				
	Estonia	7.28	7.61	7.76	2
	Latvia	8.64	8.66	8.74	1
	Lithuania	8.58	9.24	9.62	4

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
H02AB01	betamethasone				
	Estonia	0.03	0.02	0.02	-9
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H02AB02	dexamethasone				
	Estonia	1.26	1.24	1.30	5
	Latvia	3.82	3.70	3.85	4
	Lithuania	4.03	4.52	4.95	9
H02AB04	methylprednisolone				
	Estonia	2.28	2.43	2.54	5
	Latvia	2.38	2.48	2.51	1
	Lithuania	2.50	2.61	2.63	1
H02AB06	prednisolone				
	Estonia	3.14	3.27	3.26	
	Latvia	1.81	1.85	1.74	-6
	Lithuania	1.74	1.77	1.70	-4
H02AB07	prednisone				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
H02AB08	triamcinolone				
	Estonia	0.36	0.40	0.41	2
	Latvia	0.35	0.36	0.38	6
	Lithuania	0.25	0.29	0.29	1
H02AB09	hydrocortisone				
	Estonia	0.21	0.23	0.22	-3
	Latvia	0.28	0.27	0.26	-5
	Lithuania	0.05	0.06	0.06	-4
H02AB10	cortisone				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
H02AB13	deflazacort				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H02B	CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS				
	Estonia	0.01	0.01	0.01	-45
	Latvia	-	-	-	
	Lithuania	-	-	-	
H02BX	Corticosteroids for systemic use, combinations				
	Estonia	0.01	0.01	0.01	-45
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
H03	THYROID THERAPY				
	Estonia	16.04	17.13	18.01	5
	Latvia	13.66	14.76	15.13	3
	Lithuania	14.03	15.53	16.34	5
H03A	THYROID PREPARATIONS				
	Estonia	14.71	15.76	16.59	5
	Latvia	11.87	12.89	13.19	2
	Lithuania	12.58	14.07	14.80	5
H03AA	Thyroid hormones				
	Estonia	14.71	15.76	16.59	5
	Latvia	11.87	12.89	13.19	2
	Lithuania	12.58	14.07	14.80	5
H03AA01	levothyroxine sodium				
	Estonia	14.71	15.75	16.59	5
	Latvia	11.87	12.89	13.19	2
	Lithuania	12.58	14.07	14.80	5
H03AA02	liothyronine sodium				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H03B	ANTITHYROID PREPARATIONS				
	Estonia	1.33	1.37	1.42	3
	Latvia	1.79	1.87	1.94	4
	Lithuania	1.45	1.46	1.54	6
H03BA	Thiouracils				
	Estonia	0.69	0.71	0.68	-4
	Latvia	0.01	0.01	0.01	18
	Lithuania	-	-	-	
H03BA02	propylthiouracil				
	Estonia	0.69	0.71	0.68	-4
	Latvia	0.01	0.01	0.01	18
	Lithuania	-	-	-	
H03BB	Sulfur-containing imidazole derivatives				
	Estonia	0.64	0.67	0.74	11
	Latvia	1.78	1.86	1.93	4
	Lithuania	1.45	1.46	1.54	6
H03BB01	carbimazole				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
H03BB02	thiamazole				
	Estonia	0.64	0.67	0.74	11
	Latvia	1.78	1.86	1.93	4
	Lithuania	1.45	1.46	1.54	6



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
H04	PANCREATIC HORMONES				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
H04A	GLYCOGENOLYTIC HORMONES				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
H04AA	Glycogenolytic hormones				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
H04AA01	glucagon				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
H05	CALCIUM HOMEOSTASIS				
	Estonia	0.03	0.02	0.03	11
	Latvia	0.04	0.04	0.05	27
	Lithuania	0.01	<0.01	0.01	
H05A	PARATHYROID HORMONES AND ANALOGUES				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
H05AA	Parathyroid hormones and analogues				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
H05AA02	teriparatide				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
H05B	ANTI-PARATHYROID AGENTS				
	Estonia	0.03	0.02	0.03	11
	Latvia	0.04	0.04	0.05	27
	Lithuania	0.01	-	-	
H05BA	Calcitonin preparations				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
H05BA01	calcitonin (salmon synthetic)				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
H05BX	Other anti-parathyroid agents				
	Estonia	0.03	0.02	0.03	11
	Latvia	0.04	0.04	0.05	27
	Lithuania	0.01	-	-	
H05BX01	cinacalcet				
	Estonia	0.02	0.02	0.02	6
	Latvia	0.02	0.02	0.02	19
	Lithuania	0.01	-	-	
H05BX02	paricalcitol				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.02	0.02	0.03	34
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J	ANTIINFECTIVES FOR SYSTEMIC USE				
	Estonia	18.49	18.71	19.40	4
	Latvia	17.92	17.23	18.43	7
	Lithuania	23.32	20.35	21.47	6
J01	ANTIBACTERIALS FOR SYSTEMIC USE				
	Estonia	13.84	13.81	14.04	2
	Latvia	16.16	15.15	15.91	5
	Lithuania	21.81	19.09	19.86	4
J01A	TETRACYCLINES				
	Estonia	1.72	1.55	1.53	-1
	Latvia	2.50	2.35	2.32	-1
	Lithuania	1.63	1.46	1.41	-4
J01AA	Tetracyclines				
	Estonia	1.72	1.55	1.53	-1
	Latvia	2.50	2.35	2.32	-1
	Lithuania	1.63	1.46	1.41	-4
J01AA02	doxycycline				
	Estonia	1.64	1.51	1.53	2
	Latvia	2.49	2.35	2.32	-1
	Lithuania	1.63	1.46	1.41	-4
J01AA04	lymecycline				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
J01AA07	tetracycline				
	Estonia	0.08	0.05	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01AA08	minocycline				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01AA12	tigecycline				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01B	AMPHENICOLS				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01BA	Amphenicols				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01BA01	chloramphenicol				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS				
	Estonia	5.19	5.34	5.55	4
	Latvia	7.24	6.72	7.18	7
	Lithuania	11.97	10.16	10.87	7
J01CA	Penicillins with extended spectrum				
	Estonia	2.63	2.66	2.65	
	Latvia	5.01	4.53	4.79	6
	Lithuania	9.14	7.72	8.18	6
J01CA01	ampicillin				
	Estonia	0.04	0.04	0.04	-13
	Latvia	0.21	0.18	0.17	-6
	Lithuania	0.42	0.39	0.36	-7
J01CA04	amoxicillin				
	Estonia	2.59	2.62	2.61	
	Latvia	4.80	4.36	4.62	6
	Lithuania	8.72	7.33	7.82	7
J01CE	Beta-lactamase sensitive penicillins				
	Estonia	0.24	0.22	0.16	-26
	Latvia	0.06	0.08	0.08	-2
	Lithuania	0.42	0.37	0.32	-14
J01CE01	benzylpenicillin				
	Estonia	0.03	0.02	0.02	-14
	Latvia	0.02	0.01	0.01	-1
	Lithuania	0.25	0.20	0.18	-11
J01CE02	phenoxymethylpenicillin				
	Estonia	0.21	0.20	0.14	-28
	Latvia	0.04	0.07	0.07	-1
	Lithuania	0.18	0.17	0.14	-18
J01CE08	benzathine benzylpenicillin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01CE30	combinations				
	Estonia	-	<0.01	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01CF	Beta-lactamase resistant penicillins				
	Estonia	0.15	0.13	0.12	-6
	Latvia	0.02	0.01	0.03	182
	Lithuania	-	-	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01CF04	oxacillin				
	Estonia	0.14	0.13	0.12	-7
	Latvia	0.02	0.01	0.03	179
	Lithuania	-	-	<0.01	
J01CF05	flucloxacillin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors				
	Estonia	2.18	2.33	2.61	12
	Latvia	2.15	2.10	2.28	9
	Lithuania	2.41	2.07	2.37	14
J01CR01	ampicillin and enzyme inhibitor				
	Estonia	0.18	0.19	0.19	-1
	Latvia	0.06	0.02	-	
	Lithuania	-	-	-	
J01CR02	amoxicillin and enzyme inhibitor				
	Estonia	1.88	2.02	2.29	13
	Latvia	2.08	2.06	2.26	10
	Lithuania	2.26	1.94	2.23	15
J01CR04	sultamicillin				
	Estonia	0.10	0.10	0.11	15
	Latvia	-	-	-	
	Lithuania	0.13	0.11	0.12	5
J01CR05	piperacillin and enzyme inhibitor				
	Estonia	0.02	0.02	0.03	27
	Latvia	0.01	0.02	0.02	-1
	Lithuania	0.01	0.02	0.02	6
J01D	OTHER BETA-LACTAM ANTIBACTERIALS				
	Estonia	1.66	1.70	1.79	5
	Latvia	1.19	1.15	1.20	4
	Lithuania	1.82	1.71	1.91	12
J01DB	First-generation cephalosporins				
	Estonia	0.31	0.32	0.29	-9
	Latvia	0.38	0.35	0.35	1
	Lithuania	0.50	0.47	0.48	2
J01DB01	cefalexin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01DB04	cefazolin				
	Estonia	0.07	0.07	0.07	-4
	Latvia	0.18	0.18	0.18	1
	Lithuania	0.24	0.23	0.23	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01DB05	cefadroxil				
	Estonia	0.24	0.25	0.22	-10
	Latvia	0.20	0.17	0.17	
	Lithuania	0.25	0.25	0.25	3
J01DC	Second-generation cephalosporins				
	Estonia	1.23	1.26	1.36	8
	Latvia	0.32	0.33	0.34	6
	Lithuania	1.13	1.04	1.22	17
J01DC01	cefoxitin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J01DC02	cefuroxime				
	Estonia	1.13	1.17	1.28	9
	Latvia	0.32	0.32	0.34	5
	Lithuania	1.13	1.04	1.20	16
J01DC10	cefprozil				
	Estonia	0.10	0.09	0.08	-9
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	0.01	0.02	143
J01DD	Third-generation cephalosporins				
	Estonia	0.06	0.06	0.06	9
	Latvia	0.46	0.45	0.47	4
	Lithuania	0.17	0.16	0.17	9
J01DD01	cefotaxime				
	Estonia	0.03	0.03	0.03	2
	Latvia	0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J01DD02	ceftazidime				
	Estonia	0.02	0.02	0.02	24
	Latvia	0.01	0.01	0.01	5
	Lithuania	0.01	0.01	0.01	13
J01DD04	ceftriaxone				
	Estonia	0.01	0.02	0.02	3
	Latvia	0.45	0.44	0.45	3
	Lithuania	0.15	0.15	0.16	8
J01DD08	cefixime				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
J01DD12	cefoperazone				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01DD62	cefoperazone, combinations				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
J01DE	Fourth-generation cephalosporins				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J01DE01	cefepime				
	Estonia	0.02	0.02	0.02	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J01DF	Monobactams				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
J01DF01	aztreonam				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
J01DH	Carbapenems				
	Estonia	0.03	0.04	0.05	16
	Latvia	0.02	0.03	0.03	21
	Lithuania	0.03	0.03	0.04	38
J01DH02	meropenem				
	Estonia	0.01	0.01	0.02	89
	Latvia	0.01	0.02	0.02	14
	Lithuania	0.02	0.02	0.03	48
J01DH03	ertapenem				
	Estonia	0.02	0.02	0.02	-14
	Latvia	<0.01	-	-	
	Lithuania	<0.01	<0.01	-	
J01DH51	imipenem and enzyme inhibitor				
	Estonia	0.01	0.02	0.02	5
	Latvia	0.01	0.01	0.01	37
	Lithuania	0.01	0.01	0.01	18
J01E	SULFONAMIDES AND TRIMETHOPRIM				
	Estonia	0.53	0.51	0.48	-6
	Latvia	1.06	0.93	0.92	-1
	Lithuania	0.42	0.39	0.34	-13
J01EA	Trimethoprim and derivatives				
	Estonia	0.03	0.03	0.03	
	Latvia	0.01	0.01	0.01	-19
	Lithuania	0.01	0.01	0.01	-9

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01EA01	trimethoprim				
	Estonia	0.03	0.03	0.03	
	Latvia	0.01	0.01	0.01	-19
	Lithuania	0.01	0.01	0.01	-9
J01EC	Intermediate-acting sulfonamides				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01EC02	sulfadiazine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives				
	Estonia	0.50	0.48	0.45	-6
	Latvia	1.05	0.92	0.91	-1
	Lithuania	0.42	0.38	0.33	-13
J01EE01	sulfamethoxazole and trimethoprim				
	Estonia	0.50	0.48	0.45	-6
	Latvia	1.02	0.90	0.90	1
	Lithuania	0.42	0.38	0.33	-13
J01EE03	sulfametrole and trimethoprim				
	Estonia	-	-	-	
	Latvia	0.04	0.02	0.01	-50
	Lithuania	-	-	-	
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS				
	Estonia	2.65	2.59	2.62	1
	Latvia	2.15	1.95	2.30	18
	Lithuania	2.75	2.20	2.07	-6
J01FA	Macrolides				
	Estonia	2.45	2.38	2.41	1
	Latvia	2.01	1.81	2.15	19
	Lithuania	2.71	2.17	2.04	-6
J01FA01	erythromycin				
	Estonia	<0.01	<0.01	-	
	Latvia	0.06	0.04	0.03	-6
	Lithuania	0.05	0.04	0.03	-13
J01FA02	spiramycin				
	Estonia	0.01	0.01	0.01	-21
	Latvia	0.04	0.03	0.02	-19
	Lithuania	0.04	0.03	0.02	-20
J01FA06	roxithromycin				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01FA07	josamycin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01FA09	clarithromycin				
	Estonia	1.86	1.82	1.82	
	Latvia	1.37	1.25	1.56	25
	Lithuania	2.03	1.51	1.48	-2
J01FA10	azithromycin				
	Estonia	0.59	0.56	0.58	3
	Latvia	0.54	0.49	0.54	10
	Lithuania	0.60	0.59	0.51	-14
J01FF	Lincosamides				
	Estonia	0.20	0.21	0.21	2
	Latvia	0.14	0.15	0.15	2
	Lithuania	0.03	0.03	0.03	10
J01FF01	clindamycin				
	Estonia	0.20	0.21	0.21	2
	Latvia	0.13	0.13	0.13	3
	Lithuania	0.01	0.01	0.01	29
J01FF02	lincomycin				
	Estonia	-	-	-	
	Latvia	0.01	0.02	0.01	-6
	Lithuania	0.03	0.02	0.03	4
J01FG	Streptogramins				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
J01FG01	pristinamycin				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
J01G	AMINOGLYCOSIDE ANTIBACTERIALS				
	Estonia	0.06	0.07	0.04	-39
	Latvia	0.10	0.09	0.09	-4
	Lithuania	0.27	0.19	0.20	5
J01GA	Streptomycins				
	Estonia	-	0.02	-	
	Latvia	<0.01	-	-	
	Lithuania	0.01	<0.01	<0.01	
J01GA01	streptomycin				
	Estonia	-	0.02	-	
	Latvia	<0.01	-	-	
	Lithuania	0.01	<0.01	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01GB	Other aminoglycosides				
	Estonia	0.06	0.05	0.04	-11
	Latvia	0.10	0.09	0.09	-4
	Lithuania	0.26	0.18	0.19	7
J01GB01	tobramycin				
	Estonia	0.01	0.01	<0.01	
	Latvia	<0.01	0.01	0.01	-9
	Lithuania	-	<0.01	0.01	
J01GB03	gentamicin				
	Estonia	0.04	0.03	0.03	-16
	Latvia	0.09	0.08	0.07	-3
	Lithuania	0.23	0.16	0.17	3
J01GB04	kanamycin				
	Estonia	0.01	-	<0.01	
	Latvia	0.01	-	-	
	Lithuania	0.01	-	-	
J01GB06	amikacin				
	Estonia	0.01	0.01	0.01	-14
	Latvia	0.01	0.01	0.01	-6
	Lithuania	0.03	0.02	0.02	31
J01M	QUINOLONE ANTIBACTERIALS				
	Estonia	1.11	1.12	1.11	
	Latvia	1.47	1.44	1.39	-4
	Lithuania	1.18	1.14	1.25	10
J01MA	Fluoroquinolones				
	Estonia	1.11	1.12	1.11	
	Latvia	1.43	1.41	1.36	-3
	Lithuania	1.12	1.09	1.21	11
J01MA01	ofloxacin				
	Estonia	0.03	0.03	0.02	-24
	Latvia	0.13	0.11	0.11	-6
	Lithuania	0.19	0.16	0.16	1
J01MA02	ciprofloxacin				
	Estonia	0.72	0.76	0.82	9
	Latvia	1.04	1.02	0.99	-3
	Lithuania	0.70	0.68	0.68	-1
J01MA03	pefloxacin				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
J01MA06	norfloxacin				
	Estonia	0.27	0.25	0.23	-7
	Latvia	0.19	0.19	0.19	-4
	Lithuania	0.21	0.19	0.17	-10

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01MA12	levofloxacin				
	Estonia	0.09	0.01	0.03	115
	Latvia	0.04	0.05	0.06	17
	Lithuania	0.01	0.05	0.18	245
J01MA14	moxifloxacin				
	Estonia	<0.01	0.07	0.01	-91
	Latvia	0.04	0.03	0.02	-32
	Lithuania	0.02	0.01	0.03	133
J01MB	Other quinolones				
	Estonia	-	-	-	
	Latvia	0.04	0.03	0.03	-6
	Lithuania	0.05	0.04	0.04	-9
J01MB04	pipemidic acid				
	Estonia	-	-	-	
	Latvia	0.04	0.03	0.03	-6
	Lithuania	0.05	0.04	0.04	-9
J01X	OTHER ANTIBACTERIALS				
	Estonia	0.92	0.93	0.92	-1
	Latvia	0.45	0.50	0.50	1
	Lithuania	1.78	1.86	1.82	-2
J01XA	Glycopeptide antibacterials				
	Estonia	0.01	0.02	0.02	7
	Latvia	0.02	0.02	0.02	-4
	Lithuania	0.02	0.02	0.03	33
J01XA01	vancomycin				
	Estonia	0.01	0.02	0.02	7
	Latvia	0.02	0.02	0.02	-4
	Lithuania	0.02	0.02	0.03	33
J01XB	Polymyxins				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
J01XB01	colistin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
J01XC	Steroid antibacterials				
	Estonia	-	<0.01	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J01XC01	fusidic acid				
	Estonia	-	<0.01	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J01XD	Imidazole derivatives				
	Estonia	0.35	0.34	0.31	-8
	Latvia	0.15	0.15	0.15	
	Lithuania	0.29	0.30	0.26	-15
J01XD01	metronidazole				
	Estonia	0.35	0.34	0.31	-8
	Latvia	0.15	0.15	0.15	
	Lithuania	0.29	0.30	0.26	-15
J01XE	Nitrofurantoin				
	Estonia	0.56	0.56	0.58	3
	Latvia	0.24	0.28	0.29	2
	Lithuania	1.43	1.51	1.51	
J01XE01	nitrofurantoin				
	Estonia	0.56	0.56	0.58	3
	Latvia	0.24	0.28	0.29	2
	Lithuania	1.43	1.51	1.51	
J01XX	Other antibacterials				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.04	0.04	0.04	-10
	Lithuania	0.04	0.03	0.03	-9
J01XX01	fosfomicin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J01XX04	spectinomycin				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
J01XX07	nitroxoline				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.04	0.04	0.03	-10
	Lithuania	0.04	0.03	0.03	-13
J01XX08	linezolid				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	0.01	0.01	-13
	Lithuania	<0.01	<0.01	<0.01	
J02	ANTIMYCOTICS FOR SYSTEMIC USE				
	Estonia	0.39	0.33	0.34	5
	Latvia	0.35	0.31	0.32	2
	Lithuania	0.26	0.20	0.22	7
J02A	ANTIMYCOTICS FOR SYSTEMIC USE				
	Estonia	0.39	0.33	0.34	5
	Latvia	0.35	0.31	0.32	2
	Lithuania	0.26	0.20	0.22	7

Consumption of antibacterials for systemic use (J01)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J02AA	Antibiotics				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J02AA01	amphotericin B				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J02AB	Imidazole derivatives				
	Estonia	0.09	<0.01	<0.01	
	Latvia	0.08	-	-	
	Lithuania	0.07	-	-	
J02AB02	ketoconazole				
	Estonia	0.09	<0.01	<0.01	
	Latvia	0.08	-	-	
	Lithuania	0.07	-	-	
J02AC	Triazole derivatives				
	Estonia	0.30	0.32	0.33	3
	Latvia	0.27	0.31	0.32	2
	Lithuania	0.19	0.20	0.22	7
J02AC01	fluconazole				
	Estonia	0.15	0.15	0.16	5
	Latvia	0.15	0.17	0.17	-2
	Lithuania	0.13	0.14	0.15	6

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J02AC02	itraconazole				
	Estonia	0.14	0.16	0.16	1
	Latvia	0.12	0.13	0.14	6
	Lithuania	0.05	0.06	0.07	8
J02AC03	voriconazole				
	Estonia	0.01	0.01	0.01	36
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J02AC04	posaconazole				
	Estonia	<0.01	0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J02AX	Other antimycotics for systemic use				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J02AX01	flucytosine				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
J02AX04	caspofungin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J02AX05	micafungin				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	<0.01	
J02AX06	anidulafungin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04	ANTIMYCOBACTERIALS				
	Estonia	0.50	0.28	0.34	21
	Latvia	0.27	0.37	0.44	20
	Lithuania	0.79	0.72	0.73	2
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS				
	Estonia	0.48	0.26	0.32	21
	Latvia	0.27	0.37	0.44	20
	Lithuania	0.79	0.72	0.73	2
J04AA	Aminosalicic acid and derivatives				
	Estonia	0.03	0.01	-	
	Latvia	-	-	0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J04AA01	4-aminosalicylic acid				
	Estonia	0.02	0.01	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AA02	sodium aminosalicylate				
	Estonia	0.01	-	-	
	Latvia	-	-	0.01	
	Lithuania	-	-	-	
J04AB	Antibiotics				
	Estonia	0.06	0.07	0.05	-27
	Latvia	0.16	0.20	0.16	-22
	Lithuania	0.24	0.20	0.19	-5
J04AB01	cycloserine				
	Estonia	0.03	0.04	0.01	-62
	Latvia	-	-	-	
	Lithuania	-	-	-	
J04AB02	rifampicin				
	Estonia	<0.01	0.02	0.02	-17
	Latvia	0.15	0.19	0.14	-28
	Lithuania	0.24	0.20	0.19	-5
J04AB04	rifabutin				
	Estonia	-	0.01	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
J04AB30	capreomycin				
	Estonia	0.02	-	0.02	
	Latvia	0.01	0.01	0.01	76
	Lithuania	-	-	-	
J04AC	Hydrazides				
	Estonia	<0.01	0.06	0.04	-21
	Latvia	0.11	0.17	0.03	-85
	Lithuania	-	-	-	
J04AC01	isoniazid				
	Estonia	<0.01	0.06	0.04	-21
	Latvia	0.11	0.17	0.03	-85
	Lithuania	-	-	-	
J04AD	Thiocarbamide derivatives				
	Estonia	0.06	-	0.03	
	Latvia	-	-	0.03	
	Lithuania	0.04	0.04	0.05	33
J04AD01	protonamide				
	Estonia	0.06	-	0.03	
	Latvia	-	-	0.03	
	Lithuania	0.04	0.04	0.05	33

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J04AK	Other drugs for treatment of tuberculosis				
	Estonia	0.17	0.12	0.11	-8
	Latvia	<0.01	<0.01	0.22	
	Lithuania	0.47	0.43	0.44	2
J04AK01	pyrazinamide				
	Estonia	0.06	0.06	0.05	-22
	Latvia	-	-	0.09	
	Lithuania	0.24	0.22	0.25	9
J04AK02	ethambutol				
	Estonia	0.10	0.05	0.05	
	Latvia	<0.01	<0.01	0.13	
	Lithuania	0.23	0.21	0.19	-6
J04AK05	bedaquiline				
	Estonia	<0.01	<0.01	0.01	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
J04AM	Combinations of drugs for treatment of tuberculosis				
	Estonia	0.16	0.01	0.09	593
	Latvia	-	-	-	
	Lithuania	0.04	0.06	0.06	
J04AM02	rifampicin and isoniazid				
	Estonia	0.16	0.01	0.09	593
	Latvia	-	-	-	
	Lithuania	0.04	0.06	0.06	
J04B	DRUGS FOR TREATMENT OF LEPROSY				
	Estonia	0.02	0.01	0.02	17
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J04BA	Drugs for treatment of leprosy				
	Estonia	0.02	0.01	0.02	17
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J04BA02	dapsone				
	Estonia	0.02	0.01	0.02	17
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05	ANTIVIRALS FOR SYSTEMIC USE				
	Estonia	3.75	4.29	4.67	9
	Latvia	1.14	1.40	1.77	26
	Lithuania	0.46	0.33	0.66	98
J05A	DIRECT ACTING ANTIVIRALS				
	Estonia	3.75	4.29	4.67	9
	Latvia	1.14	1.40	1.77	26
	Lithuania	0.46	0.33	0.66	98

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors				
	Estonia	0.30	0.32	0.34	5
	Latvia	0.27	0.29	0.25	-13
	Lithuania	0.13	0.14	0.19	36
J05AB01	aciclovir				
	Estonia	0.05	0.05	0.05	5
	Latvia	0.06	0.06	0.06	4
	Lithuania	0.06	0.07	0.07	7
J05AB04	ribavirin				
	Estonia	0.15	0.14	0.15	
	Latvia	0.20	0.21	0.17	-19
	Lithuania	0.04	0.03	0.08	130
J05AB06	ganciclovir				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
J05AB11	valaciclovir				
	Estonia	0.10	0.12	0.13	13
	Latvia	0.01	0.01	0.01	21
	Lithuania	0.02	0.02	0.02	14
J05AB14	valganciclovir				
	Estonia	0.01	0.01	0.01	-16
	Latvia	0.01	0.01	0.01	-19
	Lithuania	0.01	0.02	0.01	-7
J05AB15	brivudine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AD	Phosphonic acid derivatives				
	Estonia	<0.01	<0.01	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
J05AD01	foscarnet				
	Estonia	<0.01	<0.01	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
J05AE	Protease inhibitors				
	Estonia	0.42	0.55	0.40	-26
	Latvia	0.09	0.14	0.20	45
	Lithuania	<0.01	0.01	0.01	57
J05AE01	saquinavir				
	Estonia	-	-	-	
	Latvia	0.02	0.01	0.01	-5
	Lithuania	-	-	-	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J05AE03	ritonavir				
	Estonia	0.05	0.06	0.05	-17
	Latvia	0.01	0.01	0.01	52
	Lithuania	<0.01	<0.01	<0.01	
J05AE04	nelfinavir				
	Estonia	<0.01	-	-	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J05AE07	fosamprenavir				
	Estonia	0.19	0.22	0.03	-88
	Latvia	0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
J05AE08	atazanavir				
	Estonia	0.03	0.03	0.02	-49
	Latvia	0.05	0.08	0.13	61
	Lithuania	<0.01	<0.01	<0.01	
J05AE09	tipranavir				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AE10	darunavir				
	Estonia	0.14	0.22	0.30	34
	Latvia	0.01	0.03	0.04	36
	Lithuania	<0.01	<0.01	<0.01	
J05AE11	telaprevir				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	<0.01	<0.01	
J05AE12	boceprevir				
	Estonia	<0.01	0.01	<0.01	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
J05AE14	simeprevir				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors				
	Estonia	0.02	0.02	0.02	3
	Latvia	0.13	0.18	0.20	7
	Lithuania	0.04	0.03	0.03	-6
J05AF01	zidovudine				
	Estonia	0.01	<0.01	<0.01	
	Latvia	0.04	0.04	0.04	2
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J05AF02	didanosine				
	Estonia	<0.01	<0.01	-	
	Latvia	0.01	0.01	0.01	-42
	Lithuania	-	-	-	
J05AF05	lamivudine				
	Estonia	0.01	0.01	0.01	36
	Latvia	0.03	0.03	0.04	26
	Lithuania	0.02	0.02	0.02	5
J05AF06	abacavir				
	Estonia	0.01	0.01	0.01	-9
	Latvia	0.02	0.03	0.04	15
	Lithuania	-	-	-	
J05AF07	tenofovir disoproxil				
	Estonia	-	-	-	
	Latvia	0.04	0.07	0.07	8
	Lithuania	0.01	0.01	0.01	-25
J05AF08	adefovir dipivoxil				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	
J05AF09	emtricitabine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AF10	entecavir				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	-	
	Lithuania	0.01	<0.01	<0.01	
J05AG	Non-nucleoside reverse transcriptase inhibitors				
	Estonia	0.75	0.79	0.93	18
	Latvia	0.22	0.27	0.33	25
	Lithuania	0.04	0.05	0.06	17
J05AG01	nevirapine				
	Estonia	0.04	0.04	0.03	-30
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	<0.01	<0.01	
J05AG03	efavirenz				
	Estonia	0.67	0.64	0.68	7
	Latvia	0.22	0.26	0.33	25
	Lithuania	0.04	0.05	0.06	17
J05AG04	etravirine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J05AG05	rilpivirine				
	Estonia	0.03	0.11	0.22	108
	Latvia	-	-	-	
	Lithuania	-	-	-	
J05AH	Neuraminidase inhibitors				
	Estonia	0.04	0.02	0.05	83
	Latvia	0.05	0.01	0.05	310
	Lithuania	0.20	0.02	0.27	1300
J05AH01	zanamivir				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.06	
J05AH02	oseltamivir				
	Estonia	0.03	0.02	0.05	83
	Latvia	0.05	0.01	0.05	310
	Lithuania	0.19	0.02	0.21	1044
J05AR	Antivirals for treatment of HIV infections, combinations				
	Estonia	2.16	2.51	2.79	11
	Latvia	0.37	0.49	0.66	34
	Lithuania	0.06	0.08	0.10	17
J05AR01	zidovudine and lamivudine				
	Estonia	0.41	0.34	0.30	-13
	Latvia	0.15	0.17	0.18	4
	Lithuania	-	-	-	
J05AR02	lamivudine and abacavir				
	Estonia	0.82	0.96	1.02	6
	Latvia	0.12	0.19	0.32	68
	Lithuania	-	-	-	
J05AR03	tenofovir disoproxil and emtricitabine				
	Estonia	0.41	0.60	0.81	34
	Latvia	0.02	0.06	0.06	5
	Lithuania	-	-	-	
J05AR04	zidovudine, lamivudine and abacavir				
	Estonia	-	-	-	
	Latvia	0.02	<0.01	-	
	Lithuania	-	-	-	
J05AR10	lopinavir and ritonavir				
	Estonia	0.52	0.61	0.66	8
	Latvia	0.06	0.08	0.11	43
	Lithuania	0.06	0.08	0.10	17
J05AR14	darunavir and cobicistat				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
J05AX	Other antivirals				
	Estonia	0.07	0.07	0.15	98
	Latvia	0.01	0.02	0.08	302
	Lithuania	-	0.01	0.01	80
J05AX05	inosine pranobex				
	Estonia	-	-	-	
	Latvia	<0.01	0.01	0.03	136
	Lithuania	-	0.01	0.01	80
J05AX07	enfuvirtide				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AX08	raltegravir				
	Estonia	0.07	0.07	0.11	55
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
J05AX09	maraviroc				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
J05AX12	dolutegravir				
	Estonia	-	-	0.02	
	Latvia	-	-	0.04	
	Lithuania	-	-	-	
J05AX15	sofosbuvir				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
J05AX16	dasabuvir				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
J05AX67	ombitasvir, paritaprevir and ritonavir				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	

Consumption of antivirals for systemic use (J05)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS				
	Estonia	9.36	10.05	10.36	3
	Latvia	5.36	5.39	5.30	-2
	Lithuania	5.88	6.55	7.54	15
L02	ENDOCRINE THERAPY				
	Estonia	4.26	4.58	4.61	1
	Latvia	3.49	3.49	3.34	-4
	Lithuania	3.81	4.14	4.86	17
L02A	HORMONES AND RELATED AGENTS				
	Estonia	0.18	0.25	0.33	34
	Latvia	1.80	1.74	1.44	-17
	Lithuania	1.74	2.24	2.45	9
L02AA	Estrogens				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
L02AA02	polyestradiol phosphate				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
L02AB	Progestogens				
	Estonia	0.01	0.01	0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.43	0.89	1.18	33
L02AB01	megestrol				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.43	0.89	1.18	33
L02AB02	medroxyprogesterone				
	Estonia	0.01	0.01	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L02AE	Gonadotropin releasing hormone analogues				
	Estonia	0.17	0.24	0.32	35
	Latvia	1.79	1.74	1.44	-17
	Lithuania	1.32	1.35	1.27	-6
L02AE01	buserelin				
	Estonia	0.01	0.01	0.01	-15
	Latvia	-	-	-	
	Lithuania	-	-	-	
L02AE02	leuporelin				
	Estonia	-	-	-	
	Latvia	0.90	0.69	0.39	-44
	Lithuania	0.07	0.07	0.10	45

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L02AE03	goserelin				
	Estonia	0.08	0.07	0.09	26
	Latvia	0.16	0.17	0.18	2
	Lithuania	0.26	0.23	0.24	4
L02AE04	triptorelin				
	Estonia	0.08	0.16	0.22	44
	Latvia	0.63	0.76	0.87	15
	Lithuania	0.94	0.99	0.93	-6
L02AE05	histrelin				
	Estonia	<0.01	-	-	
	Latvia	0.10	0.11	<0.01	
	Lithuania	0.05	0.07	<0.01	
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS				
	Estonia	4.08	4.33	4.28	-1
	Latvia	1.69	1.75	1.90	8
	Lithuania	2.06	1.90	2.42	27
L02BA	Anti-estrogens				
	Estonia	0.59	0.65	0.74	14
	Latvia	0.96	0.99	1.05	6
	Lithuania	1.21	1.10	1.61	47
L02BA01	tamoxifen				
	Estonia	0.52	0.57	0.63	11
	Latvia	0.96	0.99	1.05	6
	Lithuania	1.19	1.05	1.53	47
L02BA03	fulvestrant				
	Estonia	0.06	0.08	0.11	36
	Latvia	<0.01	-	<0.01	
	Lithuania	0.03	0.05	0.07	43
L02BB	Anti-androgens				
	Estonia	2.23	2.33	2.12	-9
	Latvia	0.22	0.22	0.24	8
	Lithuania	0.35	0.31	0.26	-19
L02BB01	flutamide				
	Estonia	-	-	-	
	Latvia	0.05	0.03	0.04	28
	Lithuania	<0.01	-	-	
L02BB03	bicalutamide				
	Estonia	1.99	1.98	1.83	-8
	Latvia	0.16	0.19	0.20	4
	Lithuania	0.35	0.31	0.26	-19
L02BB04	enzalutamide				
	Estonia	0.23	0.35	0.29	-16
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L02BG	Aromatase inhibitors				
	Estonia	1.26	1.34	1.38	3
	Latvia	0.51	0.54	0.61	13
	Lithuania	0.50	0.48	0.53	9
L02BG03	anastrozole				
	Estonia	0.41	0.41	0.41	1
	Latvia	0.42	0.46	0.52	13
	Lithuania	0.24	0.25	0.29	17
L02BG04	letrozole				
	Estonia	0.77	0.81	0.86	7
	Latvia	0.06	0.04	0.04	3
	Lithuania	0.12	0.09	0.10	4
L02BG06	exemestane				
	Estonia	0.08	0.12	0.10	-14
	Latvia	0.04	0.04	0.05	22
	Lithuania	0.14	0.14	0.14	-3
L02BX	Other hormone antagonists and related agents				
	Estonia	0.01	0.01	0.04	301
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	0.01	0.03	383
L02BX03	abiraterone				
	Estonia	0.01	0.01	0.04	301
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	0.01	0.03	383
L03	IMMUNOSTIMULANTS				
	Estonia	0.91	1.01	0.97	-4
	Latvia	1.02	0.92	0.80	-13
	Lithuania	0.89	0.90	0.93	3
L03A	IMMUNOSTIMULANTS				
	Estonia	0.91	1.01	0.97	-4
	Latvia	1.02	0.92	0.80	-13
	Lithuania	0.89	0.90	0.93	3
L03AA	Colony stimulating factors				
	Estonia	0.05	0.06	0.04	-24
	Latvia	0.10	0.10	0.09	-8
	Lithuania	0.07	0.08	0.10	26
L03AA02	filgrastim				
	Estonia	0.03	0.03	0.03	8
	Latvia	0.01	0.02	0.02	-4
	Lithuania	0.06	0.07	0.09	29
L03AA10	lenograstim				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	<0.01	<0.01	<0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L03AA13	pegfilgrastim				
	Estonia	0.02	0.03	0.01	-58
	Latvia	0.08	0.08	0.07	-15
	Lithuania	0.01	0.01	0.01	
L03AA14	lipegfilgrastim				
	Estonia	-	-	-	
	Latvia	-	<0.01	0.01	
	Lithuania	-	-	<0.01	
L03AB	Interferons				
	Estonia	0.74	0.81	0.79	-2
	Latvia	0.86	0.75	0.63	-16
	Lithuania	0.75	0.73	0.72	-1
L03AB01	interferon alfa natural				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L03AB04	interferon alfa-2a				
	Estonia	0.03	0.04	0.04	7
	Latvia	0.07	0.06	0.08	30
	Lithuania	-	-	-	
L03AB05	interferon alfa-2b				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.02	10
	Lithuania	0.09	0.08	0.09	6
L03AB07	interferon beta-1a				
	Estonia	0.42	0.46	0.49	6
	Latvia	0.40	0.36	0.34	-6
	Lithuania	0.38	0.39	0.39	2
L03AB08	interferon beta-1b				
	Estonia	0.10	0.10	0.10	2
	Latvia	0.17	0.11	0.10	-9
	Lithuania	0.06	0.07	0.07	-1
L03AB10	peginterferon alfa-2b				
	Estonia	0.09	0.11	0.07	-37
	Latvia	0.08	0.07	0.03	-54
	Lithuania	0.16	0.14	0.11	-24
L03AB11	peginterferon alfa-2a				
	Estonia	0.09	0.11	0.10	-7
	Latvia	0.13	0.14	0.07	-52
	Lithuania	0.05	0.05	0.07	32
L03AX	Other immunostimulants				
	Estonia	0.12	0.15	0.13	-8
	Latvia	0.06	0.07	0.08	15
	Lithuania	0.08	0.10	0.11	17


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L03AX03	BCG vaccine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.03	0.04	21
L03AX05	pidotimod				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
L03AX13	glatiramer acetate				
	Estonia	0.12	0.14	0.13	-6
	Latvia	0.06	0.07	0.08	15
	Lithuania	0.06	0.07	0.08	15
L03AX15	mifamurtide				
	Estonia	-	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L03AX16	plerixafor				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
L04	IMMUNOSUPPRESSANTS				
	Estonia	4.18	4.46	4.77	7
	Latvia	0.86	0.99	1.16	18
	Lithuania	1.19	1.51	1.75	16
L04A	IMMUNOSUPPRESSANTS				
	Estonia	4.18	4.46	4.77	7
	Latvia	0.86	0.99	1.16	18
	Lithuania	1.19	1.51	1.75	16
L04AA	Selective immunosuppressants				
	Estonia	0.65	0.69	0.75	9
	Latvia	0.37	0.39	0.46	16
	Lithuania	0.28	0.30	0.35	18
L04AA04	antithymocyte immunoglobulin (rabbit)				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AA06	mycophenolic acid				
	Estonia	0.22	0.24	0.24	
	Latvia	0.20	0.20	0.23	12
	Lithuania	0.20	0.21	0.24	16
L04AA10	sirolimus				
	Estonia	0.01	0.01	0.01	-7
	Latvia	0.01	0.02	0.02	7
	Lithuania	0.02	0.02	0.02	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L04AA13	leflunomide				
	Estonia	0.39	0.41	0.42	3
	Latvia	0.14	0.16	0.19	19
	Lithuania	0.06	0.06	0.06	-3
L04AA18	everolimus				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AA23	natalizumab				
	Estonia	0.01	0.02	0.02	10
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
L04AA24	abatacept				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.01	0.01	0.01	-14
	Lithuania	-	-	-	
L04AA25	eculizumab				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
L04AA26	belimumab				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
L04AA27	 fingolimod				
	Estonia	0.01	0.01	0.02	110
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	0.01	0.03	350
L04AA31	teriflunomide				
	Estonia	-	-	0.03	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L04AA33	vedolizumab				
	Estonia	-	-	0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L04AA34	alemtuzumab				
	Estonia	-	-	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
L04AB	Tumor necrosis factor alpha (TNF-) inhibitors				
	Estonia	0.54	0.62	0.74	20
	Latvia	0.17	0.22	0.27	26
	Lithuania	0.18	0.33	0.45	38

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L04AB01	etanercept				
	Estonia	0.13	0.13	0.14	5
	Latvia	0.05	0.07	0.09	39
	Lithuania	0.11	0.17	0.18	5
L04AB02	infliximab				
	Estonia	0.20	0.23	0.32	40
	Latvia	0.08	0.09	0.09	-8
	Lithuania	0.04	0.11	0.21	88
L04AB04	adalimumab				
	Estonia	0.15	0.17	0.18	6
	Latvia	0.03	0.05	0.08	63
	Lithuania	0.03	0.04	0.07	51
L04AB05	certolizumab pegol				
	Estonia	<0.01	0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	0.01	0.01	<0.01	
L04AB06	golimumab				
	Estonia	0.05	0.08	0.09	21
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
L04AC	Interleukin inhibitors				
	Estonia	0.05	0.06	0.05	-25
	Latvia	0.03	0.04	0.05	41
	Lithuania	0.01	0.01	0.02	42
L04AC02	basiliximab				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AC03	anakinra				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AC05	ustekinumab				
	Estonia	0.02	0.03	0.02	-20
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	-50
L04AC07	tocilizumab				
	Estonia	0.03	0.03	0.02	-33
	Latvia	0.02	0.03	0.05	52
	Lithuania	-	-	0.01	
L04AD	Calcineurin inhibitors				
	Estonia	0.30	0.35	0.36	2
	Latvia	0.21	0.24	0.27	14
	Lithuania	0.18	0.20	0.24	16

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
L04AD01	ciclosporin				
	Estonia	0.23	0.26	0.25	-5
	Latvia	0.14	0.14	0.11	-19
	Lithuania	0.12	0.12	0.12	-3
L04AD02	tacrolimus				
	Estonia	0.07	0.09	0.11	24
	Latvia	0.06	0.10	0.16	62
	Lithuania	0.06	0.08	0.12	44
L04AX	Other immunosuppressants				
	Estonia	2.64	2.75	2.88	5
	Latvia	0.09	0.10	0.11	6
	Lithuania	0.54	0.67	0.69	4
L04AX01	azathioprine				
	Estonia	0.27	0.32	0.33	4
	Latvia	0.09	0.10	0.11	6
	Lithuania	0.12	0.18	0.17	-3
L04AX02	thalidomide				
	Estonia	0.02	0.02	0.03	40
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
L04AX03	methotrexate				
	Estonia	2.31	2.37	2.48	5
	Latvia	<0.01	<0.01	-	
	Lithuania	0.42	0.49	0.52	6
L04AX04	lenalidomide				
	Estonia	0.04	0.04	0.04	12
	Latvia	-	<0.01	<0.01	
	Lithuania	<0.01	-	-	
L04AX05	pirfenidone				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
L04AX06	pomalidomide				
	Estonia	-	-	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	

Consumption of antineoplastic and immunomodulating agents (L)




ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M	MUSCULO-SKELETAL SYSTEM				
	Estonia	73.67	76.28	79.02	4
	Latvia	67.93	71.46	73.22	2
	Lithuania	72.56	71.87	68.46	-5
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS				
	Estonia	64.82	67.09	68.87	3
	Latvia	57.83	61.26	62.27	2
	Lithuania	65.53	64.51	60.94	-6
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS				
	Estonia	64.81	67.08	68.86	3
	Latvia	57.81	61.24	62.25	2
	Lithuania	65.50	64.49	60.92	-6
M01AA	Butylpyrazolidines				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
M01AA01	phenylbutazone				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
M01AB	Acetic acid derivatives and related substances				
	Estonia	13.10	12.51	11.54	-8
	Latvia	26.38	26.47	26.00	-2
	Lithuania	26.92	25.61	26.59	4
M01AB01	indometacin				
	Estonia	0.21	0.12	0.10	-18
	Latvia	0.33	0.31	0.27	-11
	Lithuania	1.90	0.95	1.88	99
M01AB05	diclofenac				
	Estonia	12.66	12.07	11.12	-8
	Latvia	21.34	21.48	20.98	-2
	Lithuania	21.13	20.71	20.63	
M01AB15	ketorolac				
	Estonia	-	-	-	
	Latvia	1.34	1.22	1.25	2
	Lithuania	2.59	2.54	2.58	1
M01AB16	aceclofenac				
	Estonia	0.17	0.28	0.27	-4
	Latvia	1.65	1.78	1.92	8
	Lithuania	0.52	0.61	0.70	14

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M01AB55	diclofenac, combinations				
	Estonia	0.06	0.04	0.05	25
	Latvia	1.73	1.69	1.58	-6
	Lithuania	0.78	0.79	0.81	1
M01AC	Oxicams				
	Estonia	5.97	5.89	5.67	-4
	Latvia	4.17	4.59	4.34	-6
	Lithuania	7.39	7.79	8.03	3
M01AC01	piroxicam				
	Estonia	0.18	0.21	0.23	8
	Latvia	0.08	0.08	0.10	17
	Lithuania	0.98	1.07	1.15	7
M01AC05	lornoxicam				
	Estonia	0.93	0.90	0.90	
	Latvia	0.88	1.00	1.04	4
	Lithuania	1.27	1.42	1.55	10
M01AC06	meloxicam				
	Estonia	4.85	4.77	4.55	-5
	Latvia	3.21	3.50	3.20	-9
	Lithuania	5.14	5.30	5.33	
M01AE	Propionic acid derivatives				
	Estonia	31.39	33.75	36.18	7
	Latvia	21.68	24.05	25.51	6
	Lithuania	23.73	23.39	18.50	-21
M01AE01	ibuprofen				
	Estonia	24.97	25.65	26.27	2
	Latvia	20.85	22.00	23.07	5
	Lithuania	19.62	18.59	13.35	-28
M01AE02	naproxen				
	Estonia	0.56	0.86	1.56	82
	Latvia	0.20	1.27	1.57	23
	Lithuania	1.79	2.12	2.17	2
M01AE03	ketoprofen				
	Estonia	1.15	1.34	1.43	6
	Latvia	0.24	0.26	0.25	-1
	Lithuania	0.77	0.79	0.83	5
M01AE09	flurbiprofen				
	Estonia	<0.01	-	<0.01	
	Latvia	0.02	0.03	0.04	16
	Lithuania	-	-	-	
M01AE11	tiaprofenic acid				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M01AE17	dexketoprofen				
	Estonia	0.69	1.36	1.70	25
	Latvia	0.37	0.48	0.58	20
	Lithuania	0.95	1.35	1.58	17
M01AE52	naproxen and esomeprazole				
	Estonia	4.03	4.53	5.22	15
	Latvia	-	-	-	
	Lithuania	0.60	0.54	0.57	5
M01AG	Fenamates				
	Estonia	0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
M01AG02	tolfenamic acid				
	Estonia	0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
M01AH	Coxibs				
	Estonia	4.34	5.15	5.60	9
	Latvia	1.43	1.99	2.34	17
	Lithuania	1.34	1.79	2.13	19
M01AH01	celecoxib				
	Estonia	0.45	0.53	0.63	19
	Latvia	0.16	0.14	0.28	97
	Lithuania	0.44	0.79	0.87	10
M01AH05	etoricoxib				
	Estonia	3.89	4.62	4.97	8
	Latvia	1.27	1.85	2.06	11
	Lithuania	0.90	1.00	1.26	26
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids				
	Estonia	10.00	9.77	9.87	1
	Latvia	4.14	4.14	4.07	-2
	Lithuania	6.13	5.91	5.67	-4
M01AX01	napumetone				
	Estonia	0.55	0.55	0.54	-2
	Latvia	0.01	0.01	0.01	-17
	Lithuania	0.07	0.06	0.05	-19
M01AX05	glucosamine				
	Estonia	9.45	9.22	9.33	1
	Latvia	1.77	1.91	1.88	-1
	Lithuania	1.12	1.10	0.89	-19
M01AX17	nimesulide				
	Estonia	-	-	-	
	Latvia	2.36	2.22	2.18	-2
	Lithuania	4.95	4.75	4.73	

Consumption of non-steroidal antiinflammatory and antirheumatic products (M01A)




ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M01C	SPECIFIC ANTIRHEUMATIC AGENTS				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.02	0.02	0.02	-2
	Lithuania	0.03	0.02	0.02	-5
M01CC	Penicillamine and similar agents				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.02	0.02	0.02	-2
	Lithuania	0.03	0.02	0.02	-5
M01CC01	penicillamine				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.02	0.02	0.02	-2
	Lithuania	0.03	0.02	0.02	-5
M03	MUSCLE RELAXANTS				
	Estonia	0.75	0.80	0.85	6
	Latvia	3.07	3.05	3.13	2
	Lithuania	1.54	1.51	1.60	6
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS				
	Estonia	0.75	0.80	0.85	6
	Latvia	3.07	3.05	3.13	2
	Lithuania	1.54	1.51	1.60	6
M03BA	Carbamic acid esters				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
M03BA03	methocarbamol				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M03BX	Other centrally acting agents				
	Estonia	0.75	0.80	0.85	6
	Latvia	3.07	3.05	3.13	2
	Lithuania	1.54	1.51	1.60	6
M03BX01	baclofen				
	Estonia	0.16	0.16	0.17	6
	Latvia	0.15	0.17	0.19	9
	Lithuania	0.27	0.27	0.28	4
M03BX02	tizanidine				
	Estonia	0.59	0.64	0.68	6
	Latvia	0.16	0.20	0.24	16
	Lithuania	0.12	0.17	0.20	17
M03BX04	tolperisone				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	2.76	2.68	2.70	1
	Lithuania	1.15	1.06	1.11	5
M04	ANTIGOUT PREPARATIONS				
	Estonia	3.24	3.80	4.52	19
	Latvia	1.59	1.95	2.36	21
	Lithuania	1.97	2.55	2.92	15
M04A	ANTIGOUT PREPARATIONS				
	Estonia	3.24	3.80	4.52	19
	Latvia	1.59	1.95	2.36	21
	Lithuania	1.97	2.55	2.92	15
M04AA	Preparations inhibiting uric acid production				
	Estonia	3.22	3.78	4.51	19
	Latvia	1.58	1.92	2.33	21
	Lithuania	1.97	2.55	2.92	15
M04AA01	allopurinol				
	Estonia	3.22	3.55	3.97	12
	Latvia	1.47	1.77	2.13	20
	Lithuania	1.80	2.19	2.46	12
M04AA03	febuxostat				
	Estonia	-	0.23	0.54	136
	Latvia	0.10	0.16	0.20	29
	Lithuania	0.17	0.36	0.46	28
M04AB	Preparations increasing uric acid excretion				
	Estonia	0.02	0.02	0.01	-46
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
M04AB01	probenecid				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M04AB03	benzbromarone				
	Estonia	0.02	0.02	0.01	-46
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
M04AC	Preparations with no effect on uric acid metabolism				
	Estonia	-	-	<0.01	
	Latvia	0.01	0.02	0.03	33
	Lithuania	-	-	-	
M04AC01	colchicine				
	Estonia	-	-	<0.01	
	Latvia	0.01	0.02	0.03	33
	Lithuania	-	-	-	
M05	DRUGS FOR TREATMENT OF BONE DISEASES				
	Estonia	4.86	4.59	4.78	4
	Latvia	5.43	5.18	5.44	5
	Lithuania	3.50	3.28	2.99	-9
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION				
	Estonia	4.86	4.59	4.78	4
	Latvia	5.43	5.18	5.44	5
	Lithuania	3.50	3.28	2.99	-9
M05BA	Bisphosphonates				
	Estonia	1.86	1.48	1.35	-8
	Latvia	3.20	3.27	3.50	7
	Lithuania	1.70	1.72	1.50	-12


Consumption of antigout preparations (M04A)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M05BA02	clodronic acid				
	Estonia	-	-	-	
	Latvia	0.05	0.03	0.01	-56
	Lithuania	-	-	-	
M05BA03	pamidronic acid				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	0.01	0.01	20
M05BA04	alendronic acid				
	Estonia	0.58	0.47	0.42	-10
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.31	0.29	0.23	-19
M05BA06	ibandronic acid				
	Estonia	0.85	0.66	0.61	-8
	Latvia	1.12	1.12	1.29	15
	Lithuania	0.82	0.86	0.78	-9
M05BA07	risedronic acid				
	Estonia	0.42	0.34	0.32	-7
	Latvia	2.03	2.10	2.18	4
	Lithuania	0.56	0.57	0.49	-14
M05BA08	zoledronic acid				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
M05BB	Bisphosphonates, combinations				
	Estonia	2.71	2.72	2.80	3
	Latvia	1.51	1.26	1.19	-5
	Lithuania	0.60	0.52	0.42	-19
M05BB03	alendronic acid and colecalciferol				
	Estonia	2.71	2.72	2.80	3
	Latvia	1.51	1.26	1.19	-5
	Lithuania	0.31	0.27	0.24	-12
M05BB04	risedronic acid, calcium and colecalciferol, sequential				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.29	0.25	0.18	-28
M05BX	Other drugs affecting bone structure and mineralization				
	Estonia	0.30	0.40	0.62	56
	Latvia	0.72	0.66	0.75	14
	Lithuania	1.20	1.05	1.07	2
M05BX03	strontium ranelate				
	Estonia	0.10	0.05	0.04	-21
	Latvia	0.56	0.47	0.40	-15
	Lithuania	0.57	0.23	0.11	-51

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
M05BX04	denosumab				
	Estonia	0.19	0.35	0.58	68
	Latvia	0.16	0.19	0.35	86
	Lithuania	0.63	0.82	0.96	17
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM				
	Estonia	-	-	-	
	Latvia	0.01	0.02	0.02	18
	Lithuania	0.02	0.02	0.02	
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM				
	Estonia	-	-	-	
	Latvia	0.01	0.02	0.02	18
	Lithuania	0.02	0.02	0.02	
M09AB	Enzymes				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
M09AB02	collagenase clostridium histolyticum				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
M09AX	Other drugs for disorders of the musculo-skeletal system				
	Estonia	-	-	-	
	Latvia	0.01	0.02	0.02	18
	Lithuania	0.02	0.02	0.02	
M09AX01	hyaluronic acid				
	Estonia	-	-	-	
	Latvia	0.01	0.02	0.02	18
	Lithuania	0.02	0.02	0.02	


Consumption of drugs for treatment of bone disease (M05B)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N	NERVOUS SYSTEM				
	Estonia	104.00	108.95	113.98	5
	Latvia	92.17	95.69	98.46	3
	Lithuania	140.92	149.59	153.53	3
N02	ANALGESICS				
	Estonia	15.27	16.11	17.35	8
	Latvia	15.36	15.48	14.20	-8
	Lithuania	14.63	12.89	12.73	-1
N02A	OPIOIDS				
	Estonia	3.67	4.31	4.79	11
	Latvia	3.28	3.57	3.78	6
	Lithuania	1.92	2.04	2.11	4
N02AA	Natural opium alkaloids				
	Estonia	1.59	2.03	2.47	22
	Latvia	1.06	1.16	1.33	14
	Lithuania	0.36	0.39	0.45	15
N02AA01	morphine				
	Estonia	0.16	0.17	0.17	6
	Latvia	0.09	0.10	0.08	-16
	Lithuania	0.21	0.23	0.22	-2
N02AA05	oxycodone				
	Estonia	0.16	0.24	0.27	11
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N02AA08	dihydrocodeine				
	Estonia	0.07	0.07	0.07	-2
	Latvia	0.15	0.15	0.16	6
	Lithuania	-	-	-	
N02AA59	codeine, combinations excl. psycholeptics				
	Estonia	1.19	1.55	1.96	26
	Latvia	0.83	0.91	1.08	18
	Lithuania	0.15	0.16	0.23	38
N02AB	Phenylpiperidine derivatives				
	Estonia	0.07	0.09	0.11	21
	Latvia	0.59	0.74	0.78	6
	Lithuania	0.70	0.73	0.75	4
N02AB02	pethidine				
	Estonia	0.02	0.02	0.02	-3
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.03	0.03	0.03	7
N02AB03	fentanyl				
	Estonia	0.05	0.07	0.09	28
	Latvia	0.59	0.74	0.78	6
	Lithuania	0.67	0.70	0.72	4

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N02AE	Oripavine derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N02AE01	buprenorphine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N02AX	Other opioids				
	Estonia	2.01	2.19	2.20	
	Latvia	1.63	1.67	1.68	1
	Lithuania	0.86	0.92	0.91	-1
N02AX02	tramadol				
	Estonia	1.99	2.18	2.18	
	Latvia	1.62	1.66	1.67	1
	Lithuania	0.86	0.92	0.91	-1
N02AX06	tapentadol				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
N02AX52	tramadol, combinations				
	Estonia	0.02	0.01	0.02	133
	Latvia	0.01	0.01	0.01	-10
	Lithuania	<0.01	-	-	
N02B	OTHER ANALGESICS AND ANTIPYRETICS				
	Estonia	11.11	11.23	11.90	6
	Latvia	11.90	11.70	10.19	-13
	Lithuania	12.28	10.37	10.08	-3


Consumption of opioids (N02A)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N02BA	Salicylic acid and derivatives				
	Estonia	2.18	2.13	1.97	-8
	Latvia	6.77	6.92	4.97	-28
	Lithuania	2.02	1.62	1.39	-14
N02BA01	acetylsalicylic acid				
	Estonia	1.17	1.10	0.98	-11
	Latvia	0.64	0.60	0.51	-15
	Lithuania	1.38	1.23	1.14	-8
N02BA03	choline salicylate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.07	0.07	0.07	
N02BA11	diflunisal				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N02BA51	acetylsalicylic acid, combinations excl. psycholeptics				
	Estonia	1.01	1.03	0.99	-4
	Latvia	6.13	6.32	4.46	-29
	Lithuania	0.57	0.32	0.18	-43
N02BB	Pyrazolones				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.71	0.70	0.73	4
	Lithuania	1.06	0.95	0.86	-9
N02BB02	metamizole sodium				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.71	0.70	0.73	4
	Lithuania	1.06	0.95	0.86	-9
N02BE	Anilides				
	Estonia	8.89	9.05	9.87	9
	Latvia	4.38	4.06	4.47	10
	Lithuania	9.16	7.79	7.81	
N02BE01	paracetamol				
	Estonia	6.14	6.31	6.97	10
	Latvia	1.91	1.75	2.02	15
	Lithuania	3.32	2.55	2.58	1
N02BE51	paracetamol, combinations excl. psycholeptics				
	Estonia	2.75	2.73	2.90	6
	Latvia	2.48	2.31	2.45	6
	Lithuania	5.84	5.24	5.23	
N02BG	Other analgesics and antipyretics				
	Estonia	0.03	0.04	0.06	41
	Latvia	0.03	0.03	0.03	-12
	Lithuania	0.05	0.02	0.02	-6

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N02BG07	flupirtine				
	Estonia	0.03	0.04	0.06	41
	Latvia	0.03	0.03	0.03	-12
	Lithuania	0.05	0.02	0.02	-6
N02C	ANTIMIGRAINE PREPARATIONS				
	Estonia	0.49	0.57	0.65	16
	Latvia	0.18	0.21	0.23	10
	Lithuania	0.44	0.49	0.54	12
N02CA	Ergot alkaloids				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
N02CA01	dihydroergotamine				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
N02CC	Selective serotonin (5HT₁) agonists				
	Estonia	0.49	0.57	0.65	16
	Latvia	0.18	0.21	0.23	10
	Lithuania	0.44	0.49	0.54	12

Consumption of other analgesics and antipyretics (N02B)




ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N02CC01	sumatriptan				
	Estonia	0.42	0.48	0.55	16
	Latvia	0.16	0.19	0.21	10
	Lithuania	0.38	0.43	0.48	12
N02CC02	naratriptan				
	Estonia	<0.01	<0.01	-	
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.01	17
N02CC03	zolmitriptan				
	Estonia	0.03	0.04	0.04	17
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.02	0.02	0.02	
N02CC04	rizatriptan				
	Estonia	0.01	0.01	0.01	8
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.01	
N02CC06	eletriptan				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	9
	Lithuania	<0.01	-	-	
N02CC07	frovatriptan				
	Estonia	0.03	0.04	0.05	23
	Latvia	0.01	0.01	0.01	6
	Lithuania	0.02	0.02	0.02	10
N02CX	Other antimigraine preparations				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N02CX01	pizotifen				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N03	ANTIEPILEPTICS				
	Estonia	7.26	7.67	8.12	6
	Latvia	7.88	8.35	8.54	2
	Lithuania	9.23	9.46	9.75	3
N03A	ANTIEPILEPTICS				
	Estonia	7.26	7.67	8.12	6
	Latvia	7.88	8.35	8.54	2
	Lithuania	9.23	9.46	9.75	3
N03AA	Barbiturates and derivatives				
	Estonia	0.51	0.51	0.50	-1
	Latvia	0.30	0.31	0.31	-1
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N03AA02	phenobarbital				
	Estonia	0.45	0.45	0.45	-1
	Latvia	0.30	0.31	0.31	-1
	Lithuania	-	-	-	
N03AA03	primidone				
	Estonia	0.06	0.06	0.06	-6
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N03AB	Hydantoin derivatives				
	Estonia	0.06	0.06	0.05	-14
	Latvia	0.01	0.01	0.01	-15
	Lithuania	-	-	-	
N03AB02	phenytoin				
	Estonia	0.06	0.06	0.05	-14
	Latvia	0.01	0.01	0.01	-15
	Lithuania	-	-	-	
N03AD	Succinimide derivatives				
	Estonia	0.01	0.01	0.01	1
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N03AD01	ethosuximide				
	Estonia	0.01	0.01	0.01	1
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N03AE	Benzodiazepine derivatives				
	Estonia	0.72	0.74	0.72	-2
	Latvia	1.84	1.82	1.78	-2
	Lithuania	2.39	2.34	2.21	-5
N03AE01	clonazepam				
	Estonia	0.72	0.74	0.72	-2
	Latvia	1.84	1.82	1.78	-2
	Lithuania	2.39	2.34	2.21	-5
N03AF	Carboxamide derivatives				
	Estonia	2.98	3.01	3.06	2
	Latvia	2.09	2.13	2.17	2
	Lithuania	2.81	2.80	2.93	5
N03AF01	carbamazepine				
	Estonia	2.15	2.20	2.20	
	Latvia	1.76	1.84	1.86	1
	Lithuania	1.40	1.52	1.68	11
N03AF02	oxcarbazepine				
	Estonia	0.83	0.81	0.87	7
	Latvia	0.33	0.29	0.30	3
	Lithuania	1.42	1.28	1.25	-3

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N03AF03	rufinamide				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	<0.01	<0.01	
N03AG	Fatty acid derivatives				
	Estonia	1.38	1.42	1.43	1
	Latvia	1.72	1.83	1.83	
	Lithuania	1.98	2.03	1.97	-3
N03AG01	valproic acid				
	Estonia	1.38	1.42	1.42	
	Latvia	1.71	1.82	1.82	
	Lithuania	1.96	2.02	1.97	-2
N03AG03	aminobutyric acid				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N03AG04	vigabatrin				
	Estonia	<0.01	<0.01	0.01	
	Latvia	<0.01	0.01	0.01	
	Lithuania	-	-	-	
N03AG06	tiagabine				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.02	0.02	<0.01	
N03AX	Other antiepileptics				
	Estonia	1.62	1.94	2.35	21
	Latvia	1.92	2.24	2.44	9
	Lithuania	2.04	2.29	2.64	15
N03AX03	sultiame				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N03AX09	lamotrigine				
	Estonia	0.38	0.42	0.45	8
	Latvia	0.54	0.60	0.61	2
	Lithuania	0.62	0.62	0.64	3
N03AX11	topiramate				
	Estonia	0.18	0.19	0.20	5
	Latvia	0.19	0.18	0.18	-2
	Lithuania	0.37	0.37	0.40	8
N03AX12	gabapentin				
	Estonia	0.49	0.65	0.76	17
	Latvia	0.96	1.21	1.38	15
	Lithuania	0.29	0.33	0.38	16

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N03AX14	levetiracetam				
	Estonia	0.20	0.25	0.32	28
	Latvia	0.08	0.13	0.18	34
	Lithuania	0.13	0.22	0.32	46
N03AX15	zonisamide				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
N03AX16	pregabalin				
	Estonia	0.35	0.42	0.61	44
	Latvia	0.13	0.11	0.08	-21
	Lithuania	0.64	0.75	0.90	19
N03AX17	stiripentol				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N03AX18	lacosamide				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	
N03AX21	retigabine				
	Estonia	<0.01	0.01	0.01	7
	Latvia	0.01	0.01	<0.01	
	Lithuania	0.01	0.01	<0.01	
N03AX22	perampanel				
	Estonia	0.01	0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	

Consumption of antiepileptics (N03)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N04	ANTI-PARKINSON DRUGS				
	Estonia	3.85	3.88	3.83	-1
	Latvia	4.39	4.45	4.43	-1
	Lithuania	5.43	5.66	5.52	-3
N04A	ANTICHOLINERGIC AGENTS				
	Estonia	0.58	0.62	0.63	1
	Latvia	2.00	2.04	2.06	1
	Lithuania	1.76	1.79	1.78	-1
N04AA	Tertiary amines				
	Estonia	0.58	0.62	0.63	1
	Latvia	2.00	2.04	2.06	1
	Lithuania	1.76	1.79	1.78	-1
N04AA01	trihexyphenidyl				
	Estonia	0.58	0.62	0.63	1
	Latvia	1.99	2.03	2.05	1
	Lithuania	1.76	1.79	1.78	-1
N04AA02	biperiden				
	Estonia	<0.01	-	-	
	Latvia	0.01	0.01	0.01	-15
	Lithuania	-	-	-	
N04B	DOPAMINERGIC AGENTS				
	Estonia	3.27	3.25	3.20	-2
	Latvia	2.39	2.41	2.37	-2
	Lithuania	3.67	3.88	3.74	-4
N04BA	Dopa and dopa derivatives				
	Estonia	1.34	1.35	1.38	3
	Latvia	0.83	0.87	0.88	2
	Lithuania	1.52	1.64	1.61	-2
N04BA02	levodopa and decarboxylase inhibitor				
	Estonia	1.07	1.05	1.08	3
	Latvia	0.71	0.75	0.77	3
	Lithuania	1.19	1.32	1.30	-1
N04BA03	levodopa, decarboxylase inhibitor and COMT inhibitor				
	Estonia	0.27	0.29	0.30	2
	Latvia	0.12	0.12	0.11	-4
	Lithuania	0.33	0.32	0.31	-5
N04BB	Adamantane derivatives				
	Estonia	0.36	0.35	0.34	-2
	Latvia	0.64	0.64	0.64	1
	Lithuania	0.82	0.79	0.75	-4
N04BB01	amantadine				
	Estonia	0.36	0.35	0.34	-2
	Latvia	0.64	0.64	0.64	1
	Lithuania	0.82	0.79	0.75	-4


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N04BC	Dopamine agonists				
	Estonia	0.85	0.81	0.72	-11
	Latvia	0.48	0.48	0.46	-3
	Lithuania	1.09	1.16	1.07	-8
N04BC01	bromocriptine				
	Estonia	-	-	-	
	Latvia	0.02	0.01	0.01	-9
	Lithuania	-	-	-	
N04BC04	ropinirole				
	Estonia	0.43	0.42	0.35	-17
	Latvia	0.34	0.34	0.33	-4
	Lithuania	0.73	0.79	0.71	-9
N04BC05	pramipexole				
	Estonia	0.42	0.39	0.37	-5
	Latvia	0.12	0.12	0.12	-2
	Lithuania	0.36	0.37	0.36	-4
N04BC07	apomorphine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
N04BD	Monoamine oxidase B inhibitors				
	Estonia	0.72	0.75	0.76	1
	Latvia	0.45	0.43	0.38	-11
	Lithuania	0.23	0.28	0.29	5
N04BD01	selegiline				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.44	0.42	0.38	-11
	Lithuania	-	-	-	
N04BD02	rasagiline				
	Estonia	0.72	0.75	0.76	1
	Latvia	<0.01	0.01	0.01	-11
	Lithuania	0.23	0.28	0.29	5
N04BX	Other dopaminergic agents				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	0.01	0.02	0.02	26
N04BX01	tolcapone				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
N04BX02	entacapone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	0.02	0.02	26

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N05	PSYCHOLEPTICS				
	Estonia	40.53	42.53	43.95	3
	Latvia	29.77	30.66	32.30	5
	Lithuania	60.27	61.26	62.51	2
N05A	ANTIPSYCHOTICS				
	Estonia	7.58	8.27	8.66	5
	Latvia	9.80	10.28	10.60	3
	Lithuania	11.95	12.22	13.21	8
N05AA	Phenothiazines with aliphatic side-chain				
	Estonia	0.18	0.18	0.19	10
	Latvia	0.28	0.32	0.32	1
	Lithuania	0.14	0.14	0.14	-2
N05AA01	chlorpromazine				
	Estonia	0.11	0.10	0.12	18
	Latvia	0.09	0.13	0.11	-10
	Lithuania	-	-	-	
N05AA02	levomepromazine				
	Estonia	0.07	0.08	0.08	-1
	Latvia	0.19	0.19	0.21	8
	Lithuania	0.14	0.14	0.14	-2
N05AB	Phenothiazines with piperazine structure				
	Estonia	0.11	0.10	0.11	
	Latvia	0.04	0.03	0.05	44
	Lithuania	0.11	0.10	0.10	-1
N05AB02	fluphenazine				
	Estonia	0.06	0.03	0.03	-14
	Latvia	0.01	0.02	0.03	59
	Lithuania	0.11	0.10	0.10	-1
N05AB03	perphenazine				
	Estonia	0.06	0.07	0.08	7
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N05AB06	trifluoperazine				
	Estonia	-	-	-	
	Latvia	0.02	0.02	0.02	37
	Lithuania	-	-	-	
N05AC	Phenothiazines with piperidine structure				
	Estonia	<0.01	-	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N05AC01	periciazine				
	Estonia	<0.01	-	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N05AD	Butyrophenone derivatives				
	Estonia	1.13	1.18	1.13	-5
	Latvia	3.19	3.29	3.37	2
	Lithuania	2.32	2.37	2.42	2
N05AD01	haloperidol				
	Estonia	0.77	0.81	0.78	-4
	Latvia	2.89	3.01	3.10	3
	Lithuania	1.95	2.03	2.04	
N05AD03	melperone				
	Estonia	0.34	0.34	0.32	-5
	Latvia	0.30	0.28	0.27	-6
	Lithuania	0.36	0.34	0.38	10
N05AD08	droperidol				
	Estonia	0.02	0.03	0.02	-26
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N05AE	Indole derivatives				
	Estonia	0.16	0.17	0.16	-8
	Latvia	0.27	0.25	0.24	-4
	Lithuania	0.29	0.28	0.25	-9
N05AE03	sertindole				
	Estonia	0.13	0.12	0.11	-5
	Latvia	0.10	0.10	0.10	-5
	Lithuania	-	-	-	
N05AE04	ziprasidone				
	Estonia	0.04	0.05	0.04	-15
	Latvia	0.17	0.15	0.15	-4
	Lithuania	0.29	0.28	0.25	-9
N05AF	Thioxanthene derivatives				
	Estonia	0.97	0.96	0.94	-2
	Latvia	1.89	1.81	1.86	2
	Lithuania	0.91	0.71	0.88	24
N05AF01	flupentixol				
	Estonia	0.19	0.19	0.20	2
	Latvia	0.36	0.37	0.44	18
	Lithuania	0.23	0.23	0.26	13
N05AF03	chlorprothixene				
	Estonia	0.27	0.26	0.24	-7
	Latvia	0.78	0.79	0.77	-2
	Lithuania	0.31	0.13	0.29	114
N05AF05	zuclopenthixol				
	Estonia	0.51	0.50	0.50	-1
	Latvia	0.75	0.65	0.65	-1
	Lithuania	0.38	0.35	0.34	-4

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N05AG	Diphenylbutylpiperidine derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
N05AG01	fluspirilene				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N05AG02	pimozide				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
N05AH	Diazepines, oxazepines, thiazepines and oxepines				
	Estonia	3.77	4.28	4.55	6
	Latvia	2.66	2.96	3.05	3
	Lithuania	5.10	5.41	5.80	7
N05AH02	clozapine				
	Estonia	0.55	0.56	0.57	1
	Latvia	0.48	0.49	0.42	-15
	Lithuania	0.43	0.44	0.47	6
N05AH03	olanzapine				
	Estonia	1.44	1.67	1.80	8
	Latvia	0.97	1.11	1.16	5
	Lithuania	2.48	2.60	2.77	6
N05AH04	quetiapine				
	Estonia	1.77	2.05	2.18	6
	Latvia	1.21	1.36	1.46	8
	Lithuania	2.20	2.37	2.56	8
N05AH05	asenapine				
	Estonia	<0.01	-	-	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
N05AL	Benzamides				
	Estonia	0.11	0.13	0.14	11
	Latvia	0.45	0.45	0.43	-3
	Lithuania	1.81	1.94	2.02	4
N05AL01	sulpiride				
	Estonia	0.05	0.06	0.06	
	Latvia	0.15	0.16	0.15	-6
	Lithuania	0.08	0.08	0.08	-5
N05AL03	tiapride				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	1.30	1.45	1.54	6


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N05AL05	amisulpride				
	Estonia	0.06	0.07	0.08	21
	Latvia	0.30	0.29	0.28	-1
	Lithuania	0.42	0.41	0.41	
N05AN	Lithium				
	Estonia	0.17	0.19	0.19	-1
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N05AN01	lithium				
	Estonia	0.17	0.19	0.19	-1
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N05AX	Other antipsychotics				
	Estonia	0.97	1.08	1.25	16
	Latvia	1.03	1.15	1.27	10
	Lithuania	1.27	1.27	1.61	26
N05AX08	risperidone				
	Estonia	0.56	0.60	0.64	8
	Latvia	0.75	0.85	0.92	8
	Lithuania	0.91	0.90	0.89	-1
N05AX12	aripiprazole				
	Estonia	0.40	0.45	0.57	26
	Latvia	0.28	0.31	0.34	12
	Lithuania	0.24	0.23	0.29	25
N05AX13	paliperidone				
	Estonia	0.01	0.03	0.04	37
	Latvia	-	-	0.01	
	Lithuania	0.11	0.15	0.43	197



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N05B	ANXIOLYTICS				
	Estonia	14.42	14.64	14.64	
	Latvia	14.04	14.03	14.74	5
	Lithuania	41.43	41.65	41.01	-2
N05BA	Benzodiazepine derivatives				
	Estonia	14.41	14.64	14.64	
	Latvia	13.77	13.75	14.43	5
	Lithuania	41.37	41.60	40.96	-2
N05BA01	diazepam				
	Estonia	6.81	6.84	6.65	-3
	Latvia	3.44	3.19	3.08	-3
	Lithuania	5.91	5.74	5.42	-5
N05BA02	chlordiazepoxide				
	Estonia	-	<0.01	-	
	Latvia	0.18	0.16	0.15	-4
	Lithuania	0.11	0.09	0.08	-14
N05BA03	medazepam				
	Estonia	-	-	-	
	Latvia	0.10	0.04	-	
	Lithuania	0.87	0.86	0.86	-1
N05BA04	oxazepam				
	Estonia	0.06	0.05	0.04	-6
	Latvia	0.76	0.70	0.64	-9
	Lithuania	0.30	0.27	0.23	-14
N05BA05	potassium clorazepate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.80	0.77	0.73	-6
N05BA06	lorazepam				
	Estonia	0.02	0.07	0.15	125
	Latvia	0.90	1.00	1.16	15
	Lithuania	19.88	19.48	18.90	-3
N05BA08	bromazepam				
	Estonia	1.44	1.47	1.46	
	Latvia	2.82	2.89	3.26	13
	Lithuania	6.07	6.20	6.17	-1
N05BA09	clobazam				
	Estonia	0.01	0.01	0.01	22
	Latvia	-	-	-	
	Lithuania	-	-	-	
N05BA12	alprazolam				
	Estonia	6.09	6.21	6.32	2
	Latvia	5.58	5.76	6.14	6
	Lithuania	7.43	8.19	8.58	5


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N05BB	Diphenylmethane derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N05BB01	hydroxyzine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N05BE	Azaspirodecanedione derivatives				
	Estonia	-	<0.01	-	
	Latvia	0.27	0.28	0.31	12
	Lithuania	0.06	0.05	0.05	-4
N05BE01	buspirone				
	Estonia	-	<0.01	-	
	Latvia	0.27	0.28	0.31	12
	Lithuania	0.06	0.05	0.05	-4
N05C	HYPNOTICS AND SEDATIVES				
	Estonia	18.54	19.61	20.65	5
	Latvia	5.93	6.35	6.96	10
	Lithuania	6.90	7.38	8.29	12
N05CD	Benzodiazepine derivatives				
	Estonia	1.25	0.91	0.89	-3
	Latvia	0.35	0.41	0.46	14
	Lithuania	2.02	2.28	2.70	19
N05CD02	nitrazepam				
	Estonia	0.90	0.58	0.54	-7
	Latvia	<0.01	-	-	
	Lithuania	0.57	0.48	0.48	

Consumption of anxiolytics (N05B)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N05CD04	estazolam				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.06	0.06	0.05	-13
N05CD05	triazolam				
	Estonia	0.05	0.06	0.08	37
	Latvia	0.15	0.21	0.25	19
	Lithuania	1.14	1.49	1.91	28
N05CD08	midazolam				
	Estonia	0.30	0.28	0.27	-1
	Latvia	0.19	0.20	0.22	10
	Lithuania	0.24	0.25	0.27	6
N05CF	Benzodiazepine related drugs				
	Estonia	17.22	18.64	19.71	6
	Latvia	5.56	5.94	6.49	9
	Lithuania	4.87	5.10	5.58	9
N05CF01	zopiclone				
	Estonia	14.23	15.31	16.09	5
	Latvia	3.58	3.74	4.15	11
	Lithuania	1.71	1.67	1.69	1
N05CF02	zolpidem				
	Estonia	2.99	3.33	3.62	9
	Latvia	1.99	2.20	2.34	7
	Lithuania	3.16	3.44	3.89	13
N05CH	Melatonin receptor agonists				
	Estonia	0.06	0.06	0.05	-18
	Latvia	0.01	0.01	0.01	17
	Lithuania	0.01	0.01	0.01	43
N05CH01	melatonin				
	Estonia	0.06	0.06	0.05	-18
	Latvia	0.01	0.01	0.01	17
	Lithuania	0.01	0.01	0.01	43
N05CM	Other hypnotics and sedatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	<0.01	
N05CM18	dexmedetomidine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	<0.01	
N06	PSYCHOANALEPTICS				
	Estonia	27.19	28.59	29.87	5
	Latvia	18.63	19.87	21.36	7
	Lithuania	39.56	47.70	50.46	6

Consumption of hypnotics and sedatives (N05C)




ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N06A	ANTIDEPRESSANTS				
	Estonia	21.37	23.28	24.79	6
	Latvia	10.23	11.09	12.28	11
	Lithuania	24.68	25.68	27.86	9
N06AA	Non-selective monoamine reuptake inhibitors				
	Estonia	2.08	2.10	2.07	-1
	Latvia	1.67	1.62	1.66	3
	Lithuania	1.39	1.38	1.34	-3
N06AA02	imipramine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06AA04	clomipramine				
	Estonia	0.07	0.08	0.07	-14
	Latvia	0.22	0.20	0.21	5
	Lithuania	0.06	0.07	0.06	-2
N06AA07	lofepramine				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	
N06AA09	amitriptyline				
	Estonia	1.54	1.56	1.56	
	Latvia	1.26	1.22	1.24	2
	Lithuania	1.27	1.26	1.22	-3
N06AA10	nortriptyline				
	Estonia	0.47	0.46	0.44	-5
	Latvia	0.19	0.20	0.21	3
	Lithuania	0.06	0.06	0.05	-2

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N06AA12	doxepin				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06AA21	maprotiline				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06AB	Selective serotonin reuptake inhibitors				
	Estonia	13.80	15.06	15.45	3
	Latvia	6.57	7.16	7.85	10
	Lithuania	15.92	16.61	18.62	12
N06AB03	fluoxetine				
	Estonia	2.74	2.97	2.89	-3
	Latvia	0.31	0.28	0.30	8
	Lithuania	0.57	0.62	0.66	6
N06AB04	citalopram				
	Estonia	1.55	1.59	1.51	-5
	Latvia	0.57	0.56	0.62	11
	Lithuania	1.09	1.08	2.07	91
N06AB05	paroxetine				
	Estonia	2.01	2.12	2.24	6
	Latvia	2.19	2.35	2.45	4
	Lithuania	2.89	3.02	3.10	3
N06AB06	sertraline				
	Estonia	2.31	2.76	3.02	10
	Latvia	0.76	0.84	0.89	5
	Lithuania	4.64	4.86	5.13	6
N06AB08	fluvoxamine				
	Estonia	0.01	0.01	0.01	47
	Latvia	0.15	0.15	0.16	10
	Lithuania	0.16	0.15	0.42	178
N06AB10	escitalopram				
	Estonia	5.20	5.61	5.78	3
	Latvia	2.58	2.98	3.43	15
	Lithuania	6.56	6.88	7.25	5
N06AF	Monoamine oxidase inhibitors, non-selective				
	Estonia	0.01	-	<0.01	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
N06AF03	phenelzine				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N06AF04	tranylcypromine				
	Estonia	0.01	-	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
N06AG	Monoamine oxidase A inhibitors				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06AG02	moclobemide				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06AX	Other antidepressants				
	Estonia	5.47	6.12	7.26	19
	Latvia	1.99	2.32	2.77	20
	Lithuania	7.38	7.69	7.91	3
N06AX03	mianserin				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06AX05	trazodone				
	Estonia	-	-	-	
	Latvia	<0.01	0.01	0.03	119
	Lithuania	0.09	0.10	0.13	24
N06AX11	mirtazapine				
	Estonia	1.59	1.59	1.64	3
	Latvia	0.63	0.73	0.80	10
	Lithuania	3.51	3.70	3.83	4
N06AX12	bupropion				
	Estonia	0.25	0.30	0.32	9
	Latvia	0.15	0.16	0.18	8
	Lithuania	0.15	0.15	0.15	2
N06AX14	tianeptine				
	Estonia	0.94	0.96	0.97	2
	Latvia	0.36	0.41	0.54	32
	Lithuania	0.44	0.43	0.51	18
N06AX16	venlafaxine				
	Estonia	1.69	1.88	2.15	15
	Latvia	0.50	0.58	0.66	14
	Lithuania	0.87	0.89	0.93	4
N06AX17	milnacipran				
	Estonia	0.03	0.02	0.01	-74
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N06AX18	reboxetine				
	Estonia	-	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06AX21	duloxetine				
	Estonia	0.91	1.04	1.30	25
	Latvia	0.18	0.18	0.17	-9
	Lithuania	1.16	1.30	1.27	-3
N06AX22	agomelatine				
	Estonia	0.07	0.31	0.69	124
	Latvia	0.15	0.20	0.27	39
	Lithuania	1.17	1.12	1.05	-6
N06AX23	desvenlafaxine				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
N06AX26	vortioxetine				
	Estonia	-	0.03	0.18	474
	Latvia	-	0.04	0.12	209
	Lithuania	-	-	0.04	
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS				
	Estonia	0.67	0.75	0.84	12
	Latvia	6.65	7.00	7.27	4
	Lithuania	10.28	16.42	16.18	-1
N06BA	Centrally acting sympathomimetics				
	Estonia	0.37	0.45	0.54	22
	Latvia	0.01	0.02	0.04	111
	Lithuania	0.01	0.01	0.02	67

Consumption of antidepressants (N06A)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N06BA04	methylphenidate				
	Estonia	0.35	0.40	0.48	18
	Latvia	0.01	0.02	0.04	110
	Lithuania	0.01	0.01	0.01	75
N06BA07	modafinil				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N06BA09	atomoxetine				
	Estonia	0.03	0.04	0.06	54
	Latvia	-	-	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
N06BC	Xanthine derivatives				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06BC01	caffeine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N06BX	Other psychostimulants and nootropics				
	Estonia	0.30	0.30	0.30	-2
	Latvia	6.64	6.98	7.23	4
	Lithuania	10.27	16.41	16.17	-1
N06BX02	pyritinol				
	Estonia	-	-	-	
	Latvia	0.03	0.03	0.03	4
	Lithuania	-	-	-	
N06BX03	piracetam				
	Estonia	0.27	0.27	0.27	
	Latvia	1.86	2.03	2.12	4
	Lithuania	0.84	0.95	0.91	-4
N06BX18	vinpocetine				
	Estonia	0.03	0.03	0.03	-18
	Latvia	4.74	4.93	5.08	3
	Lithuania	9.43	15.47	15.26	-1
N06D	ANTI-DEMENTIA DRUGS				
	Estonia	5.16	4.56	4.24	-7
	Latvia	1.76	1.78	1.81	1
	Lithuania	4.60	5.60	6.41	15
N06DA	Anticholinesterases				
	Estonia	0.33	0.47	0.56	18
	Latvia	0.05	0.07	0.05	-25
	Lithuania	0.89	0.91	0.87	-5


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N06DA02	donepezil				
	Estonia	0.33	0.47	0.56	18
	Latvia	<0.01	0.01	<0.01	
	Lithuania	0.89	0.91	0.87	-5
N06DA04	galantamine				
	Estonia	-	-	-	
	Latvia	0.04	0.07	0.05	-24
	Lithuania	-	-	-	
N06DX	Other anti-dementia drugs				
	Estonia	4.82	4.09	3.69	-10
	Latvia	1.71	1.71	1.76	2
	Lithuania	3.71	4.69	5.54	18
N06DX01	memantine				
	Estonia	0.08	0.10	0.12	20
	Latvia	0.07	0.14	0.19	41
	Lithuania	0.53	0.70	0.76	9
N06DX02	Ginkgo folium				
	Estonia	4.74	3.99	3.57	-10
	Latvia	1.64	1.58	1.56	-1
	Lithuania	3.17	3.99	4.78	20
N07	OTHER NERVOUS SYSTEM DRUGS				
	Estonia	9.89	10.18	10.86	7
	Latvia	16.13	16.86	17.63	5
	Lithuania	11.81	12.62	12.56	-1
N07A	PARASYMPATHOMIMETICS				
	Estonia	0.28	0.31	0.34	10
	Latvia	0.10	0.11	0.12	11
	Lithuania	0.02	0.02	0.03	4
N07AA	Anticholinesterases				
	Estonia	0.28	0.31	0.34	10
	Latvia	0.10	0.11	0.12	11
	Lithuania	0.02	0.02	0.03	4
N07AA01	neostigmine				
	Estonia	0.04	0.04	0.05	32
	Latvia	0.01	0.01	0.01	2
	Lithuania	0.02	0.02	0.03	4
N07AA02	pyridostigmine				
	Estonia	0.23	0.26	0.28	8
	Latvia	0.09	0.09	0.10	12
	Lithuania	-	-	-	
N07AA03	distigmine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N07AA51	neostigmine, combinations				
	Estonia	0.01	0.01	0.01	-6
	Latvia	-	-	-	
	Lithuania	-	-	-	
N07AX	Other parasympathomimetics				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N07AX01	pilocarpine				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
N07B	DRUGS USED IN ADDICTIVE DISORDERS				
	Estonia	2.79	2.62	2.82	8
	Latvia	1.19	1.45	1.44	-1
	Lithuania	0.82	0.77	0.71	-7
N07BA	Drugs used in nicotine dependence				
	Estonia	1.07	0.90	1.17	30
	Latvia	0.22	0.25	0.26	
	Lithuania	0.45	0.37	0.35	-5
N07BA01	nicotine				
	Estonia	1.05	0.88	1.14	30
	Latvia	0.20	0.24	0.23	
	Lithuania	0.43	0.34	0.33	-5
N07BA03	varenicline				
	Estonia	0.02	0.02	0.03	53
	Latvia	0.02	0.02	0.02	11
	Lithuania	0.02	0.02	0.02	-9
N07BB	Drugs used in alcohol dependence				
	Estonia	0.21	0.24	0.25	3
	Latvia	0.38	0.45	0.43	-6
	Lithuania	0.01	0.02	0.02	-14
N07BB01	disulfiram				
	Estonia	0.18	0.22	0.24	5
	Latvia	0.35	0.42	0.40	-5
	Lithuania	-	-	-	
N07BB03	acamprosate				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
N07BB04	naltrexone				
	Estonia	0.01	<0.01	<0.01	
	Latvia	0.02	0.02	0.02	-3
	Lithuania	0.01	0.01	0.01	-9

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N07BB05	nalmefene				
	Estonia	0.03	0.02	0.01	-27
	Latvia	<0.01	0.01	<0.01	
	Lithuania	-	0.01	0.01	-20
N07BC	Drugs used in opioid dependence				
	Estonia	1.51	1.48	1.40	-5
	Latvia	0.59	0.75	0.76	1
	Lithuania	0.35	0.38	0.35	-9
N07BC01	buprenorphine				
	Estonia	-	-	-	
	Latvia	0.02	0.03	0.04	19
	Lithuania	0.01	0.01	0.01	33
N07BC02	methadone				
	Estonia	1.50	1.47	1.38	-6
	Latvia	0.55	0.69	0.67	-2
	Lithuania	0.35	0.37	0.34	-9
N07BC51	buprenorphine, combinations				
	Estonia	0.01	0.01	0.02	34
	Latvia	0.02	0.03	0.05	42
	Lithuania	-	-	-	
N07C	ANTIVERTIGO PREPARATIONS				
	Estonia	6.79	7.23	7.67	6
	Latvia	14.83	15.30	16.07	5
	Lithuania	10.95	11.82	11.80	
N07CA	Antivertigo preparations				
	Estonia	6.79	7.23	7.67	6
	Latvia	14.83	15.30	16.07	5
	Lithuania	10.95	11.82	11.80	
N07CA01	betahistine				
	Estonia	5.05	5.58	6.11	9
	Latvia	10.31	11.18	12.10	8
	Lithuania	5.37	6.17	6.87	11
N07CA02	cinnarizine				
	Estonia	1.74	1.65	1.56	-5
	Latvia	2.96	2.67	2.52	-5
	Lithuania	3.24	3.01	2.51	-17
N07CA03	flunarizine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	0.01	
	Lithuania	-	-	-	
N07CA52	cinnarizine, combinations				
	Estonia	-	-	-	
	Latvia	1.56	1.45	1.44	
	Lithuania	2.34	2.63	2.42	-8

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
N07X	OTHER NERVOUS SYSTEM DRUGS				
	Estonia	0.02	0.02	0.02	8
	Latvia	0.01	0.01	0.01	14
	Lithuania	0.01	0.01	0.02	21
N07XX	Other nervous system drugs				
	Estonia	0.02	0.02	0.02	8
	Latvia	0.01	0.01	0.01	14
	Lithuania	0.01	0.01	0.02	21
N07XX02	riluzole				
	Estonia	0.02	0.02	0.02	16
	Latvia	0.01	0.01	0.01	10
	Lithuania	0.01	0.01	0.01	
N07XX06	tetrabenazine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	<0.01	<0.01	
	Lithuania	<0.01	<0.01	0.01	
N07XX07	fampridine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
N07XX09	dimethyl fumarate				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	

Consumption of other nervous system drugs (N07)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
P	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS				
	Estonia	0.87	0.91	0.94	3
	Latvia	0.78	0.81	0.82	2
	Lithuania	0.74	0.82	0.85	4
P01	ANTIPROTOZOALS				
	Estonia	0.69	0.73	0.74	2
	Latvia	0.40	0.40	0.40	-2
	Lithuania	0.35	0.38	0.40	5
P01A	AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES				
	Estonia	-	-	-	
	Latvia	0.25	0.24	0.23	-4
	Lithuania	0.10	0.09	0.07	-22
P01AB	Nitroimidazole derivatives				
	Estonia	-	-	-	
	Latvia	0.25	0.24	0.23	-4
	Lithuania	0.10	0.09	0.07	-22
P01AB01	metronidazole				
	Estonia	-	-	-	
	Latvia	0.25	0.24	0.23	-4
	Lithuania	0.09	0.08	0.06	-23
P01AB02	tinidazole				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.01	0.01	0.01	-10
P01AB06	nimorazole				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
P01B	ANTIMALARIALS				
	Estonia	0.69	0.73	0.74	2
	Latvia	0.15	0.16	0.17	2
	Lithuania	0.25	0.29	0.32	13
P01BA	Aminoquinolines				
	Estonia	0.67	0.71	0.72	1
	Latvia	0.15	0.16	0.16	3
	Lithuania	0.24	0.28	0.32	13
P01BA01	chloroquine				
	Estonia	-	-	-	
	Latvia	-	<0.01	-	
	Lithuania	-	-	-	
P01BA02	hydroxychloroquine				
	Estonia	0.67	0.71	0.72	1
	Latvia	0.15	0.16	0.16	3
	Lithuania	0.24	0.28	0.32	13

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
P01BA03	primaquine				
	Estonia	-	-	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
P01BB	Biguanides				
	Estonia	0.01	0.02	0.02	31
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
P01BB51	proguanil, combinations				
	Estonia	0.01	0.02	0.02	31
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	<0.01	<0.01	<0.01	
P01BC	Methanolquinolines				
	Estonia	0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
P01BC01	quinine				
	Estonia	-	-	<0.01	
	Latvia	<0.01	<0.01	-	
	Lithuania	-	-	-	
P01BC02	mefloquine				
	Estonia	0.01	<0.01	<0.01	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
P01BD	Diaminopyrimidines				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
P01BD01	pyrimethamine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
P01BD51	pyrimethamine, combinations				
	Estonia	-	<0.01	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
P02	ANTHELMINTICS				
	Estonia	0.17	0.18	0.20	9
	Latvia	0.38	0.40	0.43	5
	Lithuania	0.39	0.44	0.46	4
P02B	ANTITREMATODALS				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
P02BA	Quinoline derivatives and related substances				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
P02BA01	praziquantel				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
P02C	ANTINEMATODAL AGENTS				
	Estonia	0.17	0.18	0.20	9
	Latvia	0.38	0.40	0.43	5
	Lithuania	0.39	0.44	0.46	4
P02CA	Benzimidazole derivatives				
	Estonia	0.17	0.18	0.20	9
	Latvia	0.19	0.20	0.20	1
	Lithuania	0.32	0.36	0.37	3
P02CA01	mebendazole				
	Estonia	0.16	0.18	0.19	4
	Latvia	0.19	0.18	0.18	-2
	Lithuania	0.32	0.36	0.37	3
P02CA03	albendazole				
	Estonia	0.01	<0.01	0.01	
	Latvia	0.01	0.02	0.02	37
	Lithuania	-	-	-	
P02CC	Tetrahydropyrimidine derivatives				
	Estonia	-	-	-	
	Latvia	0.17	0.20	0.22	10
	Lithuania	0.06	0.07	0.08	7
P02CC01	pyrantel				
	Estonia	-	-	-	
	Latvia	0.17	0.20	0.22	10
	Lithuania	0.06	0.07	0.08	7
P02CE	Imidazothiazole derivatives				
	Estonia	-	-	-	
	Latvia	0.02	0.01	0.01	-14
	Lithuania	0.01	0.01	0.01	14
P02CE01	levamisole				
	Estonia	-	-	-	
	Latvia	0.02	0.01	0.01	-14
	Lithuania	0.01	0.01	0.01	14
P02D	ANTICESTODALS				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
P02DA	Salicylic acid derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	
P02DA01	niclosamide				
	Estonia	-	-	-	
	Latvia	<0.01	-	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R	RESPIRATORY SYSTEM				
	Estonia	74.51	78.89	82.65	5
	Latvia	60.83	62.49	65.43	5
	Lithuania	69.17	67.30	70.46	5
R01	NASAL PREPARATIONS				
	Estonia	31.60	33.60	35.00	4
	Latvia	28.80	30.91	33.12	7
	Lithuania	24.26	23.10	25.77	12
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE				
	Estonia	29.53	31.35	32.69	4
	Latvia	28.44	30.54	32.74	7
	Lithuania	23.40	22.31	24.89	12
R01AA	Sympathomimetics, plain				
	Estonia	22.00	22.73	23.32	3
	Latvia	19.35	20.64	20.35	-1
	Lithuania	16.81	16.41	17.43	6
R01AA05	oxymetazoline				
	Estonia	1.35	2.09	1.67	-20
	Latvia	0.93	1.12	1.00	-11
	Lithuania	1.13	1.77	1.14	-36
R01AA07	xylometazoline				
	Estonia	20.65	20.64	21.65	5
	Latvia	16.31	16.95	16.47	-3
	Lithuania	15.17	14.47	16.29	13
R01AA08	naphazoline				
	Estonia	-	-	-	
	Latvia	2.11	2.58	2.89	12
	Lithuania	0.51	0.16	<0.01	
R01AB	Sympathomimetics, combinations excl. corticosteroids				
	Estonia	0.68	0.86	1.26	47
	Latvia	4.41	4.54	6.68	47
	Lithuania	3.05	2.41	3.89	62
R01AB01	phenylephrine				
	Estonia	-	-	-	
	Latvia	3.36	2.81	3.61	29
	Lithuania	2.65	2.03	3.34	65
R01AB02	naphazoline				
	Estonia	-	-	-	
	Latvia	0.79	0.89	0.98	10
	Lithuania	<0.01	<0.01	<0.01	
R01AB06	xylometazoline				
	Estonia	0.68	0.86	1.26	47
	Latvia	0.26	0.85	2.09	147
	Lithuania	0.40	0.39	0.55	43

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R01AC	Antiallergic agents, excl. corticosteroids				
	Estonia	0.23	0.26	0.23	-11
	Latvia	0.07	0.09	0.08	-7
	Lithuania	0.11	0.10	0.09	-10
R01AC03	azelastine				
	Estonia	0.23	0.26	0.23	-11
	Latvia	0.07	0.09	0.08	-7
	Lithuania	0.11	0.10	0.09	-10
R01AD	Corticosteroids				
	Estonia	6.62	7.50	7.88	5
	Latvia	4.61	5.26	5.63	7
	Lithuania	3.43	3.39	3.47	3
R01AD01	beclometasone				
	Estonia	0.17	0.14	0.10	-24
	Latvia	0.22	0.20	0.17	-12
	Lithuania	-	-	-	
R01AD05	budesonide				
	Estonia	1.05	1.06	1.03	-3
	Latvia	1.57	1.51	1.49	-2
	Lithuania	0.24	0.23	0.23	-1
R01AD08	fluticasone				
	Estonia	0.73	0.84	0.82	-2
	Latvia	0.83	0.97	0.98	1
	Lithuania	0.41	0.36	0.32	-9
R01AD09	mometasone				
	Estonia	2.36	2.63	2.95	12
	Latvia	1.31	1.70	2.15	27
	Lithuania	2.05	2.05	2.27	11
R01AD12	fluticasone furoate				
	Estonia	2.17	2.52	2.63	4
	Latvia	0.64	0.77	0.69	-11
	Lithuania	0.73	0.75	0.65	-13
R01AD58	fluticasone, combinations				
	Estonia	0.14	0.31	0.34	10
	Latvia	0.05	0.11	0.15	38
	Lithuania	-	-	-	
R01AX	Other nasal preparations				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
R01AX03	ipratropium bromide				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE				
	Estonia	2.06	2.25	2.31	3
	Latvia	0.36	0.37	0.38	2
	Lithuania	0.86	0.79	0.88	11
R01BA	Sympathomimetics				
	Estonia	2.06	2.25	2.31	3
	Latvia	0.36	0.37	0.38	2
	Lithuania	0.86	0.79	0.88	11
R01BA02	pseudoephedrine				
	Estonia	1.26	1.31	1.30	-1
	Latvia	-	-	-	
	Lithuania	-	-	-	
R01BA52	pseudoephedrine, combinations				
	Estonia	0.80	0.94	1.02	8
	Latvia	0.36	0.37	0.38	2
	Lithuania	0.76	0.75	0.88	17
R01BA53	phenylephrine, combinations				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.11	0.04	-	
R02	THROAT PREPARATIONS				
	Estonia	0.72	0.82	0.87	6
	Latvia	1.93	1.86	1.79	-4
	Lithuania	2.74	2.61	2.75	5
R02A	THROAT PREPARATIONS				
	Estonia	0.72	0.82	0.87	6
	Latvia	1.93	1.86	1.79	-4
	Lithuania	2.74	2.61	2.75	5

Consumption of nasal preparations (R01)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R02AA	Antiseptics				
	Estonia	0.36	0.42	0.45	8
	Latvia	1.93	1.86	1.79	-4
	Lithuania	2.64	2.49	2.56	3
R02AA01	ambazone				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.10	0.07	0.07	-6
R02AA02	dequalinium				
	Estonia	0.36	0.42	0.45	8
	Latvia	0.59	0.65	0.68	5
	Lithuania	0.59	0.58	0.72	26
R02AA03	dichlorobenzyl alcohol				
	Estonia	-	-	-	
	Latvia	0.48	0.45	0.44	-2
	Lithuania	-	-	-	
R02AA05	chlorhexidine				
	Estonia	<0.01	-	-	
	Latvia	0.28	0.28	0.30	5
	Lithuania	-	0.09	-	
R02AA06	cetylpyridinium				
	Estonia	-	-	-	
	Latvia	0.23	0.20	0.15	-29
	Lithuania	0.29	0.25	0.18	-29
R02AA11	chlorquinaldol				
	Estonia	-	-	-	
	Latvia	0.01	0.01	0.01	-5
	Lithuania	-	-	-	
R02AA16	benzalkonium				
	Estonia	-	-	-	
	Latvia	0.09	0.09	0.05	-39
	Lithuania	0.08	0.07	0.03	-49
R02AA20	various				
	Estonia	-	-	-	
	Latvia	0.25	0.17	0.16	-11
	Lithuania	1.34	1.18	1.25	6
R02AD	Anesthetics, local				
	Estonia	0.25	0.26	0.26	-1
	Latvia	-	-	-	
	Lithuania	-	-	-	
R02AX	Other throat preparations				
	Estonia	0.12	0.14	0.16	13
	Latvia	-	-	-	
	Lithuania	0.09	0.12	0.19	54

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R02AX01	flurbiprofen				
	Estonia	0.12	0.14	0.16	13
	Latvia	-	-	-	
	Lithuania	0.09	0.12	0.19	54
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES				
	Estonia	22.14	23.35	24.69	6
	Latvia	15.03	15.03	15.40	2
	Lithuania	24.12	24.18	23.68	-2
R03A	ADRENERGICS, INHALANTS				
	Estonia	15.06	15.41	16.43	7
	Latvia	9.27	9.30	9.69	4
	Lithuania	17.74	18.20	17.78	-2
R03AA	Alpha- and beta-adrenoreceptor agonists				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
R03AA01	epinephrine				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
R03AC	Selective beta-2-adrenoreceptor agonists				
	Estonia	5.69	5.75	5.42	-6
	Latvia	3.02	3.04	2.69	-12
	Lithuania	8.02	8.58	8.42	-2
R03AC02	salbutamol				
	Estonia	2.84	2.91	2.96	2
	Latvia	2.73	2.74	2.46	-10
	Lithuania	6.65	6.57	6.64	1
R03AC03	terbutaline				
	Estonia	<0.01	-	<0.01	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
R03AC04	fenoterol				
	Estonia	0.35	0.33	0.29	-11
	Latvia	0.09	0.08	0.08	-7
	Lithuania	0.04	0.03	0.03	-9
R03AC12	salmeterol				
	Estonia	0.27	0.23	0.21	-10
	Latvia	0.05	0.06	0.04	-31
	Lithuania	0.34	0.28	0.24	-16
R03AC13	formoterol				
	Estonia	1.37	1.23	1.07	-13
	Latvia	0.10	0.09	0.08	-15
	Lithuania	0.85	0.91	0.70	-23


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R03AC18	indacaterol				
	Estonia	0.86	1.06	0.88	-17
	Latvia	0.05	0.06	0.04	-42
	Lithuania	0.15	0.78	0.81	3
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics				
	Estonia	8.60	8.89	9.80	10
	Latvia	5.03	5.00	5.53	11
	Lithuania	7.62	7.71	7.56	-2
R03AK06	salmeterol and fluticasone				
	Estonia	4.17	4.26	4.15	-3
	Latvia	2.96	2.90	2.75	-5
	Lithuania	3.84	3.67	3.46	-6
R03AK07	formoterol and budesonide				
	Estonia	3.98	3.80	3.87	2
	Latvia	2.06	1.99	2.15	8
	Lithuania	2.98	3.01	2.94	-2
R03AK08	formoterol and beclometasone				
	Estonia	0.45	0.62	0.71	16
	Latvia	-	-	-	
	Lithuania	0.80	1.03	1.15	12
R03AK10	vilanterol and fluticasone furoate				
	Estonia	-	0.20	1.07	425
	Latvia	-	0.11	0.63	470
	Lithuania	-	-	-	
R03AL	Adrenergics in combination with anticholinergics				
	Estonia	0.76	0.77	1.21	56
	Latvia	1.22	1.26	1.47	17
	Lithuania	2.09	1.91	1.81	-5
R03AL01	fenoterol and ipratropium bromide				
	Estonia	0.76	0.77	0.78	1
	Latvia	1.22	1.24	1.29	4
	Lithuania	2.09	1.91	1.81	-5
R03AL03	vilanterol and umeclidinium bromide				
	Estonia	-	-	0.02	
	Latvia	-	-	0.01	
	Lithuania	-	-	-	
R03AL04	indacaterol and glycopyrronium bromide				
	Estonia	-	<0.01	0.37	
	Latvia	-	0.03	0.17	551
	Lithuania	-	-	-	
R03AL05	formoterol and aclidinium bromide				
	Estonia	-	-	0.03	
	Latvia	-	-	-	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS				
	Estonia	4.02	4.86	5.14	6
	Latvia	1.95	1.95	2.05	5
	Lithuania	3.74	3.67	3.77	3
R03BA	Glucocorticoids				
	Estonia	1.76	1.82	1.82	
	Latvia	1.15	1.14	1.11	-3
	Lithuania	1.65	1.63	1.63	
R03BA01	beclometasone				
	Estonia	0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
R03BA02	budesonide				
	Estonia	1.28	1.30	1.25	-4
	Latvia	0.43	0.40	0.39	-3
	Lithuania	0.75	0.75	0.77	3
R03BA05	fluticasone				
	Estonia	0.47	0.52	0.57	10
	Latvia	0.72	0.73	0.72	-3
	Lithuania	0.90	0.88	0.85	-3
R03BB	Anticholinergics				
	Estonia	2.26	3.04	3.32	9
	Latvia	0.80	0.81	0.94	16
	Lithuania	2.10	2.03	2.14	5
R03BB01	ipratropium bromide				
	Estonia	1.12	0.93	0.80	-14
	Latvia	<0.01	<0.01	0.01	
	Lithuania	<0.01	<0.01	<0.01	
R03BB04	tiotropium bromide				
	Estonia	1.14	1.21	1.24	2
	Latvia	0.80	0.71	0.76	8
	Lithuania	2.09	2.03	1.75	-14
R03BB05	aclidinium bromide				
	Estonia	-	0.27	0.42	55
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	0.19	
R03BB06	glycopyrronium bromide				
	Estonia	<0.01	0.63	0.86	36
	Latvia	-	0.10	0.17	76
	Lithuania	-	-	0.19	
R03BC	Antiallergic agents, excl. corticosteroids				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R03BC01	cromoglicic acid				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
R03C	ADRENERGICS FOR SYSTEMIC USE				
	Estonia	0.27	0.24	0.21	-13
	Latvia	0.21	0.20	0.18	-8
	Lithuania	0.33	0.28	0.26	-5
R03CC	Selective beta-2-adrenoreceptor agonists				
	Estonia	0.27	0.24	0.21	-13
	Latvia	0.21	0.20	0.18	-8
	Lithuania	0.33	0.28	0.26	-5
R03CC02	salbutamol				
	Estonia	0.27	0.24	0.21	-13
	Latvia	0.21	0.20	0.18	-8
	Lithuania	0.33	0.28	0.26	-5
R03CC03	terbutaline				
	Estonia	<0.01	-	<0.01	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
R03CC05	hexoprenaline				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	<0.01	-	-	
R03D	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES				
	Estonia	2.79	2.83	2.90	3
	Latvia	3.60	3.59	3.48	-3
	Lithuania	2.30	2.04	1.87	-8
R03DA	Xanthines				
	Estonia	1.62	1.58	1.53	-3
	Latvia	2.62	2.41	2.34	-3
	Lithuania	1.54	1.34	1.28	-5
R03DA04	theophylline				
	Estonia	1.57	1.54	1.50	-2
	Latvia	2.25	2.08	2.03	-3
	Lithuania	0.87	0.75	0.70	-6
R03DA05	aminophylline				
	Estonia	0.05	0.04	0.03	-16
	Latvia	0.37	0.33	0.31	-5
	Lithuania	0.67	0.59	0.58	-3
R03DC	Leukotriene receptor antagonists				
	Estonia	1.17	1.24	1.35	9
	Latvia	0.98	1.18	1.14	-3
	Lithuania	0.77	0.70	0.60	-15

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R03DC03	montelukast				
	Estonia	1.17	1.24	1.35	9
	Latvia	0.98	1.18	1.14	-3
	Lithuania	0.77	0.70	0.60	-15
R03DX	Other systemic drugs for obstructive airway diseases				
	Estonia	0.01	0.01	0.02	72
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
R03DX05	omalizumab				
	Estonia	0.01	0.01	0.02	72
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
R05	COUGH AND COLD PREPARATIONS				
	Estonia	7.92	7.21	7.78	8
	Latvia	7.32	6.16	6.80	10
	Lithuania	9.11	7.06	7.73	10
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS				
	Estonia	7.78	7.06	7.62	8
	Latvia	6.65	5.59	6.17	10
	Lithuania	9.03	7.00	7.67	10
R05CA	Expectorants				
	Estonia	0.18	0.17	0.18	5
	Latvia	0.02	0.01	0.03	142
	Lithuania	0.02	0.01	0.04	267
R05CA03	guaifenesin				
	Estonia	0.18	0.17	0.18	5
	Latvia	0.02	0.01	0.03	142
	Lithuania	0.02	0.01	0.04	267

Consumption of antiasthmatics (R03)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R05CB	Mucolytics				
	Estonia	7.60	6.89	7.44	8
	Latvia	6.63	5.58	6.14	10
	Lithuania	9.01	6.98	7.62	9
R05CB01	acetylcysteine				
	Estonia	3.78	3.28	3.92	20
	Latvia	1.85	1.55	1.84	19
	Lithuania	2.99	2.10	2.66	27
R05CB02	bromhexine				
	Estonia	0.86	0.76	0.71	-6
	Latvia	2.09	1.66	1.74	5
	Lithuania	0.99	0.66	0.65	-2
R05CB03	carbocysteine				
	Estonia	0.31	0.30	0.29	-5
	Latvia	0.11	0.09	0.10	20
	Lithuania	0.17	0.15	0.16	6
R05CB06	ambroxol				
	Estonia	2.64	2.54	2.50	-1
	Latvia	2.58	2.29	2.46	8
	Lithuania	4.86	4.07	4.15	2
R05CB13	dornase alfa (desoxyribonuclease)				
	Estonia	0.01	0.01	0.02	2
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	0.01	0.01	0.01	22
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS				
	Estonia	0.11	0.10	0.11	4
	Latvia	0.12	0.10	0.11	7
	Lithuania	0.08	0.06	0.07	5
R05DA	Opium alkaloids and derivatives				
	Estonia	-	-	-	
	Latvia	0.12	0.10	0.11	6
	Lithuania	-	-	-	
R05DA09	dextromethorphan				
	Estonia	-	-	-	
	Latvia	0.12	0.10	0.11	6
	Lithuania	-	-	-	
R05DB	Other cough suppressants				
	Estonia	0.11	0.10	0.11	4
	Latvia	-	-	<0.01	
	Lithuania	0.08	0.06	0.07	5
R05DB09	oxeladin				
	Estonia	0.11	0.10	0.11	3
	Latvia	-	-	<0.01	
	Lithuania	0.08	0.06	0.07	5

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R05DB13	butamirate				
	Estonia	-	-	-	
	Latvia	-	-	<0.01	
	Lithuania	-	-	-	
R05DB27	levodropropizine				
	Estonia	-	-	<0.01	
	Latvia	-	-	-	
	Lithuania	-	-	-	
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS				
	Estonia	0.04	0.04	0.05	11
	Latvia	0.55	0.47	0.52	11
	Lithuania	-	-	-	
R05FA	Opium derivatives and expectorants				
	Estonia	0.04	0.04	0.05	11
	Latvia	0.55	0.47	0.52	11
	Lithuania	-	-	-	
R05FA02	opium derivatives and expectorants				
	Estonia	0.04	0.04	0.05	11
	Latvia	0.55	0.47	0.52	11
	Lithuania	-	-	-	
R06	ANTIHISTAMINES FOR SYSTEMIC USE				
	Estonia	12.13	13.92	14.32	3
	Latvia	7.62	8.40	8.21	-2
	Lithuania	8.95	10.35	10.53	2
R06A	ANTIHISTAMINES FOR SYSTEMIC USE				
	Estonia	12.13	13.92	14.32	3
	Latvia	7.62	8.40	8.21	-2
	Lithuania	8.95	10.35	10.53	2
R06AA	Aminoalkyl ethers				
	Estonia	0.59	0.59	0.56	-5
	Latvia	2.01	2.10	2.04	-3
	Lithuania	1.75	1.73	2.09	20
R06AA02	diphenhydramine				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
R06AA04	clemastine				
	Estonia	0.59	0.59	0.56	-5
	Latvia	2.01	2.10	2.04	-3
	Lithuania	1.75	1.73	2.09	20
R06AC	Substituted ethylene diamines				
	Estonia	-	-	-	
	Latvia	0.52	0.53	0.52	-2
	Lithuania	0.01	0.01	0.01	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R06AC03	chloropyramine				
	Estonia	-	-	-	
	Latvia	0.52	0.53	0.52	-2
	Lithuania	0.01	0.01	0.01	
R06AD	Phenothiazine derivatives				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
R06AD01	alimemazine				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
R06AE	Piperazine derivatives				
	Estonia	5.66	6.62	6.62	
	Latvia	2.56	2.96	2.86	-3
	Lithuania	2.43	2.76	2.75	
R06AE07	cetirizine				
	Estonia	5.26	6.21	6.18	-1
	Latvia	2.22	2.64	2.57	-3
	Lithuania	2.32	2.42	2.46	2
R06AE09	levocetirizine				
	Estonia	0.40	0.41	0.44	7
	Latvia	0.34	0.32	0.30	-7
	Lithuania	0.12	0.34	0.29	-14
R06AX	Other antihistamines for systemic use				
	Estonia	5.89	6.71	7.14	6
	Latvia	2.52	2.80	2.79	
	Lithuania	4.76	5.85	5.68	-3
R06AX02	cyproheptadine				
	Estonia	-	-	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
R06AX13	loratadine				
	Estonia	3.27	3.69	3.44	-7
	Latvia	1.25	1.33	1.23	-8
	Lithuania	2.86	2.86	2.73	-4
R06AX15	mebhydrolin				
	Estonia	<0.01	<0.01	-	
	Latvia	<0.01	-	-	
	Lithuania	-	-	-	
R06AX17	ketotifen				
	Estonia	0.01	0.01	<0.01	
	Latvia	0.24	0.22	0.21	-5
	Lithuania	-	-	-	


ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
R06AX22	ebastine				
	Estonia	1.18	1.32	1.23	-7
	Latvia	0.01	<0.01	<0.01	
	Lithuania	0.66	0.65	0.59	-10
R06AX26	fexofenadine				
	Estonia	-	-	-	
	Latvia	0.02	0.04	<0.01	
	Lithuania	0.05	0.25	0.09	-62
R06AX27	desloratadine				
	Estonia	0.99	1.01	1.62	61
	Latvia	0.64	0.63	0.63	
	Lithuania	0.99	1.00	0.94	-6
R06AX28	rupatadine				
	Estonia	0.06	0.09	0.14	53
	Latvia	0.04	0.06	0.08	24
	Lithuania	0.20	0.26	0.38	44
R06AX29	bilastine				
	Estonia	0.38	0.59	0.71	20
	Latvia	0.33	0.51	0.63	23
	Lithuania	-	0.83	0.95	15
R07	OTHER RESPIRATORY SYSTEM PRODUCTS				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.13	0.13	0.11	-12
	Lithuania	-	-	-	
R07A	OTHER RESPIRATORY SYSTEM PRODUCTS				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.13	0.13	0.11	-12
	Lithuania	-	-	-	
R07AA	Lung surfactants				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
R07AA02	natural phospholipids				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
R07AB	Respiratory stimulants				
	Estonia	-	-	-	
	Latvia	0.13	0.13	0.11	-12
	Lithuania	-	-	-	
R07AB02	nikethamide				
	Estonia	-	-	-	
	Latvia	0.13	0.13	0.11	-12
	Lithuania	-	-	-	

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
S	SENSORY ORGANS				
	Estonia	25.12	27.78	29.30	5
	Latvia	19.74	21.04	22.04	5
	Lithuania	20.25	21.14	22.18	5
S01	OPHTHALMOLOGICALS				
	Estonia	25.12	27.78	29.30	5
	Latvia	19.74	21.04	22.04	5
	Lithuania	20.25	21.14	22.18	5
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS				
	Estonia	25.12	27.78	29.30	5
	Latvia	19.74	21.04	22.04	5
	Lithuania	20.25	21.14	22.18	5
S01EA	Sympathomimetics in glaucoma therapy1)				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.74	0.78	0.81	4
	Lithuania	1.42	1.61	1.71	6
S01EA03	apraclonidine				
	Estonia	-	-	-	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
S01EA05	brimonidine				
	Estonia	<0.01	<0.01	0.01	
	Latvia	0.74	0.78	0.81	4
	Lithuania	-	-	-	
S01EB	Parasympathomimetics				
	Estonia	0.01	0.01	0.02	41
	Latvia	0.01	0.01	0.01	-3
	Lithuania	-	-	-	
S01EB01	pilocarpine				
	Estonia	0.01	0.01	0.01	84
	Latvia	0.01	0.01	0.01	-11
	Lithuania	-	-	-	
S01EB02	carbachol				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	<0.01	<0.01	<0.01	
	Lithuania	-	-	-	
S01EC	Carbonic anhydrase inhibitors				
	Estonia	1.99	2.23	2.44	10
	Latvia	1.85	2.15	2.57	19
	Lithuania	2.18	2.31	3.15	36
S01EC01	acetazolamide				
	Estonia	0.05	0.06	0.06	
	Latvia	0.10	0.10	0.09	-5
	Lithuania	0.07	0.07	0.08	4

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
S01EC03	dorzolamide				
	Estonia	0.74	0.83	0.83	
	Latvia	0.59	0.65	0.62	-4
	Lithuania	0.94	1.00	0.99	-1
S01EC04	brinzolamide				
	Estonia	1.19	1.33	1.44	8
	Latvia	1.17	1.41	1.65	17
	Lithuania	1.18	1.24	1.79	44
S01EC54	brinzolamide, combinations				
	Estonia	-	-	0.10	
	Latvia	-	-	0.21	
	Lithuania	-	-	0.29	
S01ED	Beta blocking agents1)				
	Estonia	15.46	17.01	17.72	4
	Latvia	10.00	10.59	10.74	1
	Lithuania	8.16	8.35	8.41	1
S01ED01	timolol				
	Estonia	7.80	8.66	9.10	5
	Latvia	3.46	3.50	3.36	-4
	Lithuania	1.93	1.86	1.77	-5
S01ED02	betaxolol				
	Estonia	1.19	1.12	1.09	-3
	Latvia	0.78	0.79	0.78	-2
	Lithuania	0.66	0.61	0.56	-8
S01ED51	timolol, combinations				
	Estonia	6.48	7.24	7.54	4
	Latvia	5.76	6.30	6.60	5
	Lithuania	5.57	5.88	6.07	3
S01EE	Prostaglandin analogues1)				
	Estonia	7.66	8.53	9.11	7
	Latvia	7.14	7.51	7.91	5
	Lithuania	8.49	8.87	8.92	1
S01EE01	latanoprost				
	Estonia	4.92	5.24	5.66	8
	Latvia	6.38	6.68	6.84	2
	Lithuania	5.91	6.34	6.28	-1
S01EE03	bimatoprost				
	Estonia	<0.01	<0.01	<0.01	
	Latvia	0.21	0.22	0.24	8
	Lithuania	0.78	0.46	0.44	-4
S01EE04	travoprost				
	Estonia	2.35	2.58	2.47	-4
	Latvia	0.25	0.21	0.33	54
	Lithuania	1.51	1.55	1.54	-1

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
S01EE05	tafluprost				
	Estonia	0.38	0.70	0.97	40
	Latvia	0.29	0.40	0.51	26
	Lithuania	0.28	0.52	0.66	26

Consumption of antiglaucoma preparations and miotics (S01E)



ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
V	VARIOUS				
	Estonia	0.14	0.13	0.14	10
	Latvia	0.37	0.36	0.36	1
	Lithuania	0.13	0.15	0.17	17
V03	ALL OTHER THERAPEUTIC PRODUCTS				
	Estonia	0.14	0.13	0.14	10
	Latvia	0.37	0.36	0.36	1
	Lithuania	0.13	0.15	0.17	17
V03A	ALL OTHER THERAPEUTIC PRODUCTS				
	Estonia	0.14	0.13	0.14	10
	Latvia	0.37	0.36	0.36	1
	Lithuania	0.13	0.15	0.17	17
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia				
	Estonia	0.10	0.08	0.09	13
	Latvia	0.33	0.31	0.31	
	Lithuania	0.09	0.10	0.11	15
V03AE01	polystyrene sulfonate				
	Estonia	0.03	0.04	0.05	21
	Latvia	0.01	0.01	0.01	14
	Lithuania	0.02	0.02	0.02	6
V03AE02	sevelamer				
	Estonia	0.01	0.01	0.02	72
	Latvia	0.01	0.02	0.02	25
	Lithuania	-	-	-	
V03AE03	lanthanum carbonate				
	Estonia	0.02	0.02	0.02	-28
	Latvia	0.01	<0.01	<0.01	
	Lithuania	-	-	-	
V03AE04	calcium acetate and magnesium carbonate				
	Estonia	-	-	-	
	Latvia	-	-	-	
	Lithuania	0.07	0.08	0.09	18
V03AE07	calcium acetate				
	Estonia	0.04	<0.01	-	
	Latvia	0.31	0.27	0.27	-3
	Lithuania	-	-	-	
V03AF	Detoxifying agents for antineoplastic treatment				
	Estonia	0.05	0.05	0.05	6
	Latvia	0.04	0.05	0.05	5
	Lithuania	0.04	0.05	0.06	21
V03AF03	calcium folinate				
	Estonia	0.01	<0.01	<0.01	
	Latvia	0.04	0.05	0.05	5
	Lithuania	0.03	0.04	0.05	14

ATC code	ATC group/ INN	DDD/1000/day			Relative change %
		2013	2014	2015	
V03AF08	palifermin				
	Estonia	-	-	-	
	Latvia	-	<0.01	<0.01	
	Lithuania	-	-	-	
V03AF10	sodium levofolate				
	Estonia	0.04	0.05	0.05	8
	Latvia	-	-	-	
	Lithuania	0.01	<0.01	0.01	

8. Top 15 of prescription-only medicines in 2015

ESTONIA			
No	ATC	Active substance	DDD/1000/day
1	C09AA05	ramipril	59.20
2	C08CA01	amlodipine	30.75
3	C10AA07	rosuvastatin	26.99
4	C07AB02	metoprolol	23.19
5	A02BC01	omeprazole	22.64
6	C09CA07	telmisartan	21.48
7	A10BA02	metformin	19.71
8	C07AB12	nebivolol	19.28
9	H03AA01	levothyroxine sodium	16.59
10	N05CF01	zopiclone	16.09
11	C10AA05	atorvastatin	15.74
12	C09AA02	enalapril	13.97
13	C09BA04	perindopril+indapamide	11.67
14	C03CA04	torasemide	11.52
15	C09BA02	enalapril+hydrochlorothiazide	11.11

LATVIA			
No	ATC	Active substance	DDD/1000/day
1	C10AA05	atorvastatin	39.26
2	C09AA05	ramipril	23.92
3	C09BA04	perindopril + indapamide	23.83
4	C10AA07	rosuvastatin	21.68
5	M01AB05	diclofenac	20.89
6	C09AA04	perindopril	20.02
7	C07AB07	bisoprolol	18.64
8	C08CA01	amlodipine	17.58
9	C09AA02	enalapril	16.84
10	A02BC01	omeprazole	16.20
11	A10BA02	metformin	14.87
12	H03AA01	levothyroxine sodium	13.19
13	C07AB02	metoprolol	13.17
14	C09BB04	perindopril and amlodipine	12.99
15	N07CA01	betahistine	12.10

LITHUANIA			
No	ATC	Active substance	DDD/1000/day
1	C07AB12	nebivolol	37.17
2	C09AA05	ramipril	30.99
3	C09AA04	perindopril	27.30
4	C09BA04	perindopril + indapamide	23.12
5	C02AC05	moxonidine	20.91
6	C07AB02	metoprolol	20.82
7	M01AB05	diclofenac	20.51
8	C09CA03	valsartan	18.95
9	N05BA06	lorazepam	18.90
10	C01EB15	trimetazidine	18.78
11	C10AA05	atorvastatin	18.42
12	A10BA02	metformin	16.72
13	N06BX18	vinpocetine	15.26
14	H03AA01	levothyroxine sodium	14.80
15	C08CA13	lercanidipine	14.43

9. Top 15 of over-the-counter medicines in 2015

ESTONIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC30	acetylsalicylic acid combinations	48.6
2	M01AE01	ibuprofen	22.1
3	R01AA07	xylometazoline	21.6
4	B01AC06	acetylsalicylic acid	14.6
5	A06AD11	lactulose	6.8
6	N02BE01	paracetamol	6.8
7	R05CB01	acetylcysteine	3.9
8	A06AB08	sodium picosulfate	3.7
9	A02BC01	omeprazole	3.7
10	N06DX02	Ginkgo folium	3.6
11	A06AB02	bisacodyl	3.3
12	R06AE07	cetirizine	2.8
13	A03AD02	drotaverine	2.6
14	R06AX13	loratadine	2.6
15	R05CB06	ambroxol	2.5

LATVIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC06	acetylsalicylic acid	66.20
2	M01AE01	ibuprofen	22.30
3	R01AA07	xylometazoline	16.47
4	A02BC01	omeprazole	9.17
5	N02BA51	acetylsalicylic acid, combinations excl. psycholeptics	4.46
6	A09AA02	multienzymes (lipase, protease etc.)	4.23
7	A03AD02	drotaverine	4.15
8	R01AB01	phenylephrine	3.61
9	A01AA01	sodium fluoride	3.49
10	A06AB02	bisacodyl	3.13
11	R01AA08	naphazoline	2.89
12	A06AB08	sodium picosulfate	2.73
13	R05CB06	ambroxol	2.46
14	N02BE51	paracetamol, combinations excl. psycholeptics	2.45
15	A06AD11	lactulose	2.44

LITHUANIA			
No	ATC	Active substance	DDD/1000/day
1	B01AC06	acetylsalicylic acid	51.12
2	R01AA07	xylometazoline	16.29
3	M01AE01	ibuprofen	9.40
4	A02BC01	omeprazole	9.22
5	N02BE51	paracetamol, combinations excl. psycholeptics	5.23
6	R05CB06	ambroxol	4.15
7	A02BA02	ranitidine	3.75
8	A06AD11	lactulose	3.66
9	R01AB01	phenylephrine	3.34
10	A03AD02	drotaverine	3.32
11	N06DX02	Ginkgo folium	3.16
12	A06AB08	sodium picosulfate	2.97
13	R05CB01	acetylcysteine	2.66
14	N02BE01	paracetamol	2.56
15	A06AB02	bisacodyl	2.45

10. Top 15 most used ATC 3rd level groups in 2015

ESTONIA			
No	ATC	Active substance	DDD/1000/day
1	C09A	ACE INHIBITORS, PLAIN	84.85
2	B01A	ANTITHROMBOTIC AGENTS	84.26
3	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	68.86
4	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	56.14
5	C10A	LIPID MODIFYING AGENTS, PLAIN	51.14
6	C07A	BETA BLOCKING AGENTS	47.53
7	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	43.73
8	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	42.49
9	C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN	42.27
10	C09B	ACE INHIBITORS, COMBINATIONS	41.31
11	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	32.69
12	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	29.30
13	C09D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	28.15
14	G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	27.99
15	N06A	ANTIDEPRESSANTS	24.79

LATVIA			
No	ATC	Active substance	DDD/1000/day
1	B01A	ANTITHROMBOTIC AGENTS	80.22
2	C09A	ACE INHIBITORS, PLAIN	65.57
3	C10A	LIPID MODIFYING AGENTS, PLAIN	62.49
4	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	62.25
5	C09B	ACE INHIBITORS, COMBINATIONS	56.74
6	C07A	BETA BLOCKING AGENTS	48.06
7	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	37.72
8	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	36.81
9	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	35.08
10	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	32.74
11	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	22.04
12	N07C	ANTIVERTIGO PREPARATIONS	16.07
13	C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	15.33
14	N05B	ANXIOLYTICS	14.74
15	C09D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	13.99

LITHUANIA			
No	ATC	Active substance	DDD/1000/day
1	C09A	ACE INHIBITORS, PLAIN	102.14
2	B01A	ANTITHROMBOTIC AGENTS	71.84
3	C07A	BETA BLOCKING AGENTS	66.71
4	M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	60.92
5	C09B	ACE INHIBITORS, COMBINATIONS	55.50
6	N05B	ANXIOLYTICS	41.01
7	A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	39.04
8	C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN	37.41
9	A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	31.83
10	C08C	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	28.43
11	N06A	ANTIDEPRESSANTS	27.86
12	R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	24.89
13	S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	22.18
14	C01E	OTHER CARDIAC PREPARATIONS	21.86
15	C10A	LIPID MODIFYING AGENTS, PLAIN	21.70

11. Contacts



REPUBLIC OF ESTONIA
AGENCY OF MEDICINES

■ **State Agency of Medicines
(Ravimiamet)**

1 Nooruse Street
50411 Tartu
Estonia
info@ravimiamet.ee
www.ravimiamet.ee



State Agency
of Medicines
Republic of Latvia

■ **State Agency of Medicines
(Zāļu valsts aģentūra)**

15 Jersikas Street
LV-1003 Riga
Latvia
info@zva.gov.lv
www.zva.gov.lv



■ **State Medicines Control Agency
(Valstybinė vaistų kontrolės tarnyba)**

139A Žirmūnų Street
09120 Vilnius
Lithuania
vvkt@vvkt.lt
www.vvkt.lt

12. References

1. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD methodology (http://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system)
2. Pudersell, K., Vetka, A., Rootslane, L., Mathiesen, M., Vendla, K., Laasalu, K.: PPRI Pharma Profile Estonia 2007. June; Pharmaceutical Pricing and Reimbursement Information; Commissioned by the European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth (<http://whocc.goeg.at/Publications/CountryReports>)
3. Estonian Health Insurance. Health Insurance in Estonia (<http://www.haigekassa.ee>)
4. Statistics Estonia (<http://www.stat.ee>)
5. Estonian Statistics on Medicines (<http://www.ravimiamet.ee/en/statistics-medicines>)
6. Statistics on medicines consumption of Latvia (<https://www.zva.gov.lv>)
7. Central Statistical Bureau of Latvia (<http://data.csb.gov.lv>)
8. World Health Organization. Global Health Expenditure Database (<http://apps.who.int/nha/database>)
9. The Centre for Disease Prevention and Control of Latvia (<http://www.spkc.gov.lv>)
10. The National Health Service of Latvia (<http://www.vmnvd.gov.lv>)
11. Food and Veterinary Service (<http://www.zm.gov.lv/partikas-un-veterinarais-dienests>)
12. Medicines consumption 2015 in Lithuania (<http://www.vvkt.lt/Annual-Reports>)
13. National Health Insurance Fund under the Ministry of Health of the Republic of Lithuania (<http://www.vlk.lt/sites/en>)

